Ryman Healthcare Limited logo

Ryman Healthcare Limited 2021 Annual Report

Annual Report17 June 2021RYMHealthcare

Ryman Healthcare
ANNUAL REPORT 2021

Cover image features Ryman residents Norris Aitken, Nola Cutting,
Muriel Feasey, Eng Dick, Helen Aitken and Richard Fisher.

RYMAN HEALTHCARE

Our mission remains
the same as it has been

for the past 37 years -

the care we offer has

to be “good enough for

Mum or Dad”.

ANNUAL REPORT 2021

2
RYMAN HEALTHCARE

4 Chair’s report
10 Stats and facts

12 Group chief executive’s report

20 Current villages under development

22 Future villages in our pipeline

26 Our directors

28 Our senior executives

31 Who we are and how we create value

39 What matters most to our stakeholders

43 Caring for our residents and our communities

55 Caring for our people

65 Caring for our environment

73 Providing a sustainable outcome for all stakeholders

77 Embracing innovation and technology

81 Our financials

139 Statement of corporate governance

156 Rymanians

162

Our village locations

164 Directory

3

ANNUAL REPORT 2021

Chair’s report
Ryman residents Norm Reid and Maggie Gubbins with chair, Dr David Kerr.

RYMAN HEALTHCARE

4

We bore the brunt
of the COVID-19

pandemic during the

2021 financial year.

I am pleased to report

that we have come

through well and are

in good shape for

future growth.

DR DAVID KERR

CHAIR, RYMAN HEALTHCARE

5

ANNUAL REPORT 2021

A good result in a difficult year
The pandemic has been a once-in-a-generation challenge, but

we kept everyone safe. We also continued to build and

innovate, and the board is proud of what has been achieved.

In the year to 31 March 2021, our audited underlying profit was

$224.4 million. This is a decrease of 7.3 percent compared to

the prior year and reflects the increased costs of responding

to COVID-19 and the impact lockdowns in New Zealand and

Victoria had on our ability to undertake construction and

transact units.

Our operations in Victoria, where we were expecting the

majority of our growth to come from in the 2021 financial year,

were significantly impacted by Melbourne being in varying

degrees of lockdown for around 6 months.

Having voluntarily repaid the New Zealand Government wage

subsidy, the impact of COVID-19 on underlying profit for the

year was a cost of $19.8 million. This was spent on additional

staffing, security and resident welfare.

Our reported IFRS profit, which includes unrealised valuation

gains, increased 59.8 percent to $423.1 million.

We reached a milestone this year with the payment of a

full-year dividend of 22.4 cents per share, meaning we have

now returned more than $1 billion to shareholders since

listing in 1999.

The board of Ryman

Healthcare is proud of what

has been achieved in the most

challenging of years.

The work we have done to turn

our villages into safe havens

has been greatly valued by our

residents and their families.

“We are enormously grateful

for the extra effort our team has

put in to keep everyone safe.”

RYMAN HEALTHCARE

6

Project Safe Haven
Keeping our villages COVID-19 free,

coping with unexpected lockdowns

and adapting to the changing

alert levels was a challenge.

Our plan, known as Project Safe Haven,

was simple. We did everything we

could think of to allow our residents

to stay home, entertained and

comfortable, but, most of all, safe.

By delivering everything they

needed, keeping them connected

and finding new and better

ways to keep them engaged, we

managed to keep them safe.

Our team has been truly amazing.

Throughout the year, they have

put the welfare of our residents

first and they continue to do so.

Some of our team have been

in varying amounts of personal

protective equipment for well over

a year. They continue to exercise

great caution with their own activities,

living arrangements and personal

health and we are enormously

grateful for their extra efforts.

At the date of printing this annual

report, our residents and staff remain

COVID-19 free, and our vaccine

roll-out programme is in full swing.

Our residents have jumped at the chance

to get vaccinated, as have our team,

which is great for everyone’s wellbeing.

CUMULATIVE DIVIDENDS PAID SINCE LISTING

UNDERLYING PROFIT

-

m

m

m

m

m



-

m

m

m

m

m

m



ANNUAL REPORT 2021

7

Investing in innovation
We have innovated more than ever in

the past year.

The pandemic meant we needed to

work in a completely different way, and

it brought technology to the fore.

The pioneering investment we made all

those years ago in myRyman – which

moved our care records into the digital

space – paid dividends.

We will continue to innovate in the year

ahead. With the help of technology,

we will lift the experience of our

independent residents to a whole new

level including health monitoring and

medication management.

We will be staging our own version of

the Tokyo Olympics – an opportunity to

empower our residents to compete, do

things they never thought they could,

and demonstrate where technology

can take us next.

Our residents are overwhelmingly

positive about their lives, and our

survey results during COVID-19

showed how much they appreciate

what we do.

We cannot rest on our laurels; we

will keep working to find the next

improvement or innovation that will

make their lives even better.

Introducing new Rymanians to the team

We continued to strengthen the skillset of our board and

senior executive team during the year.

In March we welcomed Greg Campbell to the board. Greg

is a well-respected CEO, who has strong governance and

commercial skills and has held a number of chief executive

and director roles across Australasia.

Most recently Greg has done a great job leading the team

at Ravensdown Limited for many years. Greg has great

insights into sustainability issues, which adds a valuable

new discipline to our governance team.

During the year we appointed Cameron Holland as

Chief Executive in Australia to run our Victorian operations

and drive our growth opportunities in the Australian

market. Cameron is an experienced business leader

having previously worked in the airline and travel industries

and has experience in the aged-care sector at a senior level

in Australia.

We also appointed Chris Evans as our Chief Construction

Officer during the year. Chris is an engineer who has built

a distinguished career in the construction industry in

Australia, including 25 years at John Holland, and most

recently he worked as Chief Assets and Infrastructure

Officer at Sydney Airport.

Gordon MacLeod signals intention to stand down

Group Chief Executive Gordon MacLeod let us know

recently that he had reached a point in his life where

he is keen to try something else after giving 15 years of

extraordinary service to Ryman.

During his 4 years as CEO we have opened 10 new villages,

increased our market capitalisation by $3 billion* and

returned dividends of $448 million to shareholders.

We also achieved our goal of opening five new villages in

Victoria by 2020.

“Our purpose is to provide the

best of care for our residents in

beautiful, sustainable homes.”

* Based on market capitalisation as at date of FY21 announcement.

RYMAN HEALTHCARE

8

“The safety and security
of living in a Ryman village

is more valued than ever.”

As CEO he has demonstrated an extraordinary ability

to relate very positively to the many stakeholders in the

company and has been an authentic leader.

We will be conducting an international search for a

new group CEO. Maintaining our culture of everything

we do being “good enough for Mum or Dad” is of the

utmost importance.

We are very fortunate that Gordy has committed to stay

on until a suitable replacement is found, and he will be

leaving Ryman in a great position.

I would like to thank him very much on behalf of the board

and everyone at Ryman.

Our purpose remains unchanged

As a board we are acutely aware of our intrinsic purpose as

a company and the role Ryman plays in the communities

it operates in, as well as the importance of purpose to our

staff and many stakeholders.

Our purpose is to provide the best of care for our residents

in beautiful, sustainable homes. Our work is greatly valued

by the communities we operate in.

I suggest our purpose is what drives the collaboration,

innovation, commitment and creativity of our teams and

our stakeholders.

That’s why we’re called Ryman Healthcare. The name says

it all. We care for people.

Competitive returns to shareholders are essential to the

company’s success. These returns help provide the funds

to achieve our purpose.

We have not achieved this target recently for a variety

of reasons, but the board and management of this

company are very focussed on restoring this level of

return to the owners of Ryman as we move out of the

restrictions of a global pandemic, especially in our key

growth market of Victoria.

Thank you

Our result for the year is very credible

given we were operating during the

worst pandemic in 100 years.

We have kept everyone safe, and

we have continued to grow, innovate

and develop.

We’ve proven that our model of care is

a critical part of the infrastructure of

the communities we serve.

The safety and security of living in a

Ryman village is more valued than ever

by our residents and their families,

and we are expecting demand for our

services to continue to grow in the

years ahead.

We are looking forward to what comes

next – and we are certainly well

prepared.

This company has enormous potential

and I look forward to reporting back on

our achievements in 12 months.

Thank you, as always, for your support.

Dr David Kerr

CHAIR, RYMAN HEALTHCARE

ANNUAL REPORT 2021

9

We partner with over 3,500 businesses who supply goods
and services to our villages, offices and construction sites.

In New Zealand

we have 5,563

team members

and in Australia

we have 604.

We provided more than

8 million hours

of care and services

last year.

We’ve donated over

$4 million

to New Zealand and

Australian charity

partners since 1999.

We support the health,

safety and wellbeing of over

6,100 team members

and 12,500 residents.

Stats and facts

We have offices

in Christchurch,

Auckland and

Wellington

in New Zealand

and Melbourne

in Australia.

18,500

Zoom calls

were made by care

residents to their families

during COVID-19.

RYMAN HEALTHCARE

10

736 beds and units were built in FY21.
We’ve added 2,236 care beds and 5,096 units over the last 10 years.

41 villages

villages in New Zealandsites in New Zealand

villages in Australia

36 10

5

Over $1 billion

in dividends

has been paid

to shareholders

since listing.

declaration forms

52,000

have been completed by

visitors to keep COVID-19

out of our villages.

16

sites

sites in Australia

6

in the pipeline

We recycled

1,021 tonnes

of green waste into

compost last year.

We had over

27 cranes

operating across our

construction sites.

ANNUAL REPORT 2021

11

Group chief executive’s report
Ryman residents Pat Mansell, Bruce Mansell and Kay Johnston with group chief executive Gordon MacLeod.

RYMAN HEALTHCARE

12

We faced a number
of unprecedented

challenges during

the year. We’ve

kept innovating and

improving, and as a

result we are in a strong

position to grow in the

years ahead.

GORDON MACLEOD

GROUP CHIEF EXECUTIVE, RYMAN HEALTHCARE

13

ANNUAL REPORT 2021

My highlight of the year is the way we kept
our villages free of COVID-19.

Keeping more than 18,600 residents and staff

across 41 villages and 12 construction sites

safe was a remarkable achievement.

Leading a team that has been so committed

and professional – and consistently so – is an

absolute privilege.

I am delighted that their work is so well recognised by

our residents. We won the Most Trusted Brand award

for our industry for the seventh time.

We do not take anything for granted. COVID-19 is a

tricky virus and things can change very quickly. We

are always on alert.

The COVID-19 vaccine programme is under way and

we’re encouraging everyone to take part. Take-up by

our residents and staff has been excellent.

Five villages in Victoria

Another highlight was reaching our

long-held stretch target of getting

five villages open in Victoria by the

end of 2020.

Our team in Australia has done a

wonderful job.

They spent half of last year under

lockdown, they kept everyone safe,

the construction team had to adapt to

multiple COVID-19 level restrictions,

and the sales team came out with great

February and March sales numbers

once the restrictions eased in Victoria.

We have built an extraordinary amount

of goodwill and almost 1,000 residents

in Australia now call our villages home.

A strong finish to the year

We ended the year with a flourish,

recording the highest number of

transacted sales ever in the final

quarter of a financial year.

Our reported IFRS profit was higher

than $400 million for the first time and

we had record cash collections in the

second half of $693 million, up

26.7 percent on last year.

Total cash receipts from residents

were a record $1.18 billion, an increase

of 4.1 percent and we finished the

year with $397 million of committed

new sale contracts in place. This is a

record year-end amount and this

cash will be collected over the next

12 to 18 months.

2021

A

g

e

d


C

a

r

e


&


R

e

t

i

r

e

m

e

n

t


V

i

l

l

a

g

e

s

A

g

e

d


C

a

r

e


&


R

e

t

i

r

e

m

e

n

t


V

i

l

l

a

g

e

s

RYMAN HEALTHCARE

14

“Leading a team that has been
so committed and professional

is an absolute privilege.”

This was a solid achievement given the

significant shutdowns experienced in

our two key markets. Heading into FY21,

we were expecting half of our growth

to come from Victoria, where it was

almost impossible to transact with new

residents for nearly 6 months. And in

Auckland, which is our biggest market

in New Zealand, we experienced level 3

lockdowns or above for 20 percent of

the year.

We are in a healthy financial position

with total assets of $9.17 billion, up

19.5 percent on last year. Shareholders’

equity has lifted by 23.0 percent to

$2.83 billion.

Available resales stock at 31 March was

only 1.4 percent of the portfolio, down

from 1.9 percent at 30 September.

Our low resale stock, combined with

mature care occupancy of 97 percent,

demonstrates that our villages

continue to be in strong demand.

In a year when we faced increased

operating costs and could not trade

or build for a significant amount of

time, I am pleased with what the

team has achieved.

CASH RECEIPTS FROM RESIDENTS

TOTAL ASSETS

-

ff())m

ff())m

ff())m

ff())m

ff()–––m

m



First halfSecond half

Interest-bearing debtTotal assets

-

ff(bn

ff(bn

ff(bn

ff(bn

ff()bn

Sep ff(

Mar ff(

Sep ff(

Mar ff(

Sep ff(

Mar ff(

Sep ff(

Mar ff(

Sep ff(

Mar ff(

Sep ff(

Mar ff(

Interest-bearing debt represents ‘interest-bearing loans and borrowings’

in the balance sheet.

ANNUAL REPORT 2021

15

Victorian land bank
We have recently added a new site in

Essendon, which replaces our nearby

Coburg site in the north of Melbourne.

The Essendon site is medium density

and is a more attractive prospect than

the high-rise Coburg site, which we

have sold.

We’ve got happy residents and strong

sales at Ocean Grove, John Flynn in

Burwood East and Charles Brownlow

in Highton, and our Aberfeldie village is

making great progress.

Aberfeldie will be our next village to

open its doors, our sixth in Victoria.

We are hoping to get going at Ringwood

East and Highett over the coming

months after we have finished the

planning endorsement process – both

sites have development approval.

This means we will have seven sites on

the go in Victoria, matching the seven

sites we are building at in New Zealand.

We continue to be busy in New Zealand

Our construction teams are busy building across seven sites

in New Zealand.

We are about to welcome our first residents at Keith Park in

Hobsonville and Riccarton Park in Christchurch.

Our first residents are settled at Miriam Corban in

Henderson and work is under way on the village centre.

James Wattie in Havelock North is now very established with

townhouse and apartment stages selling well, and work will

start on the care centre later in the coming year.

Development of the latter stages continues at William Sanders

in Devonport, Murray Halberg in Lynfield and Linda Jones

in Hamilton.

Our pipeline of New Zealand projects is growing.

Our development team has secured resource consents

for new villages in Takapuna and Kohimarama in Auckland

and Northwood in Christchurch.

We’ve also added a couple of great new sites in New Zealand.

The Karaka site is a broad-acre property a short drive from

Papakura, and we think it has huge potential in a growing part

of Auckland.

The Cambridge site is suited to a townhouse-style

development. It’s a popular place for retirees and has

a large catchment in a fast-growing region.

“We are in a healthy financial position

with total assets of $9.17 billion,

up 19.5 percent on last year.”

RYMAN HEALTHCARE

16

We significantly diversified our
debt funding

Last year we signalled to the market

that we were looking to diversify both

the source and tenor of our debt and

we achieved this during the year.

We have raised NZ$825 million

across three new debt markets.

In the year to March 2021 we raised

NZ$150 million through a retail bond

offer and US$350 million via a US

Private Placement. In May 2021 we

raised a further AUD$250 million via

an institutional term loan.

The weighted average debt maturity

profile of these three debt raisings is

9 years. This has seen us extend our

weighted average debt maturity profile

of all our interest-bearing loans and

borrowings to 5 years.

Through the debt issuances it

was great to be able to explain our

model to new markets. The response

we received was very positive,

with all three debt raisings heavily

oversubscribed, a further endorsement

of our business model and strength.

Our debt is productive debt

We are building across 12 sites in two countries and we will

soon be under way on another two. This compares with

development across just four sites 3 years ago.

We anticipate the 12 villages we have under way will

generate $2.8 billion in capital proceeds and recurring

income of $220 million on completion.

This level of development requires a large upfront capital

investment and we invested a record $844 million into

our portfolio over the year. This has seen our working capital

debt lift to $2.25 billion.

Our development pipeline of 25 new villages would provide

homes for more than 6,800 residents and would generate

anticipated capital proceeds of $5.3 billion with recurring

income of $420 million, subject to market conditions and

consenting outcomes.

This is why we regard debt as productive. It is predominantly

a function of the working capital required to create new

Ryman communities and these communities generate

growing recurring cash flows for decades.

On top of the $420 million of recurring profits that will

be generated each year from developing and selling down

our land bank, our current earnings will also lift as our existing

portfolio matures.

ANNUAL REPORT 2021

17

myRyman continues to develop
Technology continues to be a focus; we

see huge potential in it to improve the

lives of older people.

Our myRyman Care app is

continuously being developed and it

came into its own during the pandemic.

We are now looking at ways to roll

out new myRyman applications to

our independent residents, giving

them a digital platform to keep up

with village news and to digitise

activities such as health monitoring,

medication management, wellness,

and even everyday activities such

as food ordering, outing bookings

and payments.

We are also reviewing a nurse

practitioner model, which we think will

improve access to care and encourage

better health outcomes.

The model would also recognise the

considerable skills of our nurses and

provide another career pathway for

them, as well as easing the pressure on

our GPs.

We are really looking forward to trialling

these initiatives and getting feedback

from residents.

Sustainable Ryman

We continue to operate as sustainably as we can,

ensuring that we leave the environment in the best

shape possible for the generations to come.

Fundamentally, our whole model of operating has a

sustainable underpinning.

Each village we build creates warm, purpose-built

homes for older people with the care they need on hand.

They’re energy efficient and sustainable.

Our carbon footprint is much smaller than private

homes, our density is greater, and, in most cases, we

are also recycling brownfield sites. The traffic each site

generates is a fraction of a normal suburb.

Our medium-density villages prevent urban sprawl.

They free up homes in pressured housing markets

where demand is outstripping supply. They fit

perfectly with the aim of having people age in place.

By developing and operating our villages we create

thousands of jobs and careers.

“Each village we build creates warm,

purpose-built homes for older people

with the care they need on hand.”

RYMAN HEALTHCARE

18

We are a critical part of the
healthcare infrastructure

The public health systems in

New Zealand and Australia continue

to be under pressure.

When you consider the demand

ahead for dementia care alone –

which research shows will more than

double over the next 30 years – you

can see why our services are going

to be in demand.

It’s imperative that aged care is

seen as a critical part of the

healthcare infrastructure in

New Zealand and Australia.

Now, more than ever, it’s clear that if

the aged-care sector fails to meet this

need it will create a huge burden on

the public system.

Thank you

I’d like to take this opportunity to thank all our shareholders

and stakeholders for your support over my 15 years at Ryman.

It’s been a privilege to have this role, and I’d like to thank all our

incredible team members and residents for their support.

I will be standing down once my replacement is in place, but you

can rest assured it will be business as usual for me until then.

I know I will leave with the company in a great position to grow

– it has huge potential and a wonderful purpose – to provide

retirement homes and care that are “good enough

for Mum or Dad”.

Gordon MacLeod

GROUP CHIEF EXECUTIVE, RYMAN HEALTHCARE

ANNUAL REPORT 2021

19

Current villages under
development

Aberfeldie, Melbourne

Nellie Melba, Melbourne

Riccarton Park, Christchurch

Keith Park, Auckland

James Wattie, Havelock North

Miriam Corban, Auckland

Artist’s impression, Ryman villages under development.

RYMAN HEALTHCARE

20

Linda Jones, Hamilton
Ocean Grove, Victoria

William Sanders, AucklandMurray Halberg, Auckland

Charles Brownlow, Victoria

John Flynn, Melbourne

“We are building

across 12 sites,

up from just four

sites 3 years ago.”

Gordon MacLeod

GROUP CHIEF EXECUTIVE

ANNUAL REPORT 2021

21

Future villages in
our pipeline

Essendon, Melbourne

Highett, Melbourne

Northwood, Christchurch

Kohimarama, Auckland

Karaka, Auckland

Mt Martha, Victoria

Artist’s impression, Ryman villages in the pipeline. Map data:

Google © 2021. Site boundaries are indicative only.

Jeremy Moore

CHIEF DEVELOPMENT OFFICER

“We have 13 sites

in our land bank

providing us with

a great platform

for growth.”

RYMAN HEALTHCARE

22

Cambridge
Newtown, Wellington

Mt Eliza, Victoria

Takapuna, Auckland

Park Terrace, Christchurch

Karori, Wellington

Ringwood East, Melbourne

ANNUAL REPORT 2021

23

We have a well-consented
pipeline of villages, which

gives us a great platform

for growth.

RYMAN HEALTHCARE

24

Our pipeline of villages
DesignVillagesConsentingConstructionVillage openFinal

stages

Council

approval

The pipeline is subject to resource and building consent and various regulatory approvals.

William Sanders

Charles Brownlow

Nellie Melba

Murray Halberg

Linda Jones

John Flynn

Miriam Corban

James Wattie

Ocean Grove

Aberfeldie

Keith Park

Riccarton Park

Highett

Ringwood East

Takapuna

Northwood

Kohimarama

Park Terrace

Mt Eliza

Karori

Mt Martha

Newtown

Cambridge

Essendon

Karaka

ANNUAL REPORT 2021

25

Our directors
Dr David Kerr (Chair)

CNZM, MB CHB, FRNZCGP

David joined Ryman’s board in 1994 and has held the role of chair since

1999. A general practitioner, David is a fellow and past president of the

New Zealand Medical Association and was awarded a Fellowship with

Distinction by the Royal New Zealand College of General Practitioners.

He is chair of Centercare Limited and a director of Forté Health. David

was made a Companion of the New Zealand Order of Merit in the 2020

New Year’s Honours List.

Geoffrey Cumming

BA (HONS), MSC (ECON), LLD

Geoff re-joined the board in June 2018, having previously served as a

director from 1999 to 2000. Geoff is a Melbourne-based New Zealand

citizen who is an economist, investor and philanthropist. He has more

than 30 years’ experience as a chief executive and as a company

director and has served on more than 25 corporate boards in a wide

range of countries and industries. In 2019 Geoff was inducted into the

Alberta Business Hall of Fame.

Paula Jeffs

BA, GRAD DIP (IR), GAICD, CAHRI

Paula is a Melbourne-based human resources executive with experience

across the healthcare, finance and government sectors and deep

expertise in workforce planning, organisational capability and executive

coaching. In the early stages of her working life, Paula spent several years

as a carer in the aged and disability sector. Paula joined the board in 2019.

George Savvides

AM, BE (HONS), MBA, FAICD

George lives in Melbourne and has extensive experience in Australia’s

healthcare industry. In 2016 George retired as managing director of

Medibank, Australia’s largest health insurer, after 14 years in the role.

George joined Ryman’s board in 2013. He is chair of SBS (Broadcasting),

a non-executive director of IAG (Insurance Australia Group) and a

Fellow of the Australian Institute of Directors. In 2020 George was made a

Member of the Order of Australia for significant service to the community,

charitable groups and business.

26

RYMAN HEALTHCARE

Jo Appleyard
LLB (HONS)

Jo is a partner at Chapman Tripp. She is a skilled advocate and litigator

specialising in commercial, employment, and resource management law.

Jo was a member of the NZ Markets Disciplinary Tribunal between 2011

and 2020. Jo joined the board in 2009.

Anthony Leighs

NZCB

Anthony is managing director of Leighs Construction, which he founded in

1995 and built into one of New Zealand’s leading commercial construction

contractors. He is a former chairman of the New Zealand Registered

Master Builders Association. Anthony joined the Ryman board in 2018.

Warren Bell

MCOM, FCA

Warren joined the board in 2011. He is an experienced public and private

company director and was previously an audit partner. Warren is

currently chair of Hallenstein Glasson and St George’s Hospital, and

is a director of several private companies.

Greg Campbell

MBA (DIST) FNZIM

Greg joined the board in March 2021. He is an experienced chief

executive and board director with more than 25 years’ experience

in leading large organisations across Australasia. Greg has strong

governance and commercial skills, a deep operational understanding

of business and a strong interest in sustainability and climate change.

Claire Higgins

BCOM, FCPA, FAICD

Based in Victoria, Claire is a non-executive director with experience

across a range of sectors in both Australia and New Zealand. She joined

Ryman’s board in 2014. Claire is chair of REI Superannuation Pty Ltd and

GMHBA Limited, and holds director positions in the medical device and

philanthropic sectors.

27

ANNUAL REPORT 2021

Our senior executives
Cheyne Chalmers

CHIEF OPERATIONS OFFICER

Cheyne is a registered nurse and has worked in New Zealand and

Australia in senior roles in public health, including as Executive Director

of Residential and Support Services and Chief Nursing and Midwifery

Officer at Monash Health, Melbourne, and has been influential at a

state and national level. Cheyne is also an adjunct professor at Deakin

University in Victoria. Cheyne joined Ryman in 2020.

Gordon MacLeod

GROUP CHIEF EXECUTIVE

Gordy joined Ryman in 2007. He had previously been a corporate

finance partner with PwC and was the finance director of a

London-listed hi-tech engineering company. Gordy has a Bachelor

of Commerce degree and is a Fellow of Chartered Accountants

Australia and New Zealand (FCA). He is a board member of the

New Zealand Aged Care Association.

Cameron Holland

CHIEF EXECUTIVE OFFICER – AUSTRALIA

Cameron is an experienced business leader with over 15 years’

experience leading the commercial and operational arms of some of

Australasia’s largest and most well-known brands including Jetstar

and Lonely Planet. Cameron also has extensive experience in the

aged care, home care and retirement living sector in Australia.

Cameron joined Ryman in 2021.

David Bennett

CHIEF FINANCIAL OFFICER

Dave joined Ryman in 2013 and was promoted to Chief Financial Officer

in 2017. He is a board member of the New Zealand Retirement Villages

Association. Dave has a Bachelor of Commerce degree and is a chartered

accountant. Before joining Ryman, he worked as an accountant and auditor.

28

RYMAN HEALTHCARE

Rick Davies
HEAD OF TECHNOLOGY AND INNOVATION

Rick joined Ryman in 2019. He has a Bachelor of Science degree and

previously worked for 9 years at Trade Me in a variety of senior leadership

roles spanning digital product management, commercial management

and running Trade Me’s new goods marketplace business.

Jeremy Moore

CHIEF DEVELOPMENT OFFICER

Jeremy is an experienced property executive in the retirement sector.

He has been a senior member of the Ryman development team since

2012 and was appointed Chief Development Officer in January 2020.

Jeremy holds a Bachelor of Commerce and Management degree.

Chris Evans

CHIEF CONSTRUCTION OFFICER

Chris is an experienced construction leader with more than 25 years

working for John Holland Construction Group in a range of operational

and senior leadership positions in Australia. Most recently Chris worked

at Sydney Airport, where he was Chief Assets and Infrastructure Officer.

Chris joined Ryman in 2021.

Andrew Crerar

HEAD OF PEOPLE AND CULTURE

Andrew joined Ryman in 2018 as People Development Manager. He was

promoted to Group People Development Manager in 2019 before moving

into his current role in 2020. Prior to this, Andrew completed a Master of

Arts (Economic Psychology) and worked in the public health sector in the

UK and in professional services in New Zealand.

Mary-Anne Stone

ACTING CHIEF SALES AND MARKETING OFFICER

Mary-Anne has over 25 years’ experience in the healthcare sector

in roles ranging from village manager to business development

and general practice management. Mary-Anne has a Masters in

Population Health focused on health systems for ageing populations

and health equity. Mary-Anne re-joined Ryman in 2020.

29

ANNUAL REPORT 2021

Ryman team member Dawn Hunt
with resident Bev Jarvis.

RYMAN HEALTHCARE

30

Who we are
and how we

create value

ANNUAL REPORT 2021

31

We provide beautiful homes and the best of care
for older people.

Our aim is to bring Ryman to as many communities

as we can, providing people with a choice of

quality living options for their retirement years.

We start by finding the right site, ensuring the

village we intend to build meets our feasibility

and sustainability requirements.

It must be the right place, at the right time, and it will

become a critical part of the healthcare infrastructure

of the community it serves.

We build the village and sell down occupation rights to

the units to recycle capital, which is used to invest in the

care centre and the development of other new villages.

We reinvest 50 percent of our underlying profits back

into the company to fund future development. This

reinvestment is needed to meet the extraordinary growth

ahead as the world’s population aged over 75 grows.

Creating value

Ryman Healthcare has been

creating value since 1984 by building

communities where people love to live

and work.

Value is created in the short, medium

and long term by building communities

with a purpose.

Ryman communities are places

where older people can choose to

live in beautiful homes with access to

superb amenities to be enjoyed with

supportive friends and neighbours.

They are places where our residents

can also expect the best of care if their

health needs change.

They are a family hub where children,

grandchildren and great-grandchildren

can visit and feel welcome and at home.

Families know their loved ones have

the comfort, security and dignity that

come with the best of clinical care.

Right at the start, our co-founder Kevin

Hickman described this purpose as

providing care that had to be “good

enough for Mum or Dad”.

Our purpose hasn’t changed since

then. Our aim is the same. We see

it as our privilege to provide these

communities and care.

Every new village we build also creates

value for the broader community,

freeing up homes for new families to

move into. In the 37 years we have

been operating, we have built over

12,000 new homes.

32

RYMAN HEALTHCARE

Using our capitals to build integrated communities
Our business model draws on six capitals to create value over time.

Our people

Our team is our most precious

resource. Ensuring that

we understand, value and

celebrate the differences that

each individual brings with

them is very important to us.

So is their health, safety and

wellbeing. We want them

to love the experience of

working at Ryman, and we

want to do everything we can to

help them to develop and build

long-term careers with us.

Our expertise

Over the past 37 years we have

built a wealth of knowledge

in how to build and operate

communities where people

thrive in retirement and receive

the best of care. The collective

wisdom and experience of

our team, and the systems

we have developed over this

time, are a huge asset, which

we use to our advantage. We

do not sit still. We strive to

improve by listening to our

residents and families and

using the lessons they provide.

Our communities

The communities we serve

have a common social issue

– the growing demand for

the care of older people and

a scarcity of supply and skill.

Each of our 41 retirement

villages provides critical

healthcare infrastructure.

Our new villages are built in

areas where there is unmet

need and they quickly

become an asset to the

wider community. They also

become a social hub for the

communities they serve.

Our relationships

Each village generates a

network of relationships

between residents, their

families, our teams, and

the wider community. Each

village also creates deep

long-term relationships with

local suppliers, contractors

and, of course, a local

workforce. We value these

relationships; we regard them

as the basis of our success.

Our environment

We want to make sure all

our decisions are made with

sustainability in mind, so that

we leave the environment

in a better condition for the

generations to come. We are

committed to a zero-carbon

future, and we are actively

pursuing ways to cut our

greenhouse gas emissions.

Our aim is to lead by example,

so we encourage all our team

and the people who supply us

to think the same way.

Our financial strength

Our long-term success, and

the financial strength it has

created, allows us to reinvest

to create even more value,

as well as generating returns

for shareholders to reward

them for investing in us. Our

view is always long term.

We recognise our investors

have plenty of choice about

where to invest, and we

appreciate their support.

ANNUAL REPORT 2021

33

How we create value over time
G

O

O

D


E

N

O

U

G

H



F

O

R


M

U

M


O

R


D

A

D




























S

T

R

O

N

G


T

E

A

M

S


















L

E

A

D


A

N

D


E

M

P

O

W

E

R


































C

O

M

M

U

N

I

C

A

T

I

O

N


















R

E

S

I

L

I

E

N

C

E


A

N

D


C

O

M

P

O

S

U

R

E

K

I

N

D

N

E

S

S


A

N

D


C

A

R

E


































S

T

R

I

V

E


F

O

R


E

X

C

E

L

L

E

N

C

E

















CARING

FOR OLDER

PEOPLE

Our people

Our expertise

Our

communities

Our

relationships

Our

environment

Our financial

strength

RESOURCES

Build

integrated

retirement

villages

Develop

and support

our team

members

2.

1.

RYMAN HEALTHCARE

34

G
O

O

D


E

N

O

U

G

H



F

O

R


M

U

M


O

R


D

A

D




























S

T

R

O

N

G


T

E

A

M

S


















L

E

A

D


A

N

D


E

M

P

O

W

E

R


































C

O

M

M

U

N

I

C

A

T

I

O

N


















R

E

S

I

L

I

E

N

C

E


A

N

D


C

O

M

P

O

S

U

R

E

K

I

N

D

N

E

S

S


A

N

D


C

A

R

E


































S

T

R

I

V

E


F

O

R


E

X

C

E

L

L

E

N

C

E

















Returns for

providers of

capital

Recycle capital

to invest in

future growth

Freedom to live

with choice

Incomes, security

and wellbeing for

our team

Revenues for our

business partners

VALUE

CREATED

Care now and

into the future

Deliver

world-class

care

Create sustainable

communities

3.

4.

ANNUAL REPORT 2021

35

Freedom to live with choice
Our villages are built to provide freedom of choice

around living options. Residents can choose to live

the way they wish and do their own thing, but know that

they’re part of a supportive community where care and

safety is paramount.

Moving to a retirement village creates a sense of freedom

and liberty for many residents – they feel free of the

obligations of traditional home ownership, and less reliant

on their families for their security and social connections.

Our villages have deep roots into the local community.

These are constantly changing and being renewed as new

residents bring their outside interests and networks into the

village with them.

The pace of life does not stop at our village gates. For many

residents, it speeds up.

Freedom from mowing the lawns, cleaning windows and, in

many cases, cooking duties gives them a new lease on life.

Residents find they have more time for exercise,

volunteering, seeing their friends, building relationships,

enjoying their family relationships, and trying new things.

“I wish I’d done it years ago,” is the common response

from new residents.

When things become difficult – as we found during the

repeated COVID-19 lockdowns of 2020/2021 – the security

and assurance that village life offers comes into its own.

Care now and into the future

We believe it’s our social responsibility to

provide people living in our communities

with the full spectrum of care. We design,

build and operate purpose-built villages

that offer care options from independent

and assisted living through to resthome,

hospital, and specialist dementia care.

Knowing that care is on hand if you need

it is reassuring for our residents and

their families.

We know we can never stand still.

We regularly review our processes

and innovate to make sure that

the care we provide is always of

the highest standard. Through our

rolling refurbishment programme, we

continually reinvest in our existing

villages to maintain the quality of our

asset base and meet the expectations

residents have of a Ryman village.

Our care continues to be recognised as

the best in the industry, with 84 percent

of our care centres in New Zealand

having achieved the ‘gold standard’ of

4-year certification. In Australia, our

care centres are fully accredited.

Our local health partners – whether they

are health boards, GPs or pharmacists

– recognise that we are building critical

healthcare infrastructure for the benefit

of the area. We are on the same team

when it comes to caring for people in

their community.

That means we are top of the list when

there is an older person in need of care

quickly, and families can trust they are

in good hands.

RYMAN HEALTHCARE

36

Incomes, security and wellbeing for our team
Each village we build creates an economic engine in the

community it serves, and its impact ripples out to the

whole region.

A new village creates hundreds of long-term, sustainable

and skilled jobs.

During the peak of construction, up to 400 workers will

be on site each day.

Once it is built, the village becomes a hub which provides

a livelihood for our team members and their families.

Each member of our team is part of a wider community,

and their prosperity, happiness and wellbeing at work

extend out to their families, and further.

Revenues for our business partners

Our network of more than 3,500 suppliers forms part of

the wider Ryman family. Many have been with us since the

beginning and have grown their businesses alongside us.

Our villages also become an economic driver for

local businesses, including food suppliers, hairdressers

and florists.

Returns for providers of capital

Since 1999 we have returned

50 percent of our underlying profit to

shareholders, and we have invested

the other 50 percent for future growth.

This reinvestment creates a long tail of

compounded earnings – the more we

invest, the larger our portfolio grows

and the returns compound over time.

This formula has ensured that our

shareholders share in our success,

and they share in our plans to create

value in the medium and long term by

building a growing network of villages

that are needed to cope with the

ageing population.

More than $1.03 billion in dividends has

been returned to shareholders.

Recycling capital to invest

in future growth

We listed on the NZX in 1999 and

raised $25 million to expand, and to

create value for our shareholders

by building a portfolio of villages to

meet the extraordinary demand for

retirement living we saw ahead as the

population aged.

The value created by our business

model for investors is extraordinary.

Since 1999 we have invested

$5.24 billion in new villages and grown

our total assets to $9.17 billion.

ANNUAL REPORT 2021

37

Christine Crossen,
Ryman resident.

38

RYMAN HEALTHCARE

What matters
most to our

stakeholders

ANNUAL REPORT 2021

39

Identifying what matters most
to our stakeholders

We are responsible to thousands

of stakeholders: from our residents

and their families, our team, and

our shareholders through to our

contracting partners and suppliers in

all the communities we operate in.

Our influence cascades into the

healthcare community, research

organisations, the arts, and hundreds

of community groups.

We see our residents and their families

as our most important stakeholders

– they are the reason we exist – and

we want to know what is important

to them, what we are doing well and

where we need to improve.

In the 2020 calendar year, our

dedicated resident relations team

had more than 15,000 different

contacts with our residents and their

families through our regular survey

activities, and our team members

made a further 9,400 welfare calls to

check on residents during the various

COVID-19 lockdowns.

We know that having happy staff is key to having happy

residents. We constantly seek feedback from our team

members and contractors about what matters most to

them. The different platforms we use to engage with our

wider team include annual staff and contractor surveys –

we undertook more than 10,000 of these last year – weekly

team huddles, one-on-one catchups, focus groups in villages

and a ‘raise an idea’ platform.

To our residents and their families our team are the face of

Ryman. Being where the action is means that our team are

idea generators. They always provide feedback on how we

can improve on the things we do and how we can innovate to

provide even better care. This insight is invaluable to us as

we strive to get better.

We listen to our neighbours to make sure we can make

positive contributions to the success of the local area. Our

team of community relations managers proactively engage

with members of the local community to understand what is

important to them.

Our dedicated investor relations and corporate affairs

managers proactively engage with other stakeholders

in New Zealand and overseas including investors, our

banking partners, regulators, and government. All of these

conversations help us to identify what matters most to

our stakeholders.

We are very conscious that investors have a choice about

where they invest. We want to make sure that investors are

kept informed about Ryman and are comfortable with where

they have chosen to put their money and how we operate.

We review and collate the information received from all

stakeholders and assess its effect on our ability to create

value in the short, medium and long term.

From our discussions, we have identified and grouped the

most material issues into five areas. We cover some of these

issues in more detail throughout this annual report.

RYMAN HEALTHCARE

40

Materiality matrix
SIGNIFICANCE OF IMPACT

STAKEHOLDER IMPORTANCE

Water & waste

management

Sustainable design

Carbon reduction

Capital

management

myRyman

Community

engagement

Resident

experience

Communication

Health, safety

& wellbeing

Diversity & inclusiveness

Care quality

Culture

Profitability

Market dynamics

Supply chain

Staff recruitment & development

Data privacy

Cyber security

Governance

Material issues

CARE AND

COMMUNITY

Resident experience, safety and wellbeing • Care quality and continued

innovation • Communication • Sponsorship and community engagement

PEOPLE

Health, safety and wellbeing • Staff recruitment, development and happiness

Culture of kindness and care • Diversity and inclusiveness

ENVIRONMENT

Carbon reduction • Sustainable design • Supply chain and material choice

Waste reduction and water management

SUSTAINABLE

FINANCIAL

PERFORMANCE

Capital management • Market dynamics and regulation

Growing underlying profit • Corporate governance

TECHNOLOGY

myRyman • Data privacy • Cyber security

ANNUAL REPORT 2021

41

Pam Popenhagen, Ryman resident.
RYMAN HEALTHCARE

42

Caring for
our residents

and our

communities

ANNUAL REPORT 2021

43

Our focus since January 2020
has been on ensuring our villages

are safe havens for our residents

in New Zealand and Victoria.

The agility of our teams to respond in

a crisis and keep our 12,500 residents

and 6,100 staff safe, happy and well is

something you as shareholders can be

immensely proud of.

In 2020, 98.1 percent of our

independent residents rated their

experience of living in a village

as good or very good, and our

serviced apartment residents

gave us a 97.3 percent rating.

Of our residents in care surveyed,

94.2 percent rated us as good or

very good, and 94.4 percent of the

relatives of our residents in care also

rated us as good or very good.

These were our best results ever.

Our strong clinical governance systems and processes

played an integral part in keeping everyone safe.

As a result of the global pandemic, we have further

enhanced our processes with the establishment of an

organisation-wide Infection Prevention and Control

Committee. The committee will monitor our infection

control practices and provide advice on key risks and

issues. This group, which includes external experts, will

also provide oversight to ensure we are meeting the

infection control care standards in Australia and

New Zealand.

of our independent residents rated

their experience as good or very good

of our residents in resthome or hospital

care rated us as good or very good

COVID-19 welfare calls

made by our team

views of our virus

communication web pages

98.1%

94.2%

9,400

50,000

OVER

44

RYMAN HEALTHCARE

We’re working to improve the
wellbeing of older people

Our work to improve the health of older

people through the establishment

of the Ryman Medication Advisory

Committee in 2019 has seen a

reduction in the use of unnecessary

medications prescribed by GPs.

Backed by the insights from data

collected through myRyman Care, the

committee works to support doctors

and nurses in the safe and effective

management of medications.

Medicine groups reviewed in the

quarterly meetings include: hypnotics

and sedatives; antipsychotics;

antidepressants; opioids;

anticholinergics; insulin and oral

hypoglycaemics; anticoagulants;

antiplatelet; and long-term

corticosteroids.

We are also using the wealth of secure

data collected from myRyman Care in

an artificial intelligence project to

identify early indicators of falls. The

outcome of this project has the

potential to create a new tool that

predicts the risk of and thereby helps

prevent falls for our residents.

Revolutionising dementia care

Our myRyman Life model of dementia care has been

recognised globally. Named Innovation of the Year

(Dementia Care Model Solution) at the Asia Pacific

Eldercare Innovation Awards in Singapore, myRyman Life

is the result of research, study, and interviews with people

living with dementia and their family members.

Collaboration with dementia care experts in New Zealand

and the UK has enabled a wealth of expertise and passion

to be incorporated into this innovative model.

myRyman Life care consists of four quadrants and

10 elements of happiness and is supported by a Care

Companion staffing model, three new assessment tools

and a range of new education resources.

It aligns with our core philosophy of kindness by developing

a unique perspective on dementia and equipping the care

team with specialised knowledge and skills to provide

supportive, compassionate care.

Over 90 percent of our 6,100 staff have completed the

four eLearning modules which were introduced in the

latter part of 2020.

The modules have been designed to increase knowledge

and understanding about dementia and provide guidance

on supporting a person with dementia to live a full, happy

and content life, while supporting the shift from task-based

care to experience-based care and from doing to being.

We are immensely proud of our teams for embracing

the core concepts of myRyman Life and melding

this into their daily practice. The new Care Companion

staffing model has recently been launched and we are

expecting to see a significant increase in perceived quality

of life in the moment, and in resident, family and staff

satisfaction scores.

ANNUAL REPORT 2021

45

Our work on dementia extends beyond
the village

We have spoken at a number of conferences

throughout the year on our new model, reaching

audiences in 35 different countries.

In partnership with Otago Polytechnic, our in-house

qualifications specialist has created a new NZQA-approved

Certificate in Person-centred Dementia Care. This is a first for

the industry and has attracted interest from across the sector.

We have begun the next phase of our myRyman Life model

of dementia care, which involves the roll-out of the eLearning

tools to our residents and their families.

We continue to evolve our Delicious menu

Meals are an important part of a resident’s day and during

the year we have further lifted our focus on food.

We’ve reviewed and refined our menus, introducing a new

menu testing process that actively involves residents in the

selection of the food we offer.

A test kitchen has also been created to allow us to test

new menus and experiment with different offerings.

The feedback we have received from staff and residents

has been positive, and we can’t wait to roll out the new

menus across all of our villages over the coming year.

This year we will also launch Saffron, a comprehensive

catering solution that will support our kitchen and front

of house teams from menu design and inventory control

through to resident meal ordering and real-time satisfaction

surveys. This system is a game-changer for foodservice

delivery at Ryman.

Delighting our residents

Through COVID-19, we did a lot more

for our independent residents than ever

before and they told us how much they

valued this.

We wanted to build on this, and we’ve

been actively engaging with our

residents through focus groups to better

understand what they want and how we

can lift our residents’ experience to the

next level.

Over the coming months we will

implement Project Delight across all our

villages. The project will include tailored

activity and lifestyle programmes that

have been co-designed with residents

and are centred around their interests.

Activities include creative writing, art

classes, meditation, learning a language

or instrument, and dance lessons.

Residents at the villages where we

have been piloting this programme

have told us the new activities are

helping them to form new social

connections within the villages.

The use of technology is also playing an

increasingly important role in the lives of

our residents. This year we will deliver

some exciting new digital products.

We will trial emerging smart home

technologies and ways to make it easier

for residents to engage with technology,

including voice. These innovations will

enhance our residents’ ability to stay

connected and engage with activities

in the village as well as improve their

overall health and wellbeing.

RYMAN HEALTHCARE

46

We are a positive force in
our communities

We support dozens of charities,

bowling clubs and arts organisations.

Each year, residents and staff help

choose one principal charity partner to

support. Ryman matches any money

raised for the partner by residents and

staff, so the more they raise, the more

Ryman donates.

Over the years we’ve donated more

than $4 million to New Zealand and

Australian charity partners, and last

year we raised $440,000 for breast

cancer awareness in both countries.

Our current charity partners are

Melanoma New Zealand and the

Melanoma Institute Australia. In

New Zealand our sponsorship allowed

Melanoma New Zealand to purchase

a van which is travelling the country

offering free mole checks – and it has

been a runaway success. It’s a life saver.

We continue to support dozens of other

organisations including Alzheimers

New Zealand, Dementia Canterbury,

Age Concern, SeniorNet, Christchurch

City Mission, Auckland City Mission,

and the Antarctic Heritage Trust.

Our support of the Stroke Foundation

is also ongoing. The Ryman-sponsored

blood pressure van has been an

incredible resource for the Foundation,

helping to raise awareness about

stroke and stroke risk factors.

Matthew Mark

CHRISTCHURCH CITY MISSIONER

“We are incredibly grateful

for the ongoing generous

support of Ryman.”

Melanoma New Zealand’s new mobile spot check van.

ANNUAL REPORT 2021

47

Supporting the arts
Our residents love that we support

the arts, and we see it as an

important part of our social licence

to provide assistance wherever we

can through partnerships.

We provided substantial backing

to the Melba Opera Trust, the

Melbourne Symphony Orchestra,

the Dame Malvina Major Foundation,

the Royal New Zealand Ballet,

and the New Zealand Symphony

Orchestra during the year. As well

as providing support for dozens of

artists, the relationships mean our

residents benefit with access to

wonderful cultural events.

“With the support of all our

friends at Ryman, we were

able to give more than

32,000 Kiwis a fairy tale

ending to 2020 with The

Ryman Healthcare Season of

The Sleeping Beauty.”

Lester McGrath

EXECUTIVE DIRECTOR, ROYAL NEW ZEALAND BALLET

Royal New Zealand Ballet Principal Kate Kadow in a publicity image for

The Ryman Healthcare Season of The Sleeping Beauty. Photograph by

Ross Brown.

RYMAN HEALTHCARE

48

Our sponsorship
network

ANNUAL REPORT 2021

49

Lynn Andrews
RYMAN RESIDENT

“It’s wonderful to contribute.

We’re not just sitting around...

We’re not retired just yet!”

COMMUNITY

CONVERSATIONS

50

RYMAN HEALTHCARE

We’ve teamed up with our
residents, the Department

of Conservation, and the

Predator Free New Zealand

network to build traps to

help save New Zealand’s

endangered birds.

Made with love by

Ryman residents

Charles Upham resident Lynn Andrews is the brains

behind the initiative. A retired watchmaker and health

and safety specialist with a hankering for conservation,

he has the patience and attention to detail necessary to

turn a good idea into reality.

The traps mean business. All the materials are

supplied by Ryman, and our residents build them to

DOC’s specifications.

More than 200 have been built and they are being

used to protect endangered birds – including the great

spotted kiwi – in fragile alpine environments.

We’ve set up relationships with the Department

of Conservation and Predator Free New Zealand,

supplying both DOC and community groups.

The result is a win for the environment and for

residents, Lynn says.

Lynn has no shortage of volunteers – including a retired

woodwork tutor and a retired builder – and says the

residents love working for a good cause.

His next plan is to recruit Ryman team members to join

the assembly line and take production nationwide.

ANNUAL REPORT 2021

51

The Ryman Prize recognises innovation that
supports the wellbeing of older people

In 2015 we set out to create the equivalent of a Nobel Prize

for work to improve the health of older people.

Since then the Ryman Prize has been awarded six times by

our international jury, and it has put New Zealand on the map

as a thought leader in elder health.

The 2020 Ryman Prize was awarded to Professor Miia Kivipelto

by the Right Honourable Jacinda Ardern, Prime Minister of

New Zealand.

The award recognises Professor Kivipelto’s more than

20 years of research into the prevention, diagnosis and

treatment of cognitive impairment, Alzheimer’s Disease,

and dementia.

She was inspired to take on the research by the experience of

caring for her grandmother, who lived with Alzheimer’s Disease.

Originally from Finland, Dr Kivipelto is the principal

investigator for the world-leading Finnish Geriatric

Intervention Study to Prevent Cognitive Impairment and

Disability, which is used in 30 countries.

The failure rate in Alzheimer’s Disease drugs under

development is 99.6 percent and no new drugs have been

approved since 2002.

Professor Kivipelto’s research focuses on identifying who

is at risk and finding ways to reduce it. There isn’t just one

solution – there is no miracle cure – but there are a whole

lot of things that can be done.

PREVIOUS WINNERS

2015 Gabi Hollows

(Restoring sight)

2016 Professor Henry Brodaty

(Alzheimer’s research)

2017 Professor Peter St

George-Hyslop

(Neurodegenerative research)

2018 Professor Takanori Shibata

(Robotics)

2019 Dr Michael Fehlings

(Degenerative cervical

myelopathy research)

Miia Kivipelto, 2020 Ryman Prize recipient.

RYMAN HEALTHCARE

52

Keeping in touch
If we are going to get better at what we do, we need to

know what everyone is thinking.

Our team had 26,000 contacts with residents and their

families through regular surveys and COVID-19 welfare

checks, and we are constantly communicating with them

about what’s going on.

They rated our communications during the COVID-19

emergency particularly highly, and we appreciated the

rapid feedback we received to ensure we were on track.

COVID-19 lockdowns required us to communicate

at a whole new level, and to gather different kinds of

information to keep everyone safe.

A check-in and health declaration system to track visitors

was rapidly developed and deployed, along with a visitor

booking system for families. At its peak we handled

1,000 bookings a day and this work was essential to keep

everyone safe and connected.

We successfully deployed Zoom video calling to

approximately 3,600 resident rooms. Since the roll-out,

residents have spent 16,000 hours on Zoom in 18,500

separate video calls.

The Ryman team is connected like never before thanks to

chattR, an organisation-wide collaboration platform built

on the Slack app.

chattR cuts down on email, replaces phones, and provides

instant communication capabilities across our more than

6,100 team members, spanning villages, construction sites

and offices in New Zealand and Australia.

separate Zoom calls made by care

residents to their families

connections with residents and

families through regular surveys

and COVID-19 welfare checks

18,500

26,000

ANNUAL REPORT 2021

53

Ryman team member Jerry Shi
with resident Aincy Sutcliffe.

54

RYMAN HEALTHCARE

Caring for
our people

ANNUAL REPORT 2021

55

Our people are our
greatest resource,

and they’ve shone for

our residents during

the toughest year in

our history.

RYMAN HEALTHCARE

56

You’ll find the names of all our
team at the back of this report.

They should all take a bow.

Our village teams were on the front

line to keep COVID-19 out. We can’t

thank them enough for the countless

times they went the extra mile, and

the personal sacrifices they made to

keep everyone safe.

Despite the added pressure of

COVID-19, our teams exemplified the

characteristics of what it means to be

a great Rymanian, quickly adapting

to the different lockdown levels and

working together to keep themselves

and our residents safe.

Collaboration between our

technology and people teams

meant that our people were able to

adapt effortlessly to the new, flexible

working arrangements.

Our sales, design, development,

and construction teams also did

a fantastic job coping with the

lockdowns, and through this period

we continued to innovate, develop

and grow.

Lead and empower

We lead others with kindness, clarity

and support.

Kindness and care

Kindness is in our DNA; it underpins

everything we do.

Strong teams

We build positive, trusting teams who

work together as one.

Resilience and composure

We keep going despite the bumps in

the road.

Strive for excellence

We innovate and work hard to earn

our success.

Communication

We use simple, clear language that gets

straight to the point.

CORE CHARACTERISTICS

What it means to be a great Rymanian

LEADERSHIP CHARACTERISTIC

ANNUAL REPORT 2021

57

We won’t compromise on the safety of our people
Our philosophy of ‘do it safely or not at all’ remains the

bedrock of our approach to health, safety and wellbeing.

Safely planning the work we do across our 12 construction

sites is very important to us. Last year our construction

teams completed over 3,200 prestart meetings. These

meetings focus on ensuring everyone understands the tasks

at hand, and that all risks are appropriately managed.

We actively support the construction industry’s efforts to

raise awareness of suicide prevention, and to encourage

people to talk about mental health. In New Zealand we

have partnered with Mates in Construction to provide

support to our teams on site. In Victoria, a Beyond Blue

ambassador works closely with the construction team

to equip them with the skills to identify when people are

struggling and tips on how to listen without judgement.

As part of our wider health, safety and wellbeing strategy,

we embarked on a large-scale change process with our

contractors in New Zealand, requiring them to complete

SiteWise accreditation. This means we can be reassured

they are aware of everything they need to do to maintain a

safe working environment before they set foot on our sites or

enter our villages.

We also introduced mandatory Site Safe Foundation

Passports for everyone working on our New Zealand sites,

and White Cards in Victoria, to ensure everyone is trained to

a minimum standard in health and safety, and aware of the

hazards they face.

During COVID-19 we introduced nurses on all our

construction sites to check temperatures and ensure our

construction teams complied with the rules, and they quickly

became a welcome wellbeing safeguard for our teams.

views of our wellbeing pages

on our website

reduction in high-risk findings from

construction audits

positive safety observations reported

13,675

50%

1,130

We provided free wellbeing resources

through a dedicated website during

COVID-19, and our internet traffic

took off, with our wellbeing pages

receiving 13,675 views during the year.

The resources included everything

from mental health and diet tips to

online exercise classes, and we were

recognised for our work in the annual

Human Resources New Zealand awards.

RYMAN HEALTHCARE

58

Our priority areas in
people and safety

Achieving risk

management excellence

1

Evolving worker

engagement and

participation initiatives

2

Enhancing health,

safety and wellbeing with

our wider Ryman family

3

Developing Ryman

leaders

4

Strengthening the

health and wellbeing

of our people

5

Measuring our success in health, safety

and wellbeing

We have identified key measures to help us continuously

monitor our progress and measure our success in health,

safety and wellbeing. We will regularly assess our impact and

progression and we will use the results to adjust accordingly

to achieve our vision of everyone home safe and well.

MEASURE

Number of events with high potential consequence

Incident and near miss reporting rates

Results from health, safety and wellbeing staff

engagement survey

Absenteeism rates

Staff turnover rates

Number of team members with an annual leave balance

greater than 30 days

Results of health and safety audits and actions completed

Percentage of planned safety observations completed,

and corrective action taken

Completion rates of safety leadership and risk

management training

Rate of engagement with health and wellbeing campaigns

ANNUAL REPORT 2021

59

We recognise the value of our people
Our people underpin our success. We are committed to the

ongoing training and development of our team and ensuring

career progression opportunities within Ryman.

We know that to continue to exceed expectations we need

people who have the right skills, confidence and knowledge,

and a culture that supports innovation, excellence, safety

and kindness.

Our challenge is to continue to attract, recruit, retain and

develop highly capable, passionate people and safeguard a

culture that enables them to perform at their best every day.

Our commitment to developing our people saw us establish

the Ryman Academy in 2018. The Academy now offers

qualifications in a range of specialist professions, including

caregiving, nursing, carpentry, gardening, cookery, and health

and safety.

We recognise the importance of having strong and

capable leaders. Our Ryman Leaders LEAP and Aspiring

Leaders programmes have been specifically designed to

improve the skills of our leaders and support them to lead

and grow their teams. Over 700 of our current and emerging

leaders have received development training through our

bespoke programmes.

We measure the outcome of our investment in developing

our leaders and the benefits this has for our teams through a

range of recognised measures.

Over the last 3 years we have seen

significant improvement across

a number of measures including

leadership effectiveness, staff

turnover, and our staff Net Promoter

Scores (NPS).

In fact, our staff NPS is the highest it

has ever been since we started using

this measure of engagement and

shows that our people are happier

than ever.

In the year ahead, we plan to

launch new development options in

construction management, village

management and sales management

while increasing our focus on

high-quality training and education

for our clinical teams.

“Our staff NPS is the highest it

has ever been and shows that our

people are happier than ever.”

Andrew Crerar

HEAD OF PEOPLE AND CULTURE

RYMAN HEALTHCARE

60

A great resident experience depends on staff
who are passionate about caring

It takes great people to find great people. And when your aim

is to put your residents at the heart of every decision, who

better to help recruit than residents themselves.

So, we harnessed the power of our residents to sit on our

interview panels, helping to quiz new recruits for top jobs.

The #PioneersWanted recruitment campaign, starring

Ryman team members and our resident recruiters, received

over 40,000 views and was a runaway success.

We’ve launched a programme for new graduates

During the year we launched a new graduate programme

which is aimed at giving a group of young leaders a chance

to blaze their own trail with us.

Our graduates are offered the chance to work in different

parts of the company, learn about it, and position themselves

for a career in leadership with us in an area that interests

them, and is suited to their skills.

Each year a new intake begins a two-year journey with us,

and the graduates work on rotation through three different

placements. They can work in village roles, office, or sales

positions or on our construction sites. We’ve tailored the

programme to give them a taste of what it is like to work

across Ryman, understand our culture and get their career

off to a flying start with us.

We celebrate the differences that

each person brings to Ryman

We are an ethnically diverse company.

Over one-third of our workforce was

either born outside New Zealand or

Australia or identifies with more than

one nationality.

Ensuring that we understand, value

and celebrate the differences that

each individual brings with them is

important to us. Woven throughout

the characteristics we look for in all

Rymanians are care, compassion and

understanding for others, treating

everyone with respect and dignity,

working together as one, and making

everyone feel welcome and equal.

As part of our ongoing education

around diversity and inclusion, we

will be rolling out workshops to educate

and inspire team members to continue

building an inclusive culture, challenge

their own innate biases and act as allies

for one another.

In the coming year, we will establish a

diversity and inclusion forum drawing

together people from across the

business. Their role will be to help drive

forward initiatives to continually grow

our cultural intelligence.

Our resident recruiters.

ANNUAL REPORT 2021

61

COMMUNITY
CONVERSATIONS

62

RYMAN HEALTHCARE

Albie Calope says he is
a confident person, but

“confidence is like a muscle –

you have to keep using it”.

Albie was the inaugural winner in 2019

of the Kevin Hickman Award presented

to the Ryman team member who best

exemplifies excellence in care and

leadership, while being empathetic and

kind at the same time.

Albie began working for Ryman in

2016 as the clinical manager at

Malvina Major Retirement Village

in Wellington.

“I like working for a company and with

people who are success driven and

focused on providing the very best

care for our residents,” he says. “But

I also value the Ryman concept of

care and kindness and the supportive

workplace environment.”

While working as clinical manager,

Albie was always ready to take on

new responsibilities. At times he

deputised for the village manager,

assisted with certification audits and

also worked at other villages when

needed, which he says gave him the

opportunity to learn more.

He has shown a willingness to step up and help, which was

crucial during the COVID-19 lockdown period.

He praises Ryman for offering him these opportunities,

including the LEAP leadership development programme, and

recognising his ability and commitment to his role in the village.

“I have always wanted to progress my career, climb the

ladder, and Ryman has given me those opportunities.

“I am focused on reaching out to the community and

creating strong relationships with the DHB and ensuring

that Malvina Major Retirement Village is recognised as a

place of clinical excellence.

“When the village manager’s position became available,

I believed I was capable of the role and I was the right

person for the job. I was already acting village manager

and, as they say, ‘the show needs to go on!’. Someone

needs to be the leader and that person was me.

“It is an honour and a responsibility to manage the village;

to ensure I retain high-quality, happy staff and deliver the

best of care for residents. This is their home and I am there

for them and their families.

“A big part of my role focuses on supporting my team to do

the best job they can.”

Albie aspires to be the best at what he does. His immediate

plans are to achieve ‘gold standard’ 4-year certification in

next year’s audit at Malvina Major.

The future, he hopes, may lead to further responsibilities,

but Albie is leaving nothing to chance.

“I feel so excited every day to come to work. I have the

passion, the energy and motivation to do it. I want to excel

in everything I do.”

Building a career

with Ryman

ANNUAL REPORT 2021

63

Victor Thompson, Annette Thompson
and Carol Thompson, Ryman residents.

RYMAN HEALTHCARE

64

Caring for our
environment

ANNUAL REPORT 2021

65

The homes we build
are energy efficient

and sustainable and

help to free up existing

homes in communities

where demand is

outstripping supply.

RYMAN HEALTHCARE

66

Our aim is to do the very best we
can for the environment.

We want to leave it in good shape

for the generations to come.

Our residents, our team and our

investors all share this goal.

Our aim is to balance this with our

responsibility to our residents.

We will never compromise on

their care, comfort and safety.

Our villages are energy efficient

in their design, we help to free up

homes in the local community

and we reduce the vehicle traffic

in the areas around our villages.

The care of our residents is our number one priority. Our

business model revolves around caring for older people.

The decisions we make as a business will always have care

at the heart. We believe that we can do this sustainably, with

less impact on the environment.

We recognise that our ongoing village operations will always

have a carbon cost associated with them. We regard this

cost as unavoidable for the moment.

For example, we cannot compromise our heating and

safety systems. These systems require significant amounts

of power to operate. Where we can, we only purchase

electricity generated through renewable sources to power

these systems. In New Zealand 80 percent of the energy we

use is from renewable sources.

We have done the basics, including switching our car fleet to

EVs and hybrids, replacing inefficient lights with LEDs and

diverting waste into recycling.

We also use our existing natural capital, our gardens and our

excess land, to plant trees to offset the carbon we produce.

Our construction operations are an area where we have

made great inroads on recycling and diverting waste from

landfill. In Auckland and Victoria, all construction waste is

being taken off site to be sorted by our waste providers. We

are currently recycling, on average, just over 80 percent of

construction waste from these sites.

We have adopted 11 Principles of Sustainable Design

and we are a member of the Green Building Council,

which gives us access to the latest ideas and advances

in sustainable building.

We are looking at the way we design and procure, and we

are building whole-of-life costs into our feasibility studies.

ANNUAL REPORT 2021

67

Our Principles of Sustainable Design
Our objective is to maximise, as far as practicable, the use of sustainable design principles in our

architectural design processes.

DESIGN PRINCIPLESTRATEGY

It’s all about our

residents

To keep our residents’ care, comfort, security and accessibility needs

at the heart of all our design decisions.

Treat as unique

To treat each design project as separate and ‘unique’ and to

incorporate specific local environmental and community aspects

into each project.

In it for the long haul

To deliver functional, durable and aesthetically pleasing designs that

will last.

Energy efficiency

To maximise energy efficiency through innovation, an open-minded

approach and the effective use of modern technology.

Keep it natural To utilise natural lighting and ventilation wherever possible.

Efficient water use

To design and implement efficient water management strategies

and systems.

Manage waste To incorporate designs that minimise waste as far as practicable.

Maintain wellbeing To specify and use low or non-toxic materials wherever possible.

Make the impact low

To consider environmental impacts as a key factor in our design

decisions, and minimise any impacts as far as practicable.

A sense of community

To incorporate the needs of local communities and related

infrastructure into our design processes.

Stay informed

To communicate sustainable aspects of projects for informational

and educational purposes.

RYMAN HEALTHCARE

68

We have been measuring our carbon footprint with the
help of Toitū Envirocare since 2018 and our greenhouse

gas (GHG) emissions are certified in accordance with

ISO 14064-1 standards. Our initial carbon reduction

commitment when we joined Toitū was to achieve a

5 percent reduction per $M turnover, covering a total

of Scope 1, 2, and 3 programme-mandatory emissions,

by the year 2023.

Following a 14 percent reduction in our carbon emissions per

$M turnover since 2017, we have lifted our target intensity to

30 percent per $M turnover by 2023.

In 2020 we saw an increase in our total emissions. This was

primarily driven by an increase in electricity consumption in

Australia as we opened new villages.

Unlike New Zealand, where 80 percent of the electricity

we use is renewable, coal and gas account for around

90 percent of Australia’s electricity generation.

As such, as we open further new villages in Australia we will

see an increase in our carbon footprint.

However, we will continue our efforts to minimise this impact.

We have incorporated a number of design features into

our Aberfeldie village in Melbourne which will result in a

28 percent saving on heating and cooling consumption for

apartment residents. We are currently considering further

initiatives that will help to offset emissions across the group.

Guarding against climate change

With climate change, weather events are becoming more

extreme.

When choosing a site we look to see if it is susceptible to the

impact of changes in weather- and climate-related risks.

We have emergency plans in place for every contingency,

and all our care centres have emergency power generators

on site as a safeguard. Our emergency power generators

were used 83 times in the year to 31 March 2021.

fiffiflflfl

fiffiflffiffiffi

fififfiflflfl

fiffiflffffff

fiffiflffffff

fi

fiffiflflfl

fiffiflflfl

fiffiflffffff

fiffiflffffff



BASE



TOTAL GROSS EMISSIONS LHS

NUMBER OF RESIDENTS RHS

ELECTRICITY

NZ 

ELECTRICITY

VIC 

NATURAL GAS



AIR TRAVEL





WASTE



FUEL













BASE



TOTAL GROSS GHG EMISSIONS (tCO

2

e)

GHG OPERATIONAL EMISSIONS

BY SOURCE

TOTAL GROSS GHG EMISSIONS PER

$M TURNOVER (tCO

2

e)

ANNUAL REPORT 2021

69

COMMUNITY
CONVERSATIONS

Artist’s impression, Aberfeldie village.

70

RYMAN HEALTHCARE

Our most
sustainable village

Ryman’s most sustainable

village is quickly taking

shape in Aberfeldie, Melbourne.

The village includes a host of

sustainable design features

including rain gardens and a

solar energy generation system.

The village’s energy rating is

top of its class and will save

28 percent on heating and

cooling energy consumption for

residents’ apartments.

Designed into its roof space are

158 photovoltaic panels, generating

39.5kW of power for the village.

Its rooftop system will store rainwater for

gardening and for toilets, saving more

than 1.3 million litres of water a year.

The footprint of the village, with low

rise blocks set across the site, meant

that it could be designed to maximise

sun, light and views, making it a

lovely place to live, as well as more

environmentally sustainable.

Features of the new Aberfeldie village include:

• A 7 Star Nationwide House Energy Rating Scheme

(NatHERS) assessment, resulting in a 28 percent

saving for apartment residents on heating and cooling

energy consumption

• A 25 percent saving on heating and cooling energy

consumption in public areas

• A 100,000-litre (100 kilolitre) rainwater tank system which

will provide garden irrigation and toilet flush water

• 100m² of rain gardens which will process stormwater

run-off from the village, resulting in less pollution making

its way into Melbourne’s stormwater system

• A solar generation system with a minimum total capacity

of 39.5kW

• Electric vehicle charging stations provided on site to

encourage electric vehicle use

• Low volatile organic compound (VOC) paints and

certified timber used throughout, which are kinder on the

environment as well as on the specialists using them

• Light-coloured roofing materials, which reduce heat

• Use of the latest thermal window, LED lighting and building

system products to reduce energy consumption

ANNUAL REPORT 2021

71

Alison Sutcliffe and Sandra Humphries,
Ryman residents.

72

RYMAN HEALTHCARE

Providing a
sustainable

outcome

for all

stakeholders

ANNUAL REPORT 2021

73

How we measure our financial performance
Growth in underlying profit is a key metric used within the

business to measure our trading performance. This measure

incorporates our four earnings streams: care fees, management

fees, realised resale gains, and development margins.

Our medium-term target is to double our underlying profit

every 5 years. This equates to annual growth of 15 percent

per annum and we remain committed to achieving this.

We did not meet this target in FY21. While financial

performance is important to all our stakeholders, so

too is the care we provide for older people.

In early January 2020 we made the decision to do everything

we could to keep our residents and staff safe and turn our

villages into safe havens.

A benefit of being a profitable company was that we

were able to spend what we needed to in order to keep

everyone safe. Our response to COVID-19 has totalled

over $50 million and we are now holding pandemic levels

of personal protective equipment for future use.

This investment has been well spent. As a company we

look after more than 12,500 residents and 6,100 staff, and

have over 4,500 contractors across our 41 villages and

12 construction sites. At the date of printing this annual

report, no-one has tested positive for COVID-19.

Our business model allows us

to recycle capital

Ryman’s origins date back to

1984, when our two founders

invested $10,000 to start their first

development. The same model has

evolved to enable us to turn $25 million

into more than $9.17 billion of assets.

Key to our success has been our

ability to recycle our cash investment

in a village while creating a recurring

income stream that grows over time.

This means that by the time we’ve

sold the occupation rights to the

apartments and townhouses in a new

village, it has paid for the construction

of those apartments and townhouses

as well as the community assets

and the care centre of that village.

We continue to target recycling our

cash investment and establish future

recurring income streams.

We expect to collect $2.8 billion of

capital proceeds from the 12 sites

currently under development.

Collectively, those sites will recycle

capital, which is always our objective.

And on completion, these 12 villages

will establish a recurring income stream

of around $220 million per annum that

will continue to grow over time.

RYMAN HEALTHCARE

74

Our debt is used to build new villages
Our debt increased to $2.25 billion, reflecting our expansion into

Victoria and a lift in our construction activity, which sees us now

building across 12 sites. This is our biggest-ever build programme.

The vast majority of this debt is used to fund our land bank

and the development of our new villages. This is why we, and

our funding partners, regard our debt as productive debt. By

the time we have developed and sold down all the villages in

our land bank, we would have very little bank debt while still

generating strong earnings and cash flows.

We’re providing our residents with greater choice

on how to pay for their care

At the end of the financial year we launched refundable

accommodation deposits (RADs) for our aged-care rooms

in New Zealand.

RADs provide our care residents with an alternative way to

pay the accommodation portion for their residential aged care.

To pay for their accommodation, they can now pay either a

daily fee, an accommodation deposit which is fully refunded

when the room is vacated, or a combination of the two options.

RADs are commonplace in Australia. The introduction of

these into our New Zealand business will enable us

to recycle capital more quickly at a village and means the

funding models in both countries are much more aligned.

We are well positioned to meet the demands of

an ageing population

Following a lengthy Royal Commission investigation into

aged care, the Australian Government has committed

a further $17.7 billion to the sector in response to the

recommendation made by the Commissioners.

The government’s 5 year- 5 pillar plan

commits to major reform of home

care, residential aged-care quality

and safety, residential aged-care

services and sustainability, workforce,

and governance.

The plan includes increased funding

for residential aged-care providers

to improve care, service and

contact time with staff along with a

commitment to grow a skilled and

professional workforce.

This commitment has been

well received by the sector, with

demand for what we do stronger

than ever and growing.

Penetration rates in both New Zealand

and Australia have continued to lift, and

the growth opportunities for us in both

markets is supported by an ageing

population and an undersupply of quality

retirement living and care options.

We are well placed to meet these

demands. Our current development

programme is spread across 12 sites in

New Zealand and Victoria, reducing

our construction and sales risks as well

as our exposure to any one market.

We have a well-consented land bank

and it is of a sufficient size that we

are not dependent on any new site

acquisitions to support our build rate

over the next 3 years.

ANNUAL REPORT 2021

75

Helen Thomas, Ryman resident.
RYMAN HEALTHCARE

76

Embracing
innovation

and

technology

ANNUAL REPORT 2021

77

This year we will trial
emerging smart home

technologies and ways to

make it easier for residents

to engage with technology,

including voice.

RYMAN HEALTHCARE

78

Building on myRyman
Our myRyman app revolutionised the

way we approach aged care. The days

of caregivers and nurses handwriting

notes at the nurses’ station have been

replaced with digital record keeping,

an exponential increase in data-driven

insights, and more time for our team

to do what they love doing – spending

time with residents.

We continued to develop myRyman

during the year. We introduced

additional automation and efficiencies

for our carers, along with the ability for

allied health professionals to integrate

to myRyman.

There is more to come. In the next

12 months we plan to expand the

myRyman platform to put technology

into the hands of our serviced and

independent residents. This will allow

residents to easily engage with village

life, build social connections, improve

wellbeing and access care services.

It will also provide a platform for the

rapid delivery of future innovative

services for residents.

Across the wider business we expect

to see a significant improvement in

efficiencies as we continue to evolve

our processes, ensuring they are fit for

purpose and providing our team with

the tools and support they need.

Cyber security remains a critical focus

Our clinical care systems depend on safe and reliable

information systems. As a healthcare provider Ryman

safeguards sensitive information on behalf of many

vulnerable people. We also look after sensitive commercial

information, and failing to safeguard any of these areas puts

us at risk.

As part of our induction process, all new Rymanians

undergo data privacy training. During the year we

launched an ongoing internal cyber security awareness

campaign to train our people. These campaigns focus on

educating people on how to avoid security risks such as

phishing attacks, and on the importance of multi-factor

authentication and secure passwords.

To further improve our cyber security processes several

external reviews and assessments are completed on a regular

basis. Cyber security is dynamic and evolving, so continual

education of our people, and ongoing reassessment of

processes and technology, is fundamental to ensuring the

Ryman environment is as protected as possible.

Rick Davies

HEAD OF TECHNOLOGY

AND INNOVATION

“Our technology teams will remain

relentlessly focused on improving

the resident experience.”

ANNUAL REPORT 2021

79

Ann Groom and Henry Claassen,
Ryman residents.

80

RYMAN HEALTHCARE

Our
f inancials

ANNUAL REPORT 2021

81

We have responded well
to the challenges that

COVID-19 has presented

and we are well placed,

with a strong balance

sheet, to take Ryman to

more communities.

RYMAN HEALTHCARE

82

6-year summary
FOR THE YEAR ENDED 31 MARCH 2021

20212020201920182017

2016

Financial

Underlying profit (non-GAAP)$m224.4242.02 27.0203.5178.31 57.7

Reported net profit after tax$m423.1264.7326.0388.2356.7305.4

Net operating cash flows$m413.1449.8401.4349.3322.8315.5

Net assets$m2,829.22,301.02 ,170.11,940.51,652 .11 ,3 27.5

Interest-bearing debt to interest-

bearing debt plus equity ratio%44%42%38%35%34%29%

Dividend per sharecents22 .424.222 .720.41 7. 815.8

Villages

New sales of occupation rightsno.503513414458600518

Resales of occupation rightsno.925923824825718690

Total sales of occupation rightsno.1,4281,4361,2381,2831,3181,208

Land bank (to be developed)

1,2

no.6,1466,5956,5935,9525,5544,211

Portfolio:

Aged-care bedsno.4,0873,9113,6603,3673,2813,12 1

Retirement-village unitsno.7, 9 8 37,4 2 36,8786,4145,9685,347

Total units and bedsno.12,07011,33410,5389,7819,2498,468

1 Includes retirement-village units and aged-care beds.

2 Of the 6,146 units and beds in the land bank, 2,651 are subject to resource and building consent.

20212020201920182017

2016

Underlying profit (non-GAAP)$m224.4242.02 27.0203.5178.31 57.7

Plus unrealised fair-value movement

on retirement-village units$m201.2(70.9)102.4185.3184.7

151.6

Plus deferred tax movement

$m

12 .693.6(3.4)(0.6)(6.3)(3.9)

Less impairment – loss on disposal

$m

(15.1)-----

Reported net profit after tax$m423.1264.7326.0388.2356.7305.4

Underlying profit is a non-GAAP* measure and differs from NZ IFRS profit for the year. Underlying profit does not have a standardised

meaning prescribed by GAAP and so may not be comparable to similar financial information presented by other entities.

The Group uses underlying profit, with other measures, to measure performance. Underlying profit is a measure that the Group uses

consistently across reporting periods.

Underlying profit includes realised movement on investment property for units in which a right-to-occupy has been sold during the

period and for which a legally binding contract is in place at the reporting date. The occupancy advance for these units may have been

received or be included within the trade receivables balance at reporting date.

Underlying profit excludes deferred taxation, taxation expense, unrealised movement on investment properties, and impairment losses

on non-trading assets because these items do not reflect the trading performance of the Company. Underlying profit determines the

dividend payout to shareholders.

* Generally Accepted Accounting Principles.

ANNUAL REPORT 2021

83

The accompanying notes form part of these financial statements.
84

RYMAN HEALTHCARE

Financial statements
86 Primary statements

86 Consolidated income statement

87 Consolidated statement of comprehensive income

88 Consolidated statement of changes in equity

89 Consolidated balance sheet

90 Consolidated statement of cash flows

91 Notes to the consolidated financial statements

91 Statement of compliance

91 Basis of preparation

91 Measurement base

91 Critical judgements in applying accounting policies

92 Adopting new and amended standards and interpretations

92 Standards and Interpretations on issue but not yet adopted

92 COVID-19

92 Summary of significant accounting policies

100 Other notes

100 Operating expenses

101 Depreciation and amortisation expense

101 Finance costs

102 Income tax

104 Trade and other receivables

105 Property, plant and equipment

108 Investment properties

110 Intangible assets

111 Cash and cash equivalents

111 Trade and other payables

112 Employee entitlements

112 Interest-bearing loans and borrowings

114 Lease liabilities

115 Occupancy advances (non-interest bearing)

116 Share capital

116 Reserves

118 Dividends

118 Related-party transactions

119 Key management personnel compensation

119 Financial instruments

129 Commitments

129 Contingent liabilities

129 Reconciliation of net profit after tax with net cash flow from operating activities

130 Subsidiary companies

130 Segment information

132 Employee share schemes

133 Subsequent events

133 Authorisation

134 Independent auditor’s report

85

ANNUAL REPORT 2021

The accompanying notes form part of these financial statements.
Consolidated income statement

FOR THE YEAR ENDED 31 MARCH 2021

Notes20212020

$000

$000

Care fees359,241333,398

Management fees93,17088,713

Interest received103547

Other income3,2801,225

Total revenue455,794423,883

Fair-value movement of investment properties7416,847144,438

Total income872,641568,321

Operating expenses1(395,306)(349,249)

Depreciation and amortisation expense2(32,368)(28,616)

Finance costs3(19,365)(19,309)

Loss on disposal6(15,102)-

Total expenses(4 6 2 ,1 4 1 )(397,174)

Profit before income tax410,5001 7 1 ,1 47

Income-tax credit412,56193,563

Profit for the year423,061264,710

Earnings per share

Basic and diluted (cents per share) 1584.652.9

RYMAN HEALTHCARE

86

Consolidated statement of comprehensive income
FOR THE YEAR ENDED 31 MARCH 2021

Notes20212020

$000$000

Profit for the year423,061264,710

Items that will not be later reclassified to profit or loss

Revaluation of property, plant and equipment (unrealised)6, 16a195,793-

195,793-

Items that may be later reclassified to profit or loss

Fair-value movement and reclassification of cash-flow hedge reserve16b7,0 57(10,416)

Deferred tax movement recognised in cash-flow hedge reserve16b(1,976)2,916

Movement in cost of hedging reserve16c3,753-

Deferred tax movement in cost of hedging reserve16c(1,051)-

(Loss)/Gain on hedge of foreign-owned subsidiary net assets16d(4,414)1,205

Gain/(Loss) on translation of foreign operations16d16,546( 5,6 74 )

19,915(11,969)

Other comprehensive income215,708(11,969)

Total comprehensive income638,7692 5 2 ,741

All profit and total comprehensive income is attributable to parent company shareholders and is derived from continuing operations.

The accompanying notes form part of these financial statements.

ANNUAL REPORT 2021

87

The accompanying notes form part of these financial statements.
Consolidated statement of changes in equity

FOR THE YEAR ENDED 31 MARCH 2021

Notes

Issued

capital

Asset

revaluation

reserve

Cash-

flow

hedge

reserve

Cost of

hedging

reserve

Foreign-

currency

translation

reserve

Treasury

stock

Retained

earnings

Total

equity

$000$000$000$000$000$000$000$000

Balance at

1 April 201933,2902 5 7,7 7 5(9,643)-(5,876)( 2 7, 4 6 5 )1,922,0492 ,1 7 0,1 3 0

Profit for the year16------264,710264,710

Other comprehensive

income for the year

16

--(7,500)-(4,469)--(11,969)

Total comprehensive

income for the year

16

--(7,500)-(4,469)-264,7102 5 2 ,74 1

Treasury stock

movement

16

-----(4,894)-(4,894)

Dividends paid to

shareholders

17

------(117,000)(117,000)

Balance at

31 March 202033,2902 5 7,7 7 5(1 7,1 4 3 )-(10,345)(32,359)2,069,7592,300,977

Balance at

1 April 202033,2902 5 7,7 7 5(1 7,1 4 3 )-(10,345)(32,359)2,069,7592,300,977

Profit for the year16------423,061423,061

Other comprehensive

income for the year

16

-195,793

5,0812 ,70212,132--215,708

Total comprehensive

income for the year

16

-195,7935,0812 ,70212,132-423,061638,769

Treasury stock

movement

16

-----(3,030)-(3,030)

Dividends paid to

shareholders

17

------(107,500)(107,500)

Balance at

31 March 202133,290453,568(12,062)2 ,70 21,7 87(35,389)2,385,3202,829,216

RYMAN HEALTHCARE

88

The accompanying notes form part of these financial statements.
Consolidated balance sheet

AT 31 MARCH 2021

Notes20212020

$000

$000

Assets

Cash and cash equivalents920,17134,374

Trade and other receivables5542,798425,942

Inventory26,738-

Advances to employees2611,14110,224

Property, plant and equipment61,658,5831,386,072

Investment properties76, 8 3 7, 2785,760,060

Intangible assets842,44438,119

Deferred tax asset (net)432,45622 ,455

Total assets9,171,6097,6 7 7, 2 4 6

Equity

Issued capital1533,29033,290

Reserves16410,606197,928

Retained earnings16f2,385,3202,069,759

Total equity2,829,2162,300,977

Liabilities

Trade and other payables10106,072183,975

Employee entitlements1132,03425,678

Revenue in advance71,81764,301

Derivative financial instruments2028,61123,809

Refundable accommodation deposits113,66674 ,57 1

Interest-bearing loans and borrowings122,274,0931,741,613

Occupancy advances (non-interest bearing) 143,702,2153,247,177

Lease liabilities1313,88515,145

Total liabilities 6,342,3935,376,269

Total equity and liabilities9,171,6097,6 7 7, 2 4 6

Net tangible assets

Basic and diluted (cents per share)155 57.4452 .6

ANNUAL REPORT 2021

89

The accompanying notes form part of these financial statements.
Consolidated statement of cash flows

FOR THE YEAR ENDED 31 MARCH 2021

Notes20212020

$000

$000

Operating activities

Receipts from residents231,176,4011,129,933

Interest received229573

Payments to suppliers and employees(421,135)(345,765)

Receipt from Government for wage subsidy14,227-

Repayment to Government for wage subsidy(14,227)-

Payments to residents(323,810)(315,903)

Interest paid(18,566)(19,047)

Net operating cash flows23413,119449,791

Investing activities

Purchase of property, plant and equipment(219,416)(265,177)

Purchase of intangible assets(9,462)(9,712)

Purchase of investment properties(577,504)(401,612)

Capitalised interest paid(37,179)(34,911)

Advances to employees(917)(2,071)

Net investing cash flows(844,478)(713,483)

Financing activities

(Repayment)/Drawdown of bank loans (net)(36,713)4 2 1 , 874

Proceeds from the issue of retail bonds150,000-

Proceeds from US Private Placement notes416,874-

Dividends paid(107,500)(117,000)

Purchase of treasury stock (net)(3,029)(4,895)

Repayment of lease liabilities (2 ,476)(1,913)

Net financing cash flows417,156298,066

Net (decrease)/increase in cash and cash equivalents(14,203)34,374

Cash and cash equivalents at the beginning of the year34,374-

Cash and cash equivalents at the end of the year2 0,1 7 134,374

RYMAN HEALTHCARE

90

Notes to the consolidated financial statements
FOR THE YEAR ENDED 31 MARCH 2021

The notes to the financial statements include

information which is considered relevant and material

to assist the reader in understanding changes in

the Group’s financial position and performance.

Information is considered relevant and material if:

• the amount is significant because of its size

or nature

• it is important for understanding the results of

the Group

• it helps explain changes in the Group’s business

• it relates to an aspect of the Group’s operations

that is important to future performance.

STATEMENT OF COMPLIANCE

The financial statements presented are those of

Ryman Healthcare Limited (the Company), and its

subsidiaries (the Group). Ryman Healthcare Limited is

a profit-oriented entity incorporated in New Zealand

that develops, owns, and operates integrated

retirement villages, resthomes, and hospitals for the

elderly within New Zealand and Australia.

Ryman Healthcare Limited is a Financial Markets

Conduct Act reporting entity under the Financial

Reporting Act 2013 and the Financial Markets Conduct

Act 2013. Its financial statements comply with these Acts.

The consolidated financial statements have been

prepared in line with Generally Accepted Accounting

Principles in New Zealand (NZ GAAP). The statements

comply with New Zealand equivalents to International

Financial Reporting Standards (NZ IFRS) and other

applicable financial reporting standards.

The consolidated financial statements also comply

with International Financial Reporting Standards (IFRS).

BASIS OF PREPARATION

Accounting policies are selected and applied in a

way that ensures the resulting financial information

satisfies the concepts of relevance and reliability, and

the substance of the underlying transactions or other

events is reported.

The accounting policies set out below have been

consistently applied in preparing the financial

statements for the year ended 31 March 2021.

These policies have also been applied to the

comparative information presented for the year

ended 31 March 2020.

The information is presented in thousands of

New Zealand dollars.

All reference to AUD refers to Australian dollars.

All reference to USD refers to US dollars.

MEASUREMENT BASE

The Group follows the accounting principles

recognised as appropriate for measuring and reporting

financial performance and financial position on a

historical-cost basis, except when:

• certain property, plant and equipment is

subject to revaluation (note 6)

• investment property is measured at fair

value (note 7)

• certain financial assets and liabilities are

measured at fair value (note 20).

CRITICAL JUDGEMENTS IN APPLYING

ACCOUNTING POLICIES

In applying the Group’s accounting policies,

management must make judgements, estimates,

and assumptions about the carrying value of assets

and liabilities that are not readily apparent from

direct sources.

The estimates and associated assumptions are based

on historical experience and various other factors that

are reasonable under the circumstances. The results

form the basis of making the judgements. Actual

results may differ from these estimates.

The estimates and underlying assumptions are reviewed

on an ongoing basis. Revisions to accounting estimates

are recognised in the period in which the estimate

is revised, if the revision affects only that period.

Revisions to accounting estimates are recognised

in the period of the revision and future periods, if the

revision affects both current and future periods.

ANNUAL REPORT 2021

91

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

The following accounting policies and notes contain

information about significant areas of estimation

uncertainty and critical judgements in applying

accounting policies that have the most significant

effect on the amounts recognised in the financial

statements.

• Valuation of property, plant and equipment –

policy (d) and note 6

• Valuation of investment property –

policy (f) and note 7.

ADOPTING NEW AND AMENDED

STANDARDS AND INTERPRETATIONS

In the current year, the Group adopted all mandatory

new and amended standards and interpretations.

STANDARDS AND INTERPRETATIONS ON

ISSUE BUT NOT YET ADOPTED

We are not aware of any NZ IFRS Standards or

Interpretations that have recently been issued or

amended that have not yet been adopted by the Group

that would materially impact the Group for the annual

report period ending 31 March 2021.

COVID-19

The outbreak of COVID-19, declared by the World Health

Organization as a global pandemic on 11 March 2020,

resulted in an increase in uncertainty in both global

and local markets.

Both New Zealand and Australia have responded well

to the virus with strong public health measures and

a range of economic stimulus packages. However,

despite the response, there remains uncertainty

as to the ongoing impact of the virus on market

conditions in New Zealand and Australia. In Australia,

Victoria has been through two waves of infection and

corresponding lockdowns, succeeding in reducing the

spread of infection, and New Zealand has responded

with localised increases in alert level to suppress

transmission of the virus.

Throughout the pandemic the Group’s primary focus

has been to protect the safety of both residents and

staff. When necessary, access restrictions have been

put in place at villages, additional personal protective

equipment has been procured for staff, and other costs

have been incurred in supporting residents and staff.

Under lockdown conditions the ability of new residents

to enter villages is limited, meaning fewer sales can

be settled, and the restrictions at development sites

results in construction activity being reduced. The

Group continues to adapt its policies and procedures

to operate in the conditions created by COVID-19.

The Group has assessed the impact of COVID-19

and has concluded that additional uncertainty

regarding the valuation of property, plant and

equipment (note 6) and valuation of investment

properties (note 7) has resulted from the pandemic.

Further disclosure as to the impact of COVID-19 is

included in the relevant notes.

SUMMARY OF SIGNIFICANT ACCOUNTING

POLICIES

The following significant accounting policies have

been adopted to prepare and present the financial

statements of the Group.

a. Basis of consolidation – purchase method

The consolidated financial statements are

prepared by combining the financial statements of

all the entities that comprise the Group, being the

Company (the parent entity) and its subsidiaries

as defined in NZ IFRS 10 Consolidated Financial

Statements. A list of subsidiaries appears in note

24 to the financial statements.

Consistent accounting policies are used

to prepare and present the consolidated

financial statements. All significant inter-company

transactions and balances are eliminated in full

on consolidation.

The financial statements of subsidiaries are prepared

for the same reporting period as the parent company,

using consistent accounting policies.

Income and expenses for each subsidiary whose

functional currency is not New Zealand dollars are

translated at exchange rates that approximate

the rates at the actual dates of the transactions.

Assets and liabilities of such subsidiaries are

translated at exchange rates at balance date.

All resulting exchange differences are recognised

in the foreign-currency translation reserve, which

is a separate component of equity.

RYMAN HEALTHCARE

92

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

b. Revenue recognition

The Group recognises revenue and income from

the following major sources.

• Care fees

• Management fees

• Interest received.

Revenue and income are recognised as follows.

Care fees

Care-facility and retirement-village service

fees are linked to providing service on a specific

day (service date). Revenue from care and

retirement-village service fees are recognised on

completion of the service date.

Management fees

Residents of the Group’s independent-living units

and serviced apartments pay a management

fee for the right to share in the use of the

village centre and other common facilities. The

management fee is calculated as a percentage of

the occupation-right agreement amount. The fee

accrues monthly, for a set period, based on the

terms of individual contracts.

Management fees are recognised on a straight-line

basis over the period of service.

The period is determined as being the greater of

the expected period of tenure, or the contractual

right to management fees.

The expected periods of tenure, based on

historical experience across our villages, are

estimated to be 7 years for independent units

and 3 to 4 years for serviced units. The estimated

expected periods of tenure are unchanged from

last year.

The timing of when management fees are

recognised is an accounting estimate. Historical

experience across all villages is used in

determining periods of tenure.

Interest received

Interest income is recognised in the income

statement as it accrues, using the effective

interest method.

c. Borrowing costs

Borrowing costs directly attributable to the

acquisition, construction, or production of

qualifying assets (assets that take a substantial

period of time to get ready for their intended use)

are added to the cost of those assets until the

assets are substantially ready for use.

All other borrowing costs are recognised in profit

and loss in the period in which they are incurred.

d. Property, plant and equipment

Property, plant and equipment comprises

completed care facilities, corporate assets and

land (including long-term leases of land), and care

facilities under development.

All property, plant and equipment is initially

recorded at cost. Typically, these costs include

the cost of land, materials, wages, and interest

incurred during the period required to complete

and prepare the asset for its intended use.

Following initial recognition at cost, completed

care-facility land and buildings are carried at a

revalued amount, which is the fair value at the

date of the revaluation, less any subsequent

accumulated depreciation on buildings and

accumulated impairment losses.

Independent valuations are performed with

sufficient regularity to ensure that the carrying

amount does not differ materially from the asset’s

fair value at the balance-sheet date.

Any revaluation surplus is recorded in other

comprehensive income and credited to the

asset revaluation reserve included in the equity

section of the balance sheet, unless it reverses a

revaluation decrease of the same asset previously

recognised in the income statement. In this case,

the increase is credited to the income statement

to the extent of the decrease previously charged.

ANNUAL REPORT 2021

93

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

Any revaluation deficit is recognised in the income

statement unless it directly offsets a previous

surplus of the same asset in the asset revaluation

reserve, in which case the revaluation deficit is

recorded in other comprehensive income.

In addition, any accumulated depreciation at the

revaluation date is eliminated against the gross

carrying amount of the asset, and the net amount

is restated to the revalued amount of the asset.

On disposal, any revaluation reserve relating to

the particular asset being sold is transferred to

retained earnings.

An item of property, plant and equipment is

derecognised on disposal or when no future

economic benefits are expected to arise from the

continued use of the asset.

Any gain or loss arising on disposal of the asset

(calculated as the difference between the net

disposal proceeds and the carrying amount of the

item) is included in the income statement in the

period the item is derecognised.

e. Depreciation

Depreciation is provided on all property, plant

and equipment, other than freehold land, at

straight-line (SL) rates calculated to allocate the

assets’ cost or valuation, less estimated residual

value, over their estimated useful lives, starting from

the time the assets are ready for use, as follows.

• Buildings 2% SL

• Plant and equipment 10–20% SL

• Furniture and fittings 20% SL

• Motor vehicles 20% SL

The estimated useful lives, residual value and

depreciation method are reviewed at the end

of each reporting period, with the effect of

any changes in estimate accounted for on a

prospective basis.

No depreciation is provided for investment

properties.

Right-of-use assets relating to leases are

depreciated on a straight-line basis over the

term of the lease.

f. Investment properties

Investment properties include land and buildings

(including long-term leases of land), equipment

and furnishings relating to retirement-village units

and community facilities, including units and

facilities under development. They are intended to

be held for the long term to earn rental income and

for capital appreciation.

Retirement-village units and community facilities

are revalued on a semi-annual basis and restated

to fair value as determined by an independent

registered valuer. Any change in fair value is taken to

the income statement. The fair value is determined

using discounted cash-flow methodology.

Rental income from investment properties, being the

management fee and retirement-village service fees,

is accounted for in line with accounting policy (b).

g. Intangible assets

Expenditure on research activities is recognised as

an expense in the period in which it is incurred.

An internally generated intangible software

asset arising from development (or from the

development phase of an internal project) is

only recognised if all the following criteria have

been demonstrated.

• It is technically feasible to complete the

intangible asset so that it is available for

use or sale.

• The Group intends to complete the

intangible asset and use or sell it.

• The intangible asset can be used or sold.

• Probable future economic benefits of the

intangible asset can be generated.

• Adequate technical, financial, and other

resources are available to complete

the development and use or sell the

intangible asset.

• The expenditure attributable to the

intangible asset can be measured

during its development.

The amount initially recognised for internally

generated intangible assets is the sum of the

expenditure incurred from the date when the

RYMAN HEALTHCARE

94

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

intangible asset first meets the recognition criteria

listed above. Where no internally generated

intangible asset can be recognised, development

expenditure is recognised in profit or loss in the

period in which it is incurred.

After initial recognition, internally generated

intangible assets are reported at cost less

accumulated amortisation and accumulated

impairment losses, on the same basis as intangible

assets that are acquired separately.

Internally generated intangible assets are

amortised using the straight-line (SL) method at

a rate of 10 percent from the point at which the

asset is ready for use. Amortisation is recognised

in profit or loss.

h. Impairment of assets

At each interim and annual balance-sheet

date, the Group reviews the carrying amounts

of its assets to determine whether there is any

indication that those assets have suffered an

impairment loss. If such an indication exists, the

recoverable amount of the asset is estimated to

determine the extent of any impairment loss.

Where the asset does not generate cash flows

that are independent from other assets, the

Group estimates the recoverable amount of the

cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value

less costs to sell and value in use. In assessing

value in use, the estimated future cash flows are

discounted to their present value. The Group

uses a discount rate that reflects current market

assessments of the time value of money and the

risks specific to the asset, for which the estimates

of future cash flows have not been adjusted.

If the recoverable amount of an asset

(cash-generating unit) is estimated to be

less than its carrying amount, the carrying

amount of the asset (cash-generating unit)

is reduced to its recoverable amount.

An impairment loss is immediately recognised as

an expense, unless the asset is carried at fair value.

In this case, the impairment loss is treated as a

revaluation decrease.

Where an impairment loss subsequently reverses,

the carrying amount of the asset (cash-generating

unit) is increased to the revised estimate of its

recoverable amount. However, this is only to the

extent that the increased carrying amount does

not exceed the carrying amount that would have

been determined had no impairment loss been

recognised for the asset (cash-generating unit) in

prior years.

A reversal of an impairment loss is immediately

recognised as income, unless the asset is carried at

fair value. In this case, the reversal of the impairment

loss is treated as a revaluation increase.

i. Leases

Apart from short-term or low-value assets, leases

are included on the balance sheet through the

recognition of right-of-use assets and associated

lease liabilities. Right-of-use assets are presented

within property, plant and equipment.

At inception of the lease a lease liability is

calculated based on the present value of the

remaining cash flows, discounted using the

Group’s incremental borrowing rate. Subsequently,

the lease liability is adjusted for interest and

lease payments, as well as the impact of lease

modifications. The right-of-use asset is initially

measured at the value of the initial lease liability,

and subsequently measured at cost less

accumulated depreciation, adjusted for any

remeasurement of the lease liability.

Where a lease contract contains both lease

and non-lease components (for example, tower

cranes), the Group does not separate non-lease

components from lease components, and instead

accounts for the whole contract as a lease.

The Group calculates its incremental borrowing

rate with reference to the external borrowing

facilities available to the Group. The incremental

borrowing rate is used to measure lease liabilities.

Depreciation and finance costs associated with

right-of-use assets and lease liabilities associated

with equipment used in the construction of assets

are capitalised as a cost of constructing the asset.

ANNUAL REPORT 2021

95

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

The lease payment for short-term leases and

leases of low-value assets is recognised in the

profit and loss over the lease term.

Long-term leases of land are recognised

within property, plant and equipment and

investment property.

j. Revenue in advance

Revenue in advance represents those amounts by

which the management fees over the contractual

period exceed recognition of the management fee

based on expected tenure.

k. Financial instruments

Financial assets and financial liabilities are

recognised on the Group’s balance sheet when

the Group becomes party to the contractual

provisions of the instrument.

Cash and cash equivalents

Cash and cash equivalents comprise cash on

hand, cash in banks and on-demand deposits,

and other short-term, highly liquid investments

readily convertible to a known amount of cash

and subject to an insignificant risk of changes in

value. This includes all call borrowing, such as

bank overdrafts, used by the Group as part of

its day-to-day cash management.

Financial assets at amortised costs

Trade receivables are held to collect contractual

cash flows. The cash flows are the payment of

principal and interest.

Trade receivables are measured at amortised

cost, less any impairment. This is equivalent to

fair value, being the receivable face (or nominal)

value, less appropriate allowances for estimated

irrecoverable amounts.

The allowance recognised is the lifetime expected

credit losses based on an assessment of each

individual debtor. It is estimated based on the

Group’s historical credit loss experience and

general economic conditions. Expected credit

loss represents the expected credit losses that will

result from all possible default events over

the expected life of the debtor.

Trade receivables are written off when there

is no realistic chance of recovery.

Occupancy advances

Occupation agreements confer to residents the

right of occupancy of the retirement-village unit for

life, or until the resident terminates the agreement.

Amounts payable under occupation agreements

(occupancy advances) are non-interest bearing

and recorded as a liability in the balance sheet,

net of management fees and resident loans

receivable. The resident-occupancy advance

is initially recognised at fair value and later at

amortised cost.

As the resident may terminate their occupancy

with limited notice, and the occupancy advance is

non-interest bearing, the occupancy advance has

demand features and so is carried at face value,

which is the original advance received.

The advance, net of management fee, is repayable

following both the termination of the occupation

agreement and the settlement of a new occupancy

advance for the same retirement-village unit.

Refundable accommodation deposits

Refundable accommodation deposits relate

to deposits held on behalf of residents who

reside in rooms in the care centres in Australia

and New Zealand. Refundable accommodation

deposits confer to residents the right of

occupancy of the room for life, or until the resident

terminates the agreement.

Amounts payable under refundable

accommodation deposits are non-interest bearing

and recorded as a liability in the balance sheet.

As the resident may terminate their occupancy

with limited notice, and the refundable

accommodation deposit is non-interest bearing,

the refundable accommodation deposit has

demand features and so is carried at face value,

which is the original deposit received.

The deposit is repayable following the termination

of the right-to-occupy.

RYMAN HEALTHCARE

96

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

Trade and other payables

Trade and other payables are measured at

amortised cost. This is equivalent to the face (or

nominal) value of payables, which is assumed to

approximate their fair value.

Interest-bearing loans and borrowings

Bank loans and borrowings are initially recorded

at fair value, less directly attributable transaction

costs. After initial recognition, loans and

borrowings are measured at amortised cost. Any

differences between the initial amount recognised

and the redemption value is recognised in profit

and loss using the effective interest-rate method.

Fair-value estimation

The fair value of financial assets and financial

liabilities must be estimated for recognition and

measurement, or for disclosure purposes.

The face (or nominal) value less estimated credit

adjustments of trade receivables and payables is

assumed to approximate their fair values.

Hedge accounting

The Group designates certain derivatives as

hedging instruments. At the start of the hedge

relationship, the Group documents the relationship

between the hedging instrument and the

hedged item. Risk management objectives and

strategies for undertaking hedge transactions are

documented. The Group also documents at the

start and on an ongoing basis whether the hedging

instrument is effective.

Derivative financial instruments

The Group uses derivative financial instruments

to manage cash-flow interest-rate and foreign-

currency risk.

Interest-rate swaps and cross-currency interest-rate

swaps (CCIRS) are initially recognised at fair value on

the date a contract is entered into and remeasured to

their fair value at each reporting date.

When Group-swap arrangements meet the

requirements of cash-flow hedge accounting,

changes in the fair value of the swaps are

recognised in other comprehensive income and

accumulated as a separate component of equity.

Amounts deferred in equity are recycled in profit

or loss in the periods when the hedged item is

recognised in profit.

When Group-swap arrangements meet the

requirements of fair-value hedge accounting,

changes in the fair value of the swaps are taken

directly to the income statement for the year, to

offset the change in fair value of the hedged item

also recorded in the income statement.

Changes in the fair value of the cost to convert

foreign currency to New Zealand dollars (NZD)

of cross-currency interest-rate swaps are

separately accounted for as a cost of hedging

and recognised within a new reserve within equity

(cost of hedging reserve).

Hedges of a net investment

Hedges of a net investment in a foreign operation,

including a hedge of a monetary item that is

accounted for as part of the net investment,

are accounted for in two ways. Gains or losses

relating to the effective portion of the hedge are

recognised in other comprehensive income. Any

gains or losses relating to the ineffective portion of

the hedge are recognised in profit or loss.

l. Employee entitlements

A liability for benefits accruing to employees for

wages and salaries, annual leave, long-service

leave, and sick leave is accrued and recognised

in the balance sheet when it is probable that

settlement will be required, and the liabilities are

capable of being measured reliably. The liability is

equal to the present value of the estimated future

cash outflows as a result of employee services

provided at balance date.

ANNUAL REPORT 2021

97

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

m. Taxation

Income tax on the profit or loss for the year

comprises current and deferred tax. Income tax

is recognised in the income statement except

when it relates to items recognised in other

comprehensive income or directly in equity. In

this case, it is recognised in other comprehensive

income or in equity.

Current tax

Current tax is the expected tax payable on the

taxable income for the year, using tax rates enacted

or substantively enacted at the balance-sheet date,

and any adjustment to tax payable for previous

years. Current tax for current and prior periods

is recognised as a liability (or asset) if it is unpaid

(or refundable).

Deferred tax

Deferred tax is provided using the comprehensive

balance-sheet liability method. This method

provides for temporary differences between the

carrying amount of assets and liabilities for financial

reporting purposes and the amounts used for

taxation. Deferred tax is not provided for on

non-depreciating assets included within property,

plant and equipment, and investment properties.

The amount of deferred tax provided is based

on the way the carrying amount of assets and

liabilities is expected to be realised and settled.

The tax rates used are those expected to apply

in the period of settlement, based on tax rates

enacted or substantively enacted.

A deferred tax asset is recognised only when

it is probable that future taxable profits will be

available, and against which the asset can be used.

Deferred tax assets are reduced if it is no longer

probable that the related tax benefit will

be realised.

Deferred tax assets and liabilities are offset when

they relate to income taxes levied by the same

taxation authority and the Group intends to settle

current tax assets and liabilities on a net basis.

n. Treasury stock

Shares purchased on market under the leadership

share scheme are treated as treasury stock on

acquisition at cost. On vesting to the employee,

treasury stock shares are credited to equity and

an employee advance is recorded initially at fair

value and later at amortised cost.

Any loss on disposal by the Company (for

example, when the employee elects not to take

full responsibility for the loan or leaves before the

end of the 3-year restrictive period) accrues to the

Company and is taken directly against equity.

o. GST

Revenues, expenses, assets, and liabilities are

recognised net of the amount of Goods and

Services Tax (GST) except when:

• the GST incurred on a purchase of goods

and services is not recoverable from the

taxation authority

• receivables and payables are stated with the

amount of GST included.

The net amount of GST recoverable from,

or payable to, the taxation authority is included

as part of the receivables or payables in the

balance sheet.

Commitments and contingencies are disclosed

net of the amount of GST recoverable from, or

payable to, the taxation authority.

p. Statement of cash flows

The statement of cash flows is prepared exclusive

of GST. This is consistent with the method used in

the income statement.

Cash and cash equivalents comprise:

• cash on hand and demand deposits

• other short-term, highly liquid investments.

Short-term, highly liquid investments are

investments that are readily convertible to a

known amount of cash and are subject to an

insignificant risk of changes in value. These

investments include all call borrowing such as

bank overdrafts used by the Group as part of its

day-to-day cash management.

RYMAN HEALTHCARE

98

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

Operating activities represent all transactions and

other events that are not investing or financing

activities and include receipts and repayments of

occupancy advances.

Investing activities are those activities relating

to the acquisition and disposal of investments

and any other property, plant and equipment, or

investment properties.

Financing activities are those activities relating to

changes in the equity and debt capital structure of

the Group and those activities relating to the cost

of servicing the Company’s equity capital.

q. Foreign-currency translation

Functional and presentation currency

Both the functional and presentation currency of

Ryman Healthcare Limited and its New Zealand

subsidiaries is New Zealand dollars ($). The

functional currency for its Australian subsidiaries

is Australian dollars (AUD).

Transactions and balances

Transactions in foreign currencies are initially

recorded in the functional currency by applying the

exchange rates ruling at the date of the transaction.

Monetary assets and liabilities denominated in

foreign currencies are retranslated at the rate of

exchange ruling at the balance-sheet date.

All exchange differences relating to the following

two items are recognised in other comprehensive

income and accumulated in reserves.

• The effective portion of a hedge of a net

investment in foreign operations

• Differences arising on translation of a foreign

operation.

Non-monetary items that are measured at

historical cost in a foreign currency are translated

using the exchange rate as at the date of the initial

transaction. Non-monetary items carried at fair

value that are denominated in foreign currencies

are retranslated at the rates at the date when the

fair value was determined.

ANNUAL REPORT 2021

99

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

1. OPERATING EXPENSES

20212020

$000

$000

Employee costs (see below)264,400233,549

Property-related expenses54,91146,951

Other operating costs (see below)75,99568,749

Total operating expenses395,306349,249

Employee costs and other operating costs include:

Post-employment benefits (KiwiSaver/Superannuation)8,8427, 2 5 9

Auditor’s remuneration to Deloitte Limited comprises:

• Audit of financial statements358293

• Australia aged-care reporting77

Directors’ fees (note 19)1,0941,011

Donations^433452

^ No donations have been made to any political party (2020: $Nil).

As part of the response to COVID-19, the New Zealand and Australian Governments provided wage subsidies

and other financial support over specific periods during the year to 31 March 2021. This support was available

to eligible businesses to allow those businesses to retain employees and to assist with covering some of the

additional employee costs incurred in protecting aged-care residents. The Group made claims under a number

of the available schemes in New Zealand and Australia.

The Group has applied NZ IAS 20 – Accounting for Government Grants and Disclosure of Government

Assistance in accounting for the funds received from the various COVID-19 subsidies and support packages. Any

funding received has been accounted for as government grants and offset against the expenses to which they

relate in the same period as they are incurred.

In New Zealand the Group made a claim under the COVID-19 Wage Subsidy scheme. The claim was made on a

subsidiary-by-subsidiary basis with not all subsidiaries meeting the eligibility criteria of the scheme. As a result

of the claim, the Group received a total subsidy of $14.2 million. Subsequently the directors made the decision

to repay the New Zealand COVID-19 Wage Subsidy and the full $14.2 million was returned to the New Zealand

Government. Both the receipt and repayment of the wage subsidy occurred in the year to 31 March 2021.

RYMAN HEALTHCARE

100

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

2. DEPRECIATION AND AMORTISATION EXPENSE

20212020

$000

$000

Depreciation (note 6)

• Buildings8,3537,6 8 3

• Plant and equipment10,5988,722

• Furniture and fittings4,3915,477

• Motor vehicles1,4131,338

• Right-of-use assets2 ,4761,787

27, 2 3 125,007

Amortisation (note 8)

• Software5,1373,609

5,1373,609

Total32,36828,616

3. FINANCE COSTS

20212020

$000

$000

Total interest paid on loans and borrowings (including related fees)50,81651,118

Release of cash-flow hedge reserve (note 16)5,3542,859

Release of cost of hedging reserve (note 16)--

Amount of interest capitalised (note 6)(37,179)(34,911)

Net interest expense on borrowings18,99119,066

Interest on lease liabilities (note 13)3 74243

Total finance costs19,36519,309

ANNUAL REPORT 2021

101

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

4. INCOME TAX

a. Income tax recognised in income statement

20212020

$000

$000

Tax expense comprises:

Current tax expense--

Deferred tax credit(12,561)(93,563)

Total income-tax credit(12,561)(93,563)

The income-tax expense on pre-tax accounting profit from operations reconciles to the income-tax expense

in the financial statements as follows.

2021202120202020

$000%$000

%

Profit before income-tax expense 410,500171,147

Income-tax expense calculated at 28%114,94028.0%47, 9 2 128.0%

Tax effect of:

Non-taxable income(116,717)(28.4)%(40,443)(23.7)%

Property temporary differences15,5023.8%(65,7 71)(38.4)%

Tax losses recognised(45,122)(11.0)%(49,967)(29.2)%

Other18,8364.6%14,6978.6%

Total tax credit(12,561)(3.0)%(93,563)(54.7)%

Non-taxable income arises principally from the fair-value movement of investment property.

The tax rate used in the above reconciliation is the corporate tax rate of 28 percent (2020: 28 percent)

payable by New Zealand corporate entities on taxable profits under New Zealand tax law. The corporate tax

rate in Australia is 30 percent (2020: 30 percent).

Total Group tax losses available in New Zealand amounted to $410.7 million (2020: $289.5 million).

Recognition of the deferred tax asset is based on expected taxable earnings in future periods. There are no

unrecognised tax losses in New Zealand (2020: $Nil).

Total tax losses available in Australia amounted to AUD$105.8 million (2020: AUD$71.3 million). Recognition of

the deferred tax asset is based on expected taxable earnings in future periods. There are no unrecognised tax

losses in Australia (2020: AUD$Nil).

RYMAN HEALTHCARE

102

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

4. INCOME TAX (CONTINUED)

b. Taxable and deductible temporary differences arise from the following items.

Opening

balance

Recognised

in income

Recognised

in equity

Closing

balance

$000$000$000

$000

2021

Property, plant and equipment(34,894)(8,292)(40)(43,226)

Investment properties(7,845)(7,210)(508)(15,563)

Deferred management-fee revenue in advance(49,623)(18,868)(401)(68,892)

Cash-flow hedge reserve6,667-(1,976)4,691

Cost of hedging reserve--(1,051)(1,051)

Other5,1321,809116,952

Tax value of loss carry-forwards recognised103,01845,1221,405149,545

Total deferred taxation22,45512,561(2,560)32,456

Opening

balance

Recognised

in income

Recognised

in equity

Closing

balance

$000$000$000

$000

2020

Property, plant and equipment

(58,574)23,64931(34,894)

Investment properties(50,377)42 ,122410(7,845)

Deferred management-fee revenue in advance(26,899)(23,042)318(49,623)

Cash-flow hedge reserve3,751-2,9166,667

Other4,275867(10)5,132

Tax value of loss carry-forwards recognised54,16049,967(1,109)103,018

Total deferred taxation(73,664)93,5632,55622,455

In 2010 legislation was enacted removing tax depreciation on buildings with an estimated useful life of

50 years or more. These rules came into effect from 1 April 2011 (for a standard 31 March income-tax year).

As part of the New Zealand Government’s COVID-19 Economic Response Package, included within

the COVID-19 Response (Taxation and Social Assistance Urgent Measures) Act, which received Royal

Assent on 25 March 2020, depreciation deductions were reintroduced for new and existing industrial and

commercial buildings.

The reinstatement of tax deductions for depreciation increases the tax base of the relevant assets. The Group

has determined that tax depreciation should not be applied to independent townhouses and apartments as

these would meet the definition of a dwelling. Care centres, village centres and serviced apartments are not

considered to meet the definition of a dwelling.

This increase in the tax base created deductible temporary differences which reduced the taxable temporary

differences (deferred tax liabilities) previously recognised.

The impact of these changes was recognised in the tax expense in the 2020 financial year.

ANNUAL REPORT 2021

103

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

4. INCOME TAX (CONTINUED)

c. Imputation credit memorandum account

20212020

$000

$000

Closing balance94163

Imputation credits available directly and indirectly

to shareholders of the parent company, through:

• parent company--

• subsidiaries94163

Closing balance94163

5. TRADE AND OTHER RECEIVABLES

20212020

$000

$000

Trade debtors 498,695410,103

Other receivables44,10315,839

Total trade and other receivables542,798425,942

Debtors are non-interest bearing, although the Group has the right to charge interest on overdue settlements of

occupancy advances or overdue care fees. Debtors principally comprise amounts due for occupancy advances

and care fees.

Occupancy advances are payable by residents on occupation of a retirement-village unit. The receivable for the

occupancy advance is recognised when a legally binding contract with the resident is in place. At the same time as

recognising the occupancy advance receivable the Group recognises the corresponding occupancy advance liability.

Care fees are received from residents (payable 4-weekly in advance) and various government agencies.

Government-agency payment terms vary but are typically paid fortnightly in arrears for care services provided

to residents.

There is no significant concentration of credit risk as trade debtors are either individual residents or government

agencies. No changes have been made in the techniques or significant assumptions used in determining expected

credit losses during the reporting period.

The Group has considered the impact of COVID-19 on trade and other receivables and, given the nature of the

receivables, does not consider there to be any change in credit risk as a result of the pandemic.

RYMAN HEALTHCARE

104

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

6. PROPERTY, PLANT AND EQUIPMENT

Freehold

land at

valuation

Buildings

at

valuation

Property

under

development

at cost

Plant and

equipment

at cost

Furniture

and fittings

at cost

Motor

vehicles

at cost

Right-of-

use

assetsTotal

$000$000$000$000$000$000$000$000

2021

Gross carrying amount

Balance at 1 April 2020328,972391,336584,810100,85252,03813,84920,6011,492,458

Additions1497,906117,09122,9611,2321,0587,4 1 1157,808

Net foreign-currency

exchange difference2 ,6112,27516,7051901464727222,246

Transfer from property

under development12,73431,118(49,359)2,5782,929---

Transfer from property

under development to

investment property--(31,429)----(31,429)

Disposals--(38,072)----(38,072)

Revaluation195,793(17,058)-----178,735

Balance at 31 March 2021540,259415,577599,746126,58156,34514,95428,2841,7 8 1,74 6

Accumulated depreciation

Balance at 1 April 2020-(9,784)-(39,482)(43,235)(8,301)(5,584)(106,386)

Depreciation-(8,353)-(10,598)(4,391)(1,413)(2 ,476)(27, 2 3 1 )

Depreciation capitalised

to property under

development------(6,604)(6,604)

Revaluation-17,058-----17,058

Balance at 31 March 2021-(1,079)-(50,080)(47,6 2 6 )(9,7 1 4 )(14,664)(123,163)

Total book value540,259414,498599,74676,5018,7195,24013,6201,658,583

ANNUAL REPORT 2021

105

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

6. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

Freehold

land at

valuation

Buildings

at

valuation

Property

under

development

at cost

Plant and

equipment

at cost

Furniture

and fittings

at cost

Motor

vehicles

at cost

Right-of-

use

assetsTotal

$000$000$000$000$000$000$000$000

2020

Gross carrying amount

Balance at 1 April 2019321,798359,482444,28482,15047,30511,503-1,266,522

Recognition of right-of-use

asset on initial application

of NZ IFRS 16------13,38113,381

Adjusted balance at

1 April 2020321,798359,482444,28482,15047,30511,50313,3811,279,903

Additions806,483289,74917,5881,9512,3517,3 2 3325,525

Net foreign-currency

exchange difference(584)(182)(3,475)(18)9(5)(103)(4,358)

Transfer from property

under development7,67825,553(3 7,1 3 6 )1,1322 ,7 73---

Transfer from property

under development to

investment property--(108,612)----(108,612)

Balance at 31 March 2020328,972391,336584,810100,85252,03813,84920,6011,492,458

Accumulated depreciation

Balance at 1 April 2019-(2,101)-(30,760)(37,758)(6,963)-(77,582)

Depreciation-(7,683)-(8,722)(5,477)(1,338)

(1,787)(25,007)

Depreciation capitalised

to property under

development------(3,797)(3,797)

Balance at 31 March 2020-(9,784)-(39,482)(43,235)(8,301)(5,584)(106,386)

Total book value328,972381,552584,81061,3708,8035,54815,0171,386,072

All completed resthomes and hospitals included within the definition of freehold land and buildings were

revalued to fair value based on an independent valuation report prepared by registered valuers, CBRE Limited,

at 31 March 2021, in line with NZ IFRS 13 – Fair Value Measurement. These revaluations are undertaken every

2 years, unless there is sustained market evidence of a significant change in fair value.

The valuers used multiple valuation techniques to estimate and determine fair value. The valuer made key

assumptions that include capitalisation of earnings (using capitalisation rates ranging from 11.0 percent to

15.0 percent), together with observed transactional evidence of the market value per care bed (ranging from

$70,000 to $230,000 per care bed).

As the fair value of land and buildings is determined using inputs that are unobservable, the Group

has categorised property, plant and equipment as Level 3 under the fair-value hierarchy in line with

NZ IFRS 13 – Fair Value Measurement.

RYMAN HEALTHCARE

106

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

6. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

The significant unobservable inputs used in the fair-value measurement of the Group’s freehold land and buildings

are the capitalisation rate and the market value per care bed.

As the valuer uses several valuation techniques, a significant decrease in the capitalisation rate could but may

not necessarily result in a significantly higher fair-value measurement. Conversely, a significant increase in the

capitalisation rate could but may not necessarily result in a significantly lower fair-value measurement.

A significant increase in the market value per care bed could but may not necessarily result in a significantly higher

fair-value measurement. Conversely, a significant decrease in the market value per care bed could but may not

necessarily result in a significantly lower fair-value measurement.

Property under development includes land held pending the development of a retirement village amounting to

$343.4 million (2020: $459.1 million) and is valued at cost.

Interest for the Group of $37.2 million (2020: $34.9 million) has been capitalised during the period of construction

in the current year. The weighted-average capitalisation rate on funds borrowed is 2.72 percent per annum

(2020: 3.51 percent per annum).

The assets shown at cost are care-facility assets under development, plant and equipment, furniture and fittings,

and motor vehicles, plus additions since the last valuation.

The carrying amount at which each revalued class of property, plant and equipment would have been carried had

the assets been measured under historical cost is shown below.

Freehold landBuildingsTotal

$000$000

$000

Carrying amount (at cost)

Carrying amount at 31 March 2021103,730414,268517,998

Carrying amount (at cost)

Carrying amount at 31 March 202088,236372,969461,205

Uncertainty due to COVID-19

The valuation of completed resthomes and hospitals performed by CBRE Limited at 31 March 2021 is based on

the information available to them at the time of the valuation and relies on several inputs.

Given the current situation with COVID-19 there is an increase in the estimation uncertainty in determining the fair

value of completed resthomes and hospitals at 31 March 2021 compared to previous valuations.

CBRE comment that the ultimate economic impact COVID-19 will have on the aged-care sector is unknown and

will depend on both the scale and longevity of the pandemic, future outbreaks, and the lockdown responses of the

Governments in New Zealand, Victoria and Australia.

Given the heightened uncertainty and unknown impact that COVID-19 may have in the future, a higher degree of

caution should be exercised when relying upon the valuation. Values and incomes may change more rapidly and

significantly than during standard market conditions.

Occupancy in the Group’s mature aged-care facilities has not been impacted by COVID-19.

ANNUAL REPORT 2021

107

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

6. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

Right-of-use assets

Included within property, plant and equipment are the right-of-use assets relating to leases.

Buildings

Plant and

equipmentTotal

$000$000

$000

Balance at 1 April 2020

11,8543,16315,017

Additions1,1846,2277,4 1 1

Net foreign-currency exchange difference272-272

Depreciation(2 ,476)-(2 ,476)

Depreciation capitalised to property under development(313)(6,291)(6,604)

Balance at 31 March 202110,5213,09913,620

Disposal of land

During the year, the Group sold the land in Coburg, Melbourne. The sale led to a loss on disposal of $15.1 million,

which has been recognised in the income statement.

7. INVESTMENT PROPERTIES

20212020

$000

$000

At fair value

Balance at beginning of financial year5,760,0605,081,607

Additions624,926541,272

Fair-value movement:

Realised fair-value movement:

• new retirement-village units108,377105,757

• existing retirement-village units107,317109,565

215,694215,322

Unrealised fair-value movement201,153(70,884)

416,847144,438

Net foreign-currency exchange differences35,445(7,257)

Net movement for the year1 ,07 7, 2 1 8678,453

Balance at end of financial year6 , 8 3 7, 2 7 85,760,060

RYMAN HEALTHCARE

108

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

7. INVESTMENT PROPERTIES (CONTINUED)

The realised fair-value movement arises from the sale and resale of rights to occupy to residents. Investment

properties are not depreciated and are fair valued. As the fair value of investment property is determined using

inputs that are unobservable, the Group has categorised investment property as Level 3 under the fair-value

hierarchy in line with NZ IFRS 13 – Fair Value Measurements.

The carrying value of completed investment property is the fair value as determined by an independent valuation

report prepared by registered valuers CBRE Limited, at 31 March 2021. This report combines discounted future

cash flows and occupancy advances received from residents for retirement-village units that are complete or

nearing completion, for which there is an agreement to occupy.

Uncertainty due to COVID-19

The valuation of investment properties performed by CBRE Limited at 31 March 2021 is based on the information

available to them at the time of the valuation and relies on several inputs, as outlined below.

Given the current situation with COVID-19 there is an increase in the estimation uncertainty in determining the fair

value of investment property at 31 March 2021 compared to previous years.

The material valuation uncertainty within the New Zealand and Australian valuations at 31 March 2020 has

been removed. This has been replaced with CBRE commenting on higher than normal market uncertainty

within their valuations.

Given the heightened uncertainty and unknown impact that COVID-19 may have in the future, a higher degree of

caution should be exercised when relying upon the valuation. Values and incomes may change more rapidly and

significantly than during standard market conditions.

Comparable transactions and market evidence has been limited during the pandemic and CBRE have placed less

reliance on previous market evidence for comparison purposes.

To reflect this uncertainty CBRE Limited adjusted their assumptions on recycle frequencies for independent units

at mature villages, near-term house price inflation for independent units, and discount rates in their valuation at

31 March 2020. As the level of uncertainty has decreased and markets have become more accustomed to

operating under COVID-19 conditions, CBRE have reversed some of the adjustments in determining the valuation

at 31 March 2021.

Key assumptions

The valuer used significant assumptions that include house-price inflation (ranging from 0.5 percent to

4.2 percent nominal) (2020: -2.0 percent to 3.5 percent) and discount rate (ranging from 12.00 percent

to 16.50 percent) (2020: 12.25 percent to 16.25 percent).

Sensitivity

A 0.5 percent decrease in the discount rate would result in a $91.3 million higher fair-value measurement.

Conversely, a 0.5 percent increase in the discount rate would result in a $85.3 million lower fair-value measurement.

A 0.5 percent decrease in the 5-year plus growth rate would result in a $168.7 million lower fair-value

measurement. Conversely, a 0.5 percent increase in the 5-year plus growth rate would result in a $140.8 million

higher fair-value measurement.

Other inputs used in the fair-value measurement of the Group’s investment property portfolio include the average

age of residents and the occupancy period.

ANNUAL REPORT 2021

109

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

7. INVESTMENT PROPERTIES (CONTINUED)

A significant increase in the average age of entry of residents or the long-term nominal house-price inflation rate

would result in a significantly higher fair-value measurement. Conversely, a significant decrease in the average

age of entry of residents or the long-term nominal house-price inflation rate would result in a significantly lower

fair-value measurement.

Work in progress

Investment property includes investment property work in progress of $653.0 million (2020: $508.2 million),

which has been valued at cost. For work in progress cost represents fair value.

Operating expenses

Direct operating expenses arising from investment property that generated income from management fees

during the period amounted to $7.9 million (2020: $5.7 million). All investment property generated income from

management fees during the period for the Group, except for investment property work in progress.

Security

Residents make interest-free advances (occupancy advances) to the retirement villages in exchange for the right

to occupy retirement-village units. Under the terms of the occupancy agreement, the resident receives a unit title

for life and a first mortgage over the residual interest for security purposes, or a first mortgage is held over the

individual title by the statutory supervisor.

8. INTANGIBLE ASSETS

Internally

generated

softwareTotal

$000

$000

2021

Gross carrying amount

Balance at 1 April 202045,85645,856

Additions9,4629,462

Balance at 31 March 202155,31855,318

Accumulated amortisation

Balance at 1 April 2020(7,737)(7,737)

Amortisation (note 2)(5,137)(5,137)

Balance at 31 March 2021(12,874)(12,874)

Total book value42,44442,444

RYMAN HEALTHCARE

110

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

8. INTANGIBLE ASSETS (CONTINUED)

Internally

generated

softwareTotal

$000

$000

2020

Gross carrying amount

Balance at 1 April 201932,09632,096

Additions13,76013,760

Balance at 31 March 202045,85645,856

Accumulated amortisation

Balance at 1 April 2019(4,128)(4,128)

Amortisation (note 2)(3,609)(3,609)

Balance at 31 March 2020(7,737)(7,737)

Total book value38,11938,119

Interest for the Group of $0.8 million (2020: $0.4 million) has been capitalised during the current year.

The weighted-average capitalisation rate on funds borrowed is 2.72 percent per annum (2020: 3.51 percent

per annum).

9. CASH AND CASH EQUIVALENTS

The Group has an arrangement with ANZ that on a nightly basis a sweep is performed across all transactional

bank accounts. This consolidates all transactional bank accounts into a single account.

There is a right to offset cash balances against bank debt documented in the Group’s facility agreement.

The Group has access to an overdraft facility. The bank overdraft facilities are secured by a general security

agreement and mortgages over the freehold land and buildings of the Group in the same manner as the bank

loans (note 12). The interest rate on all overdraft facilities at 31 March 2021 was 8.90 percent (2020: 8.90 percent).

10. TRADE AND OTHER PAYABLES

20212020

$000

$000

Trade payables72,36679,7 75

Other payables33,706104,200

Total trade and other payables106,072183,975

Trade payables are typically paid within 30 days of the invoice date or on the 20th of the month following the

invoice date. Other payables at 31 March 2021 includes $26.0 million (2020: $102.4 million) for the purchase

of land.

ANNUAL REPORT 2021

111

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

11. EMPLOYEE ENTITLEMENTS

20212020

$000

$000

Holiday-pay accrual and other benefits32,03425,678

12. INTEREST-BEARING LOANS AND BORROWINGS

Interest-bearing loans and borrowings include secure bank loans, unsubordinated fixed-rate retail bonds and

USPP notes.

20212020

$000$000

Bank loans12a1,728,0181,741,613

Retail bonds – RYM01012b150,000-

USPP notes12c428,736-

Total loans and borrowings at face value2,306,7541,741,613

Issue costs for the retail bond capitalised12b(3,139)-

Issue costs for the USPP capitalised12c(2,049)-

Total loans and borrowings at amortised cost2,301,5661,741,613

Revaluation of debt in fair-value hedge relationship12c(27,473 )-

Total loans and borrowings2,274,0931,741,613

a. Bank loans (secured)

20212020

$000

$000

Bank loans (secured) – NZD1,162,0001,354,000

Bank loans (secured) – AUD in NZD566,0183 87,6 1 3

Total bank loans (secured) 1,728,0181,741,613

Less cash and cash equivalents (note 9)(20,171)(34,374)

Net bank loans1,707,8471 ,7 0 7, 2 3 9

Less than 1 year25,000-

Within 1–5 years1,703,0181,741,613

Total bank loans (secured)1,728,0181,741,613

Average interest rates for bank loans – NZD2 .71%3.11%

Average interest rates for bank loans – AUD1.86%2 .7 7%

The average interest rates disclosed above exclude the impact of interest-rate swap agreements described in

note 20.

RYMAN HEALTHCARE

112

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

12. INTEREST-BEARING LOANS AND BORROWINGS (CONTINUED)

b. Retail bonds (secured)

20212020

$000

$000

Retail bond – RYM010150,000-

Total retail bonds at face value 150,000-

Issue costs for the retail bond capitalised

Opening balance--

Capitalised during the year(3,297)-

Amortised during the year158-

(3 ,1 3 9 )-

Total retail bonds at amortised cost146,861-

The Group issued a retail bond for $150.0 million in December 2020. The retail bond has a maturity date of

18 December 2026 and is listed on the NZX Debt Market (NZDX) with the ID RYM010.

The coupon rate for the retail bond is 2.55 percent.

Retail bond issue expenses, fees and other costs incurred in arranging retail bond finance are capitalised and

amortised over the term of the relevant debt instrument.

c. USPP notes

20212020

$000

$000

USPP notes428,736-

Total USPP notes at face value 428,736-

Issue costs for the USPP notes capitalised

Opening balance--

Capitalised during the year(2,070)-

Amortised during the year21-

(2,049)-

Total USPP notes at amortised cost426,687-

Revaluation of debt in fair-value hedge relationship(27,473 )-

Total USPP notes399,214-

ANNUAL REPORT 2021

113

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

12. INTEREST-BEARING LOANS AND BORROWINGS (CONTINUED)

On 17 February 2021 the Group completed a United States Private Placement (USPP) note issuance, securing

USD$300 million of long-term debt. The USPP issuance is made up of six tranches with varying maturity dates

and amounts as listed below. In conjunction with the USPP issuance, the Group entered into cross-currency

interest-rate swaps to formally hedge the exposure to foreign-currency risk over the term of the notes.

At 31 March 2021, the USPP notes had a fair value of $399.2 million. This debt is carried at amortised cost and

translated to New Zealand dollars using foreign exchange rates at balance date.

USPP note expenses, fees and other costs incurred in arranging USPP finance are capitalised and amortised over

the term of the relevant debt instrument.

Security

The bank loans, retail bonds and USPP notes are secured by a general security agreement over the parent

and subsidiary companies and supported by first mortgages over the freehold land and buildings (excluding

retirement-village unit titles provided as security to residents – note 7).

The subsidiary companies listed at note 24 have all provided guarantees for the Group’s secured loans as parties

to the general security agreement.

Full repayment terms are disclosed in note 20.

13. LEASE LIABILITIES

The Group leases office buildings, sales offices, office equipment (such as photocopiers), and plant and

equipment used in the construction of retirement-village units and aged-care beds.

The right-of-use assets relating to these leases are included within property, plant and equipment (note 6).

Amounts recognised in profit and loss

20212020

$000

$000

Depreciation of right-of-use assets (note 6)2 ,4761,787

Interest expense on lease liabilities (note 3)3 74243

Expenses relating to short-term or low-value leases1,212985

The maturity profile for lease liabilities and how the Group manages liquidity risk is included in note 20 –

financial instruments.

At 31 March 2021 the Group is committed to $5.7 million for short-term leases (including short-term construction

equipment leases) (2020: $7.2 million).

RYMAN HEALTHCARE

114

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

14. OCCUPANCY ADVANCES (NON-INTEREST BEARING)

20212020

$000

$000

Gross occupancy advances (see below)4,205,1053,686,813

Less management fees and resident loans(502,890)(439,636)

Closing balance3,702,2153,247,177

Movement in gross occupancy advances

20212020

$000

$000

Opening balance3,686,8133,203,851

Plus net increases in occupancy advances:

• new retirement-village units395,094386,673

• existing retirement-village units. 107,317109,566

Net foreign-currency exchange differences21,807(4, 276)

Decrease in occupancy advance receivables(5,926)(9,001)

Closing balance4,205,1053,686,813

Gross occupancy advances are non-interest bearing.

The decrease in occupancy advance receivables shows the net movement in occupancy advance that has

resulted from:

• units that have been re-sold but the previous resident has yet to be repaid; and

• units that have been repaid but the unit remains unsold at balance date.

ANNUAL REPORT 2021

115

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

15. SHARE CAPITAL

Issued and paid-up capital consists of 500,000,000 fully paid ordinary shares (2020: 500,000,000) less treasury

stock of 2,655,017 shares (2020: 2,711,244 shares) (note 26). All shares rank equally in all respects.

Basic and diluted earnings and net tangible assets per share have been calculated on the basis of 500,000,000

ordinary shares (2020: 500,000,000 shares).

Shares purchased on market under the leadership share scheme (note 26) are treated as treasury stock (note 16)

until vesting to the employee.

16. RESERVES

20212020

$000$000

Reserves

Asset revaluation reserve16a453,5682 57,7 75

Cash-flow hedge reserve16b(12,062)( 1 7,1 4 3 )

Cost of hedging reserve16c2 ,702-

Foreign-currency translation reserve16d1,787(10,345)

Treasury stock16e, 26(35,389)(32,359)

410,606

197,928

RYMAN HEALTHCARE

116

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

16. RESERVES (CONTINUED)

20212020

$000$000

a. Asset revaluation reserve

Opening balance2 57,7 752 57,7 75

Revaluation195,793-

Closing balance453,5682 5 7,7 7 5

b. Cash-flow hedge reserve

Opening balance( 1 7,1 4 3 )(9,643)

Valuation of interest-rate swap1,116(13,275)

Valuation of cross-currency interest-rate swap587-

Released to income statement5,3542,859

Deferred tax movement on cash-flow hedge reserve(1,976)2,916

Closing balance(12,062)(1 7,1 4 3 )

c. Cost of hedging reserve

Opening balance--

Valuation of cross-currency interest-rate swap3,753-

Released to income statement--

Deferred tax movement on cost of hedging reserve(1,051)-

Closing balance2 ,70 2-

d. Foreign-currency translation reserve

Opening balance(10,345)(5,876)

(Loss)/Gain on hedge of foreign-owned subsidiary net assets(4,414)1,205

Gain/(Loss) on translation of foreign operations16,546( 5,6 74 )

Closing balance1,7 87(10,345)

e. Treasury stock (note 26)

Opening balance(32,359)(27,4 6 5 )

Acquisitions(13,425)(13,7 70)

Vesting /forfeiture of shares10,3958,876

Closing balance(35,389)(32,359)

f. Retained earnings

Opening balance2,069,7591,922,049

Net profit attributable to shareholders423,061264,710

Dividends paid(107,500)(117,000)

Closing balance2,385,3202,069,759

The cost of hedging reserve captures changes in the fair value of the cost to convert foreign currency to NZD

of the cross-currency interest-rate swaps on USPP debt.

ANNUAL REPORT 2021

117

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

17. DIVIDENDS

2021202120202020

Cents per shareTotal $000Cents per share

Total $000

Recognised amounts

Final dividend paid – prior year12 .7063,50011.9059,500

Interim dividend paid – current year8.8044,00011.5057,500

107,500117,000

Unrecognised amounts

Final dividend – current year13.6068,00012 .7063,500

Full-year dividend – current year22 .40112,00024.20121,000

18. RELATED-PARTY TRANSACTIONS

Parent company

The parent entity in the Group is Ryman Healthcare Limited.

Equity interests in related parties

Details of the percentage of ordinary shares held in subsidiaries are disclosed in note 24.

20212020

$000

$000

Transactions with companies associated with directors

Rental costs1,654514

Sub-contractor labour690254

Since August 2012 Ryman Healthcare Limited has leased office accommodation from the Airport Business Park

Christchurch Limited (the Airport Business Park).

On 1 December 2019 Warren Bell became an independent director or trustee of the Airport Business Park’s

shareholders. He does not have any personal ownership interest.

The lease of the office accommodation is recognised as a right-of-use asset and associated lease liability. Rental

costs detailed in the table above are the total cash payments made in the current financial year in respect of the

lease agreement (2020: payments made from 1 December 2019).

Anthony Leighs is Managing Director of Leighs Construction Limited, which has supplied sub-contractor labour to

Ryman Healthcare Limited since December 2019.

Any transactions undertaken with these entities have been entered into on an arm’s-length basis and in the

ordinary course of business.

RYMAN HEALTHCARE

118

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

19. KEY MANAGEMENT PERSONNEL COMPENSATION

20212020

$000

$000

Compensation

Short-term employee benefits (senior executive team)3,9714,633

Directors’ fees1,0941,011

Total key management personnel and directors’ compensation5,0655,644

Key management personnel are the senior executive team of the Group and include the group chief executive and

six senior executive team members at 31 March 2021 (2020: group chief executive and six senior executive team

members).

In addition, NZ IAS 24 – Related Party Disclosures requires directors’ fees to be included within key management

personnel compensation. All directors are non-executive and are not involved in the day-to-day operations of the

Group (2020: all directors).

Directors’ fees relate to the fees paid to eight directors that were in place for the full financial year (2020: eight directors,

of which one was in place for part of the financial year).

Post-employment benefits (KiwiSaver/Superannuation) employer contributions included in short-term employee

benefits (senior executive team) above is $111,769 (2020: $128,983 senior executive team).

In addition, the Company provides certain senior employees with limited recourse loans on an interest-free basis

to support employees’ participation in the leadership share scheme (note 26).

20. FINANCIAL INSTRUMENTS

The financial instruments consist of cash and cash equivalents, trade and other receivables, cross-currency

interest-rate swaps, trade and other payables, occupancy advances, refundable accommodation deposits,

employee advances, loans, overdrafts, interest-rate swaps, and lease liabilities.

Categories of financial instruments

20212020

$000

$000

Financial assets

Cash and cash equivalents (note 9)20,17134,374

Financial assets at amortised cost (loans and receivables)553,939436,166

574,110470,540

Financial liabilities

Amortised cost6,196,0465,247,336

Derivative instruments in designated hedge accounting

relationships (interest-rate swaps)17,33923,809

Derivative instruments in designated hedge accounting

relationships (cross-currency interest-rate swaps (CCIRS))11,272-

Lease liabilities13,88515,145

6,238,5425,286,290

ANNUAL REPORT 2021

119

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

a. Credit risk management

Credit risk is the risk of the failure of a debtor or counterparty to honour its contractual obligation resulting in

financial loss to the Group.

Financial assets, which potentially subject the Group to credit risk, consist principally of cash and cash

equivalents, trade and other receivables, advances to employees, and derivative financial instruments.

The maximum credit risk at 31 March 2021 is the fair value of these assets. The Group’s cash equivalents are

placed with high-credit, quality financial institutions. The Group does not require collateral from its debtors.

The directors consider the Group’s exposure to any concentration of credit risk from trade and other

receivables and advances to employees to be minimal, given that (typically):

• the occupation of a retirement-village unit does not take place until an occupation

advance has been received

• care fees are payable 4-weekly in advance when due from residents

• care fees not due from residents are paid by government agencies

• advances to employees are subject to the terms of the employee share schemes (note 26).

The total credit risk to the Group from trade and other receivables and advances to employees at

31 March 2021 was $553.9 million (2020: $436.2 million) and there were no material overdue debtors at

31 March 2021 (2020: $Nil). The composition of financial assets is shown in the table below.

20212020

$000

$000

Trade and other receivables (note 5)542,798425,942

Advances to employees (note 26)11,14110,224

553,939436,166

Credit risk relating to derivative financial instruments is managed by restricting the amount of cash

and marketable securities that can be placed with any one institution. The Group minimises its credit

risk by spreading such exposures across a range of institutions with reference to the credit ratings of

these institutions.

b. Interest-rate risk

Interest-rate risk is the risk that fluctuations in interest rates impact the Group’s financial performance, future

cash flows or the fair value of its financial instruments.

The Group’s interest-rate risk arises from loans and borrowings. Loans and borrowings issued at variable

interest rates expose the Group to changes in interest rates. Loans and borrowings issued at fixed rates

expose the Group to changes in the fair value of the borrowings.

The Group’s policy is to manage its interest-rate exposure using a mix of fixed and variable rate debt and

interest-rate derivatives that are accounted for as cash-flow hedges or fair-value hedges.

The interest rate applicable to the bank overdraft is variable. The interest rates applicable to the bank loans

are reviewed at each 3-monthly rollover. The Group always seeks to obtain the most competitive interest rate.

RYMAN HEALTHCARE

120

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

Cash-flow hedges

Interest-rate swaps

The Group has entered into an interest-rate swap agreement to provide an effective cash-flow hedge against

floating interest-rate variability on a defined portion of core debt.

These interest-rate swaps qualify for cash-flow hedge accounting. Interest-rate swaps are initially

recognised at fair value on the date a contract is entered into and remeasured to their fair value at each

reporting date. The effective portion of the change in the fair value of the swaps is recognised in other

comprehensive income and accumulated as a separate component of equity. The ineffective portion is

recognised in the income statement.

The hedge ratio is 1:1. The face value of the interest-rate swaps is the same value as the face value of the bank

loans. As the critical terms of the interest-rate swap contracts and the hedged item are the same, significant

hedge ineffectiveness is not expected.

At 31 March 2021, the Group had several interest-rate swaps in place, which are set out in the table below.

The agreement effectively changes the Group’s interest-rate exposure on the principal of up to $250 million

(2020: $250 million) from a floating rate to an average fixed rate of 2.757 percent (2020: 2.930 percent).

The fair value of the swaps at 31 March 2021 was a liability of $17.3 million (2020: liability of $23.8 million).

The interest-rate swaps cover notional debt amounts for a term of up to 5 years at a composite interest

rate of 2.757 percent (2020: 2.930 percent).

No interest-rate swaps have been taken out for the Australian dollar borrowings.

The balance of the interest-rate swap reserve is expected to be released to the income statement over the

maturity profile of the underlying debt as detailed in the table below. At the end of the reporting period, the fair

value of interest-rate swaps is determined by discounting the future cash flows using the yield curves at the

end of the reporting period and the credit risk inherent in the contract.

The notional amortising principal amounts and remaining terms of interest-rate swap contracts outstanding at

31 March are shown below.

Average contracted fixed-interest rateNotional principal amount

2021202020212020

%%$000

$000

Outstanding

Less than 1 year2 .757%2.930%250,000180,000

1 to 2 years2 .757%2.930%250,000250,000

2 to 3 years2 .757%2.930%200,000250,000

3 to 4 years2 .757%2.930%150,000200,000

4 to 5 years2 .757%2.930%150,000150,000

ANNUAL REPORT 2021

121

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

Cross-currency interest-rate swaps

The Group manages its interest-rate risk on USPP notes through cross-currency interest-rate swaps (CCIRS).

The cross-currency interest rate swaps transform a series of known fixed interest-rate cash flows in a foreign

currency to floating rate NZD cash flows, mitigating exposure to fair-value changes in USPP notes.

For hedge accounting purposes, these swaps are aggregated and designated as cash-flow hedges and a

fair-value hedge. The fair-value component hedges USD fixed interest rates to NZD floating interest rates.

The USD amount received in AUD is not hedged.

The hedge ratio is 1:1. The face value of the CCIRS is the same value as the face value of the USPP notes. As

the critical terms of the CCIRS contracts and the hedged item are the same, significant hedge ineffectiveness

is not expected.

The change in the fair value of the hedged risk is attributed to the carrying value of the USPP. This debt revaluation

is recognised in the income statement to offset the mark-to-market revaluation of the hedging derivative.

The cross-currency basis element of the cross-currency interest-rate swaps are excluded from the designation

and are separately recognised in other comprehensive income in a cost of hedging reserve (note 16).

The cash-flow components are hedge accounted as described under Cash-flow hedges above.

At inception, each hedge relationship is formalised in hedge documentation. Hedge accounting is discontinued

when the hedge instrument expires or is sold, terminated, exercised or no longer qualifies for hedge accounting.

The Group uses Bancorp Treasury Services Limited (BTSL), as an independent valuer, to determine the

existence of an economic relationship between the hedging instrument and the hedged item based on the

currency, amount and timing of respective cash flows, interest rates, tenors, repricing dates, maturities and

notional amounts. BTSL then assesses whether the derivative designated in each hedging relationship is

expected to be, and has been, effective in offsetting the changes in cash flows of the hedged item.

The fair value of the USPP notes have been determined at balance date on a discounted cash-flow basis using

the USD Bloomberg curve and applying discount factors to the future USD interest payment and principal

cash flows. The fair value of the associated CCIRS has been calculated using the discounted cash-flow

method, estimated using forward interest and foreign exchange rates (from observable yield curves and

forward exchange rates).

The details of the hedging instruments are as follows.

Currency

Average

rateMaturity

Notional

amount of

hedging

instrument

Carrying

amount of

the hedging

instrument

Change in

value used for

calculating hedge

effectiveness

(years) $000 $000

2021

Fair-value and cash-flow

hedges

Cross-currency swapsUSD

USD:NZDFloating10–15$275 million11,27211,272

11,27211,272

RYMAN HEALTHCARE

122

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

AmountCurrencyMaturityNote coupon

2021

Fair value

USD$000%

$000

Swap participants

Bank of New Zealand55,000USD:NZD18/02/20314.06%932

MUFG45,000USD:NZD18/02/20314.06%2,001

Bank of New Zealand60,000USD:NZD16/02/20334.16%2 ,152

ANZ Bank New Zealand Ltd40,000USD:NZD16/02/20334.16%1,877

ANZ Bank New Zealand Ltd75,000USD:NZD16/02/20364.26%4,310

275,00011,272

Unhedged notes

1

25,000USD:AUD16/02/20314.28%

300,000

1 AUD equivalent of USD$25 million was received as part of the USPP issuance. This is currently not hedged.

There is no material hedge ineffectiveness. The maturity of the USPP notes and associated CCIRS are

matched.

Sensitivity of the cross-currency interest-rate swaps to a change in interest rate

The following table demonstrates the sensitivity to a change in floating interest rates of plus/(minus) 50 basis

points, with all other variables held constant, of the Company’s profit and equity.

2021

$000

Increase in interest rates of 50 basis points

Effect on profit after taxation-

Effect on equity after taxation(15,077)

Decrease in interest rates of 50 basis points

Effect on profit after taxation-

Effect on equity after taxation16,194

Based on the Group’s average net level of interest-bearing debt, the Group’s profit and total comprehensive

income for the year ended 31 March 2020 would not have changed materially if there was a movement of

plus/(minus) 50 basis points.

ANNUAL REPORT 2021

123

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

c. Foreign-currency risk

Foreign-currency risk is the risk that the value of the Group’s assets, liabilities, and financial performance will

fluctuate due to changes in foreign-currency rates.

The Group is exposed to currency risk in Australian (AUD) and US dollars (USD).

Exposure to the Australian dollar arises primarily as a result of its subsidiaries in Australia as well as the USPP

borrowings received in AUD.

The risk to the Group is that the value of the overseas Australian subsidiaries’ financial position and financial

performance will fluctuate in economic terms and, as recorded in the consolidated accounts, due to changes

in the overseas exchange rates.

The Group hedges the currency risk relating to its Australian subsidiaries by holding a portion of its

borrowings (both bank debt and USPP notes) in Australian dollars. Any foreign-currency movement in the net

assets of the Australian subsidiary is partially offset by an opposite movement in the Australian dollar debt.

Exposure to the US dollar arises from USPP borrowings. This exposure has been fully hedged by way of

cross-currency interest-rate swaps hedging both principal and interest.

The cross-currency interest-rate swaps correspond in amount and maturity to the relevant US dollar

borrowings with no residual foreign-currency risk exposure.

The cross-currency interest rate swaps consist of a fair-value hedge component and a cash-flow hedge

component. The effective movements on the fair-value hedge component are taken to the income statements

along with all movements of the hedged risk on the USPP notes (USD only). The effective movements of the

cash-flow hedge components are all taken to the cash-flow hedge reserve.

The following sensitivity analysis is based on the foreign-currency risk exposures in existence at the reporting

date. At 31 March 2021, had the New Zealand dollar moved either up or down by 10 percent, with all other

variables held constant, profit and equity would have been affected as follows.

2021

$000

Increase in value of NZ dollar of 10%

Impact on profit after taxation-

Impact on equity after taxation(44,781)

Decrease in value of NZ dollar of 10%

Impact on profit after taxation-

Impact on equity after taxation54,732

The net exposure at balance date is representative of what the Group was and is expecting to be exposed to

in the next 12 months from balance date.

The Group’s profit and total comprehensive income for the year ended 31 March 2020 would not have

changed materially by a movement of plus/(minus) 1 cent in AUD/NZD.

RYMAN HEALTHCARE

124

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

d. Liquidity risk

Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due

without incurring unacceptable losses or risking reputational damage. The Group manages liquidity to

ensure that it has sufficient liquidity to meet its liabilities when due. This includes under both normal and

stressed conditions.

The Group manages the liquidity risk on occupancy advances through the contractual requirements in the

occupation agreement.

Following termination of the agreement, in New Zealand the occupancy advance is repaid at the earlier of:

• receipt of the new occupancy advance from the incoming resident

• at the end of 3 years.

Following termination of the agreement, in Australia the occupancy advance is repaid at the earlier of:

• 14 days after a new resident takes up residence

• receipt of the new occupancy advance from the incoming resident

• at the end of 6 months.

The repayment obligation for refundable occupation deposits in New Zealand is within 30 working days of the

resident vacating their care room.

The repayment obligation for refundable occupation deposits in Australia is within 14 days of the resident

vacating their care room.

Ultimate responsibility for liquidity risk management rests with the directors, who have built an appropriate

liquidity risk management framework for the management of the Group’s short, medium, and long-term

funding and liquidity management requirements.

The Group manages liquidity risk by maintaining adequate reserves, banking facilities, and reserve borrowing

facilities, and by regularly monitoring forecast and actual cash flows and the maturity profiles of financial

assets and liabilities.

At balance date, the Group had NZD$647.3 million (2020: NZD$306.3 million) and AUD$36.0 million

(2020: AUD$231.0 million) of undrawn facilities at its disposal to further reduce liquidity risk.

The Group does not face a significant liquidity risk with regard to lease liabilities (note 13).

ANNUAL REPORT 2021

125

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

Maturity profile

The following table details the Group’s exposure to liquidity risk (including contractual interest obligations for

bank loans, retail bonds and USPP notes).

Contractual maturity dates

20212020

On

demand

Less

than

1 year1–5 years

Greater

than

5 yearsTotal

On

demand

Less

than

1 year1–5 years

Greater

than

5 yearsTotal

$000$000$000$000$000$000$000$000$000$000

Financial

liabilities:

Trade and other

payables

-106,072--106,072-183,975--183,975

Interest-rate

swaps

-17,339--17,339-23,809--23,809

CCIRS-11,272--11,272-----

Refundable

accommodation

deposits

113,666---113,66674 ,57 1---74 ,57 1

Bank loans

(secured)

-26,0351,703,018 -1,729,053-3,5331,741,613-1,745,146

Retail bond-3,68715,300152,869171,856-----

USPP notes-16,44158,755518,302593,498-----

Occupancy

advances (non-

interest bearing)

-438,9263,263,289-3,702,215-382,7452,864,432-3,247,177

Lease liabilities-6,2558,230-14,485-6,2249,908-16,132

113,666626,0275,048,592671,1716,459,45674 ,57 1600,2864,615,953-5,290,810

Gross occupancy advances and refundable accommodation deposits are non-interest bearing.

The above figures have been calculated on the anticipated level of occupancy advance repayments based on

historical experience. To date, new occupancy advances received have always exceeded repaid occupancy

advances (net of management fees) and represent a positive net operating cash flow to the Group.

RYMAN HEALTHCARE

126

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

The Group maintains the following lines of credit.

• $2.8 million (2020: $2.8 million) overdraft facility that is secured. Interest would be payable at the 3-month

BKBM rate, plus a specified margin (note 9).

• Bank debt facilities of the Group total approximately $2.4 billion (2020: $2.3 billion) made up as follows.

– An NZD loan facility of $1.90 billion (2020: $1.80 billion), of which $135.0 million (2020: $35.0 million) is

for 1 year, $144.0 million (2020: $144.0 million) is for 1.5 years, $521.3 million (2020: $521.3 million) is for

3 years, $485.3 million (2020: $485.3 million) is for 4 years, and $616.3 million (2020: $616.3 million) is

for 5 years.

– An AUD loan facility of AUD$471.0 million (2020: AUD$471.0 million), of which AUD$36.0 million

(2020: $36.0 million) is for 1.5 years, AUD$235.0 million (2020: AUD$235.0 million) is for 4 years, and

AUD$200.0 million (2020: $200.0 million) is for 5 years.

– In 2021 the NZD loan facility of $1.90 billion is provided by ANZ Bank New Zealand Ltd

($390.0 million), Commonwealth Bank of Australia ($274.9 million), Bank of New Zealand/National

Australia Bank ($470.5 million), Westpac ($291.4 million), MUFG ($175.0 million), Bank of China

($200.0 million) and the Industrial and Commercial Bank of China ($100.0 million) under the terms

of a syndicated loan agreement. The facility allows for the funds to be drawn down in NZD up to the

$1.90 billion NZD limit.

–In 2021 the AUD loan facility of AUD$471.0 million is provided by ANZ Bank New Zealand Ltd

(AUD$136.0 million), Commonwealth Bank of Australia (AUD$242.5 million), Bank of New Zealand/

National Australia Bank (AUD$42.0 million), and Westpac (AUD$50.5 million) under the terms of a

syndicated loan agreement.

– In 2020 the NZD loan facility of $1.80 billion is provided by ANZ Bank New Zealand Ltd ($390.0 million),

Commonwealth Bank of Australia ($274.9 million), Bank of New Zealand/National Australia Bank

($370.5 million), Westpac ($291.4 million), MUFG ($175.0 million), Bank of China ($200.0 million) and

the Industrial and Commercial Bank of China ($100.0 million) under the terms of a syndicated loan

agreement. The facility allowed for the funds to be drawn down in NZD up to the $1.80 billion NZD limit.

– In 2020 the AUD loan facility of AUD$471.0 million is provided by ANZ Bank New Zealand Ltd

(AUD$136.0 million), Commonwealth Bank of Australia (AUD$242.5 million), Bank of New Zealand/

National Australia Bank (AUD$42.0 million), and Westpac (AUD$50.5 million) under the terms of a

syndicated loan agreement.

The Group renews its facilities annually to ensure an appropriate portion matures on a rolling 1, 3, 4, and 5-year basis.

ANNUAL REPORT 2021

127

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

20. FINANCIAL INSTRUMENTS (CONTINUED)

e. Fair values

Apart from the retail bonds and US Private Placement notes (USPP), the carrying amounts of financial

instruments in the Group’s balance sheet are the same as their fair value in all material aspects, due to the

demand features of these instruments and/or their interest-rate profiles.

The fair value of the retail bond is based on the price traded at on the NZX market at 31 March 2021.

The fair value of the retail bond is categorised as Level 1 under the fair-value hierarchy in accordance with

NZ IFRS 13 – Fair Value Measurement.

The fair value of the US Private Placement notes has been determined at balance date on a discounted

cash-flow basis and applying discount factors to the future USD interest payment and principal payment cash

flows. The fair value of the USPP is categorised as Level 2 under the fair-value hierarchy in accordance with

NZ IFRS 13 – Fair Value Measurement.

2021

Carrying amount

2021

Fair value

2020

Carrying amount

2020

Fair value

$000$000$000

$000

Retail bond

146,861149,880

--

US Private Placement notes

399,214401,263

--

The fair value of interest-rate swaps and CCIRS are derived using inputs supplied by third parties that are

observable, either directly (prices) or indirectly (derived from prices). The Group has therefore categorised

these liabilities as Level 2 under the fair-value hierarchy contained within IFRS 13 – Fair Value Measurement.

f. Market risk

The Group is primarily exposed to interest-rate risk (note 20 (b)) and foreign-currency risk (note 20 (c)).

g. Capital management

The Group’s capital includes share capital, reserves, and retained earnings. The objective of the Group’s capital

management is to ensure a strong credit rating to support business growth and maximise shareholder value.

The Group’s capital is managed at parent-company level. The Group is subject to capital requirements

imposed by its bank and the lenders included in the banking syndicate through covenants agreed as part of

the lending facility arrangements, bond holders through covenants in the Master Trust Deed and USPP note

holders through covenants in the Note Purchase Agreement.

The Group has met all externally imposed capital requirements for the 12 months ended 31 March 2021 and

31 March 2020.

The Group’s capital structure is managed, and adjustments are made with board approval to the structure,

considering economic conditions at the time. There were no changes to objectives, policies, or processes

during the year.

RYMAN HEALTHCARE

128

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

21. COMMITMENTS

Capital expenditure commitments

The Group had commitments relating to construction contracts amounting to $180.6 million at 31 March 2021

(2020: $200.9 million).

The Group has an ongoing commitment for maintaining the land and buildings of the integrated retirement

villages, resthomes, and hospitals.

22. CONTINGENT LIABILITIES

The Group had no contingent liabilities at 31 March 2021 (2020: $Nil).

23. RECONCILIATION OF NET PROFIT AFTER TAX WITH NET CASH FLOW FROM

OPERATING ACTIVITIES

20212020

$000

$000

Net profit after tax423,061264,710

Adjusted for:

Movements in balance-sheet items

Occupancy advances518,292482,962

Accrued management fees(59,116)(64,051)

Refundable accommodation deposits32 ,47040,558

Revenue in advance7,5 1 56,456

Trade and other payables4,8455,507

Trade and other receivables(92,565)(81,124)

Inventory(26,738)-

Employee entitlements6,3561,844

Non-cash items:

Depreciation and amortisation29,89226,829

Depreciation of right-of-use assets2 ,4761,787

Loss on disposal15,102-

Deferred tax(12,561)(93,563)

Unrealised foreign-exchange (gain)/loss(19,063)2,314

Adjusted for:

Fair-value movement of investment properties(416,847)(144,438)

Net operating cash flows413,119449,791

Net operating cash flows includes net occupancy advance receipts from retirement-village residents of

$787.7 million (2020: $755.3 million).

Also included in operating cash flows are net receipts from refundable accommodation deposits of

$27.9 million (2020: $41.1 million).

Net operating cash flows also include management fees collected of $48.0 million (2020: $44.6 million).

ANNUAL REPORT 2021

129

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

24. SUBSIDIARY COMPANIES

All trading subsidiaries operate in the aged-care sector in New Zealand and Australia, are 100 percent owned, and

have a balance date of 31 March. The operating subsidiaries are listed below.

• Anthony Wilding Retirement Village Limited

• Bert Sutcliffe Retirement Village Limited

• Bob Owens Retirement Village Limited

• Bob Scott Retirement Village Limited

• Bruce McLaren Retirement Village Limited

• Café Ryman Russley Road Limited

• Charles Brownlow Retirement Village Pty Ltd

• Charles Fleming Retirement Village Limited

• Charles Upham Retirement Village Limited

• Diana Isaac Retirement Village Limited

• Edmund Hillary Retirement Village Limited

• Ernest Rutherford Retirement Village Limited

• Essie Summers Retirement Village Limited

• Evelyn Page Retirement Village Limited

• Frances Hodgkins Retirement Village Limited

• Grace Joel Retirement Village Limited

• Hilda Ross Retirement Village Limited

• James Wattie Retirement Village Limited

• Jane Mander Retirement Village Limited

• Jane Winstone Retirement Village Limited

• Jean Sandel Retirement Village Limited

• John Flynn Retirement Village Pty Ltd

• Julia Wallace Retirement Village Limited

• Keith Park Retirement Village Limited

• Kiri Te Kanawa Retirement Village Limited

• Linda Jones Retirement Village Limited

• Logan Campbell Retirement Village Limited

• Malvina Major Retirement Village Limited

• Margaret Stoddart Retirement Village Limited

• Miriam Corban Retirement Village Limited

• Murray Halberg Retirement Village Limited

• Nellie Melba Retirement Village Pty Ltd

• Ngaio Marsh Retirement Village Limited

• Possum Bourne Retirement Village Limited

• Riccarton Park Retirement Village Limited

• Rita Angus Retirement Village Limited

• Rowena Jackson Retirement Village Limited

• Ryman Aged Care (Australia) Pty Ltd

• Ryman Construction Pty Ltd

• Ryman Healthcare (Australia) Pty Ltd

• Ryman Healthcare (Australia) No. 10 Pty Ltd

• Ryman Napier Limited

• Shona McFarlane Retirement Village Limited

• Weary Dunlop Retirement Village Pty Ltd

• William Sanders Retirement Village Limited

• Yvette Williams Retirement Village Limited

25. SEGMENT INFORMATION

Products and services from which reportable segments derive their revenue

The Ryman Group operates in one industry, being the provision of integrated retirement villages for older people

in New Zealand and Australia. The service provision process for each of the villages is similar, and the class of

customer and methods of distribution and regulatory environment are consistent across all the villages.

Segment revenues and results

The accounting policies of the reportable segment are the same as the Group’s accounting policies. The segment

profit represents profit earned for the segment after all costs including all administration costs, directors’ fees,

interest revenue, finance costs, and income-tax expense.

The board makes resource allocation decisions to the segment, based on the expected cash flows and results of

Group operations as a whole. No operations were discontinued during the year. To monitor segment performance

and allocate resources to the segment, the board monitors assets attributable to the segment. All assets are

allocated to the reportable segment.

RYMAN HEALTHCARE

130

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

25. SEGMENT INFORMATION (CONTINUED)

Information about major customers

Included in total revenue are revenues that arose from sales to the Group’s largest customers.

The Group derives care-fee revenue for eligible government-subsidised, aged-care residents who receive

resthome, hospital, or dementia-level care. The government aged-care subsidies received from the New Zealand

Ministry of Health included in Group care fees amounted to $122.5 million (2020: $114.9 million). There are no other

significant customers.

Geographical information

The Group operates in New Zealand and Australia.

In presenting information based on geographical areas, net profit, underlying profit, and revenue are based on the

geographical location of operations. Assets are based on the geographical location of the assets.

New ZealandAustraliaGroup

$000$000

$000

Year ended 31 March 2021

Revenue405,39650,398455,794

Underlying profit (non-GAAP)192,28632,163224,449

Deferred tax credit (note 4)

5,8616,70012,561

Unrealised fair-value movement (note 7)192,5828,571201,153

Impairment – loss on disposal (note 6)-(15,102)(15,102)

Profit for the year390,72932,332423,061

Non-current assets7,230,2981,340,4638,570,761

Year ended 31 March 2020

Revenue383,11740,766423,883

Underlying profit (non-GAAP)199,87742,154242,031

Deferred tax credit (note 4)

86,1427,4 2 193,563

Unrealised fair-value movement (note 7)(44,092)(26,792)(70,884)

Profit for the year241,92722 ,783264,710

Non-current assets6,260,370946,3367,206,706

Underlying profit is a non-GAAP (Generally Accepted Accounting Principles) measure and differs from NZ IFRS

profit for the year. Underlying profit does not have a standardised meaning prescribed by GAAP and so may not

be comparable to similar financial information presented by other entities. The Group uses underlying profit, with

other measures, to measure performance. Underlying profit is a measure that the Group uses consistently across

reporting periods.

ANNUAL REPORT 2021

131

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

25. SEGMENT INFORMATION (CONTINUED)

Underlying profit includes realised movement on investment property for units in which a right-to-occupy

has been sold during the period and for which a legally binding contract is in place at the reporting date. The

occupancy advance for these units may have been received or be included within the trade receivables balance at

reporting date (see note 5).

Underlying profit excludes deferred taxation, taxation expense, unrealised movement on investment properties,

and impairment losses on non-trading assets because these items do not reflect the trading performance of the

Company. Underlying profit determines the dividend payout to shareholders.

26. EMPLOYEE SHARE SCHEMES

Leadership share scheme

The Group operates an employee share scheme for certain senior employees, other than non-executive directors,

to purchase ordinary shares in the Company.

The Group provides the employees with limited recourse loans on an interest-free basis to support employees’

participation in the scheme. These shares are treated as treasury stock when purchased on market, due to the

features of the scheme.

The loans are applied to the purchase of shares on market, so the number of shares and the consideration

for each share are determined by the market price at that time. The scheme holds 2,655,017 fully allocated

shares, which represents 0.53 percent of the total shares on issue (2020: 2,711,244 fully allocated shares, which

represented 0.54 percent of the total shares on issue).

Shares purchased under the scheme are held by two directors as custodians, and the shares carry the same

rights as all other ordinary shares. The loan is repayable if the employee is no longer employed by the Group.

The following table reconciles the shares purchased on market under the scheme at the beginning and end of

the financial year.

20212020

Number of

shares

Number of

shares

Balance at beginning of the financial year2,711,2442 ,57 7, 27 2

Purchased on market during the year994,8601,026,708

Forfeited during the financial year(236,003)(213,479)

Vested during the financial year(815,084)(679,257)

Balance at end of the financial year2,655,0172,711,244

Shares were purchased under the scheme in August 2020 at a price of $13.468 per share. Remaining shares held

by the scheme were purchased in August 2019 ($13.40) and August 2018 ($12.98).

Shares vested in August 2020 were originally purchased at $9.32 per share in 2017 and are now held directly by

employees. The amounts owed by employees in these vested shares are included within advances to employees.

This balance includes $277,083 owing by the senior executive team (as defined in note 19) in the share scheme

(2020: $1,776,967).

RYMAN HEALTHCARE

132

Notes to the consolidated financial statements (continued)
FOR THE YEAR ENDED 31 MARCH 2021

26. EMPLOYEE SHARE SCHEMES (CONTINUED)

The directors estimate the fair value of each employee advance granted at the time of the purchase of shares on

market, on behalf of the selected employee. Due to the on-market purchase and sale features of the scheme, and

the scheme agreement arrangements, the directors consider any such value to be immaterial. Shares subject to

this scheme vest 3 years from the date of purchase.

All staff employee share scheme

In addition, the Group operates a share scheme that is available for all staff.

Participants of this scheme contribute a minimum of $500 (and up to a maximum amount of $10,000) towards the

on-market purchase of Ryman Healthcare Limited shares. To help the staff member purchase more shares, the Group

advanced an interest-free loan equal to the employee’s contribution towards the share purchase (financial assistance).

The loan is repayable when the staff member leaves the Group. Shares purchased under the scheme are held in

the employee’s name. The financial assistance provided by the Group is recorded in advances to employees.

27. SUBSEQUENT EVENTS

The directors resolved to pay a final dividend of 13.6 cents per share or $68 million, with no imputation credits

attached, to be paid on 18 June 2021.

Refinance of loans and borrowings

Subsequent to 31 March 2021, the Group refinanced the NZD and AUD bank loan facilities. Following the refinance,

the facilities total $1.65 billion (NZD bank loan facility) and AUD$370 million (AUD bank loan facility).

The Group also entered into an AUD$250 million, 7-year institutional term loan (ITL).

Following the refinance, the total interest-bearing loans and borrowing facilities of the Group (including bank loans,

retail bonds, USPP notes and ITL) are NZD$2.18 billion and AUD$652 million. The weighted average maturity

profile of the Group’s interest-bearing loans and borrowings is 4.79 years.

28. AUTHORISATION

The directors authorised the issue of these financial statements on 20 May 2021.




Claire Higgins

Non-Executive Director and

Chair of Audit and Financial Risk Committee

Dr David Kerr

Chair

ANNUAL REPORT 2021

133

OpinionWe have audited the consolidated financial statements of Ryman Healthcare Limited and its
subsidiaries (the ‘Group’), which comprise the consolidated balance sheet as at 31 March 2021, and

the consolidated income statement, statement of comprehensive income, statement of changes in

equity and statement of cash flows for the year then ended, and notes to the consolidated financial

statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements, on pages 86 to 133, present

fairly, in all material respects, the consolidated financial position of the Group as at 31 March 2021,

and its consolidated financial performance and cash flows for the year then ended in accordance

with New Zealand Equivalents to International Financial Reporting Standards (‘NZ IFRS’) and

International Financial Reporting Standards (‘IFRS’).

Basis for opinionWe conducted our audit in accordance with International Standards on Auditing (‘ISAs’) and

International Standards on Auditing (New Zealand) (‘ISAs (NZ)’). Our responsibilities under those

standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated

Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a

basis for our opinion.

We are independent of the Company in accordance with Professional and Ethical Standard 1

International Code of Ethics for Assurance Practitioners (including International Independence

Standards) (New Zealand) issued by the New Zealand Auditing and Assurance Standards Board

and the International Ethics Standards Board for Accountants’ International Code of Ethics for

Professional Accountants (including International Independence Standards), and we have fulfilled

our other ethical responsibilities in accordance with these requirements.

Our firm carries out an assurance engagement for the Group relating to Australian aged care.

These services have not impaired our independence as auditor of the Company and Group.

In addition to this, partners and employees of our firm deal with the Company and its subsidiaries

on normal terms within the ordinary course of trading activities of the business of the Company

and its subsidiaries. The firm has no other relationship with, or interest in, the Company or any of

its subsidiaries.

Audit materialityWe consider materiality primarily in terms of the magnitude of misstatement in the financial

statements of the Group that in our judgement would make it probable that the economic

decisions of a reasonably knowledgeable person would be changed or influenced (the ‘quantitative’

materiality).

In addition, we also assess whether other matters that come to our attention during the audit would

in our judgement change or influence the decisions of such a person (the ‘qualitative’ materiality). We

use materiality both in planning the scope of our audit work and in evaluating the results of our work.

We determined materiality for the Group financial statements as a whole to be $17.5m.

Key audit mattersKey audit matters are those matters that, in our professional judgement, were of most significance

in our audit of the consolidated financial statements of the current period. These matters were

addressed in the context of our audit of the consolidated financial statements as a whole, and in

forming our opinion thereon, and we do not provide a separate opinion on these matters.

Independent Auditor’s Report

TO THE SHAREHOLDERS OF RYMAN HEALTHCARE LIMITED

RYMAN HEALTHCARE

134

Valuation of investment propertiesHow our audit addressed the key audit matter
As explained in policy (f) and note 7 in the consolidated

financial statements, investment properties are carried

at fair value on the consolidated balance sheet. The

fair value was determined by independent registered

valuers appointed by the Group.

These properties were valued at $6,837m

(2020: $5,760m). The revaluation gain recognised

in the consolidated income statement was $417m

(2020: $144m).

We include the valuation of investment properties as a

key audit matter for two reasons:

1. The significance to the financial statements:

The investment properties account for 75% of

the total assets (2020: 75%), making it the most

significant balance on the balance sheet.

2. The complexity of the valuation model:

The valuation model is complex and combines

discounted future cash flows and occupancy

advances received from residents. The valuation

relies on various estimates and underlying

assumptions, including current unit pricing,

discount rates, long term house price inflation

and the occupancy periods of residents. A

small percentage difference in certain input

assumptions could result in a material change

to the valuation.

Our procedures focused on:

• The appropriateness of the valuation methodology

• The reasonableness of underlying assumptions in the

valuation model.

Our procedures included, amongst others:

• Evaluating the Group’s processes for the independent

valuation of the investment properties

• Reading the valuation reports for properties within the

group and reviewing the valuation methodology and the

reasonableness of the significant underlying assumptions

• Discussing with management the nature of key assumptions

• Assessing the competence, objectivity, and integrity of

the independent registered valuers. We assessed their

professional qualifications and experience. We also obtained

representation from them about their independence and the

scope of their work

• Meeting with the valuers to understand the valuation

process adopted. The purpose of the meeting was to

identify and challenge the critical judgment areas in the

valuation model and to confirm the valuation approach was

in accordance with NZ IFRS 13 Fair Value Measurement.

We specifically discussed the impact of COVID-19 with the

valuers and critically challenged the changes made to key

assumptions and their reasonableness relative to the

31 March 2020 valuation

• Using our in-house valuation specialists to assess the

appropriateness of the valuation methodology and challenge

the reasonableness of the underlying assumptions. Our

specialists focused on the appropriateness of the valuation

methodology, as well as assumptions for current unit pricing,

long term house price inflation and discount rates

• Agreeing a sample of sales and resales to contracts,

recalculating actual growth rates on resales to compare to

growth applied by the valuer, and recalculating the average

tenure of residents based on a sample of contracts to compare

to assumed occupancy periods applied by the valuer

• Comparing a sample of current unit market values

determined by the valuer to actual prices received at

comparable units within the village

• Assessing the discount rates for reasonableness by

comparing the rates to those adopted in the previous year

and the rates adopted by comparable entities, challenging

the adjustments made to take into account the changing

impacts of COVID-19

• Considering the appropriateness of the disclosures in note 7

ANNUAL REPORT 2021

135

Valuation of care-facility land and buildingsHow our audit addressed the key audit matter
As explained in policy (d) and note 6 in the

consolidated financial statements, care facility land

and buildings are carried at their fair value at the date

of revaluation less any subsequent accumulated

depreciation and impairment losses.

The fair value was determined by independent

registered valuers appointed by the Group.

The net book value of care facility land and buildings

as reflected in note 6 is $955m (2020: $711m). The

revaluation gain recognised in other comprehensive

income was $196m (2020: $nil).

We included the valuation of care-facility land and

buildings as a key audit matter for two reasons:

1. The materiality of the account balance, and the

revaluation movements.

2. The complexity of the valuation model:

The valuation model includes both observable

and non-observable inputs. It uses significant

assumptions, including the determination of the

earnings that were capitalised, the capitalisation

rates adopted, and the assessment of the

market value per care bed. These inputs require

significant judgement.

Our procedures focused on:

• the appropriateness of the valuation methodology

• the reasonableness of underlying assumptions in the

valuation model.

Our procedures included, amongst others:

• Evaluating the Group’s processes regarding the independent

valuation of the care facility land and buildings

• Reviewing the valuation methodology and the

reasonableness of the significant valuation assumptions

• Assessing the competence, objectivity, and integrity of

the independent registered valuers. We assessed their

professional qualifications and experience. We also obtained

representation from them about their independence and the

scope of their work

• Meeting with the valuers to understand the valuation process

adopted. The purpose of the meeting was to identify and

challenge the critical judgement areas in the valuation model

and to confirm the valuation approach was in accordance

with NZ IFRS 13 Fair Value Measurement. We specifically

discussed the impact of COVID-19 with the valuers and

critically challenged any related adjustments made to key

assumptions and their reasonableness

• Using our in-house valuation specialists to assess the

appropriateness of the valuation methodology and challenge

the reasonableness of the underlying assumptions. Our

specialists focused on the assumptions for earnings

capitalisation rates

• Assessing the reasonableness of the capitalisation rates and

market value per care bed adopted in the valuation

• Agreeing, on a sample basis, the earnings capitalised to the

underlying accounting records and challenging the valuers

on the adjustments made to actual earnings in arriving at the

earnings used in the valuation

• Considering the appropriateness of the disclosures in note 6

RYMAN HEALTHCARE

136

Other information The directors are responsible on behalf of the Group for the other information. The other
information comprises the information in the Annual Report that accompanies the consolidated

financial statements and the audit report. The Annual Report will be made available to us after the

date of this auditor’s report.

Our opinion on the consolidated financial statements does not cover the other information and we

do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and consider whether it is materially inconsistent

with the consolidated financial statements or our knowledge obtained in the audit or otherwise

appears to be materially misstated. If so, we are required to report that fact.

When we read the other information in the Annual Report, if we conclude that there is a material

misstatement therein, we are required to communicate the matter to the directors and consider

further appropriate actions.

Directors’

responsibilities for the

consolidated financial

statements

The directors are responsible on behalf of the Group for the preparation and fair presentation of

the consolidated financial statements in accordance with NZ IFRS and IFRS, and for such internal

control as the directors determine is necessary to enable the preparation of consolidated financial

statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible on behalf of the

Group for assessing the Group’s ability to continue as a going concern, disclosing, as applicable,

matters related to going concern and using the going concern basis of accounting unless the

directors either intend to liquidate the Group or to cease operations, or have no realistic alternative

but to do so.

Auditor’s

responsibilities

for the audit of the

consolidated financial

statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial

statements as a whole are free from material misstatement, whether due to fraud or error, and

to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of

assurance, but is not a guarantee that an audit conducted in accordance with ISAs and ISAs (NZ)

will always detect a material misstatement when it exists. Misstatements can arise from fraud

or error and are considered material if, individually or in the aggregate, they could reasonably be

expected to influence the economic decisions of users taken on the basis of these consolidated

financial statements.

A further description of our responsibilities for the audit of the consolidated financial statements is

located on the External Reporting Board’s website at:

https://www.xrb.govt.nz/standards-for-assurance-practitioners/auditors-responsibilities/audit-

report-1

This description forms part of our auditor’s report.

Restriction on use This report is made solely to the Company’s shareholders, as a body. Our audit has been

undertaken so that we might state to the Company’s shareholders those matters we are required

to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by

law, we do not accept or assume responsibility to anyone other than the Company’s shareholders

as a body, for our audit work, for this report, or for the opinions we have formed.

Paul Bryden, Partner

for Deloitte Limited

Christchurch, New Zealand

20 May 2021

ANNUAL REPORT 2021

137

Sidney Humphries and
Sandra Humphries, Ryman residents.

138

RYMAN HEALTHCARE

Statement
of corporate

governance

ANNUAL REPORT 2021

139

Statement of corporate governance
Ryman believes in the benefit of good

corporate governance and the value it

provides for our shareholders, residents,

staff, and other stakeholders.

Ryman’s board of directors is responsible

for the company’s corporate governance.

The board undertakes this role with reference

to best practice and takes into consideration

the recommendations outlined in the NZX

Corporate Governance Code (the Code).

The company’s approach to applying the

recommendations outlined in the Code are

set out below. The section is set out in the

order of the principles detailed in the Code

and explains how Ryman is applying the

Code’s recommendations.

Ryman’s policy documents referred to in this

section are available at www.rymanhealthcare.

co.nz/about-us/investors/governance.

NZX Listing Rules

The company applies the NZX Main Board Listing

Rules (the Listing Rules). At the date of this report,

the current version of the Listing Rules are those

dated 10 December 2020.

COVID-19 Class Waiver – 2020 results

announcement and annual report

As a result of the COVID-19 situation, on 19 March 2020

NZX Regulation granted a class waiver, under which

the timing requirements for the release of results

announcements and annual reports were extended

for issuers with certain balance dates, if those issuers

considered they required that additional time to meet

their periodic reporting requirements.

Under the class waiver, issuers were given up to an

additional 30 days to prepare and release results

announcements, and up to an additional 2 months

to prepare and release annual reports.

Ryman considered the impact of COVID-19 and

determined that additional time was required to

meet its periodic reporting requirements, and relied

on the class waiver in relation to its full-year results

announcement for the year ended 31 March 2020.

The 2020 full-year results announcement was

released on 12 June 2020.

The 2020 annual report was released on 29 June 2020,

which met the standard periodic reporting requirements

under the Listing Rules and did not make use of the

class waiver.

PRINCIPLE 1 – CODE OF ETHICAL

BEHAVIOUR

“Directors should set high standards of ethical

behaviour, model this behaviour and hold

management accountable for these standards

being followed throughout the organisation.”

Code of ethics

As part of the board’s commitment to the highest

standards of behaviour and accountability, the

company has adopted a code of ethics to guide

directors, senior management, and employees in

carrying out their duties and responsibilities.

Ryman’s code of ethics is the framework of standards by

which the directors, senior management, and employees

are expected to conduct their professional lives. It is

intended to support decision-making that is consistent

with Ryman’s values, business goals, and legal and policy

obligations, rather than to prescribe an exhaustive list of

acceptable and non-acceptable behaviour.

The board approves the code of ethics, which covers

matters such as:

• interacting with residents and their families,

employees, and suppliers

• accepting gifts or other benefits

• dealing with conflicts of interest

• protecting company assets

• complying with laws and policies

• maintaining confidentiality

• reporting breaches.

RYMAN HEALTHCARE

140

Statement of corporate governance (continued)
New employees receive a copy of the code of ethics,

which is accessible to all staff on the Ryman intranet

and the company website.

The company has a whistleblower and protected

disclosure policy. The purpose of the policy is to

protect an employee who wishes to raise concerns of

serious wrongdoing from reprisals or victimisation for

reporting their concerns.

Financial product trading policy

Ryman supports the integrity of New Zealand’s

financial markets. This integrity is maintained, in

part, through the insider trading laws that apply in

New Zealand. Ryman’s financial product trading policy

outlines how those laws apply, as well as the rules that

Ryman has put in place so that those laws are followed.

Directors, certain employees, and their related parties

must seek approval from the company to trade in the

company’s shares. Trading is limited to two ‘trading

windows’: between the full-year announcement

date and 31 August, and between the half-year

announcement date and 31 January each year.

The directors’ shareholdings and all trading of shares

during the year by the directors is disclosed in the

section headed Directors’ disclosures. A director or

senior manager is obliged to advise the NZX promptly

if they trade in the company’s shares.

PRINCIPLE 2 – BOARD COMPOSITION AND

PERFORMANCE

“To ensure an effective board, there should be

a balance of independence, skills, knowledge,

experience and perspectives.”

The board of directors

The directors are responsible for the corporate

governance practices of the company. The practices

adopted by the board are prescribed in a charter that

sets out the protocols for how the board operates.

The charter complies with the relevant recommendations

in the Code and is reviewed annually.

The board’s primary role is to effectively represent and

promote the interests of shareholders, with a view to

adding long-term value to the company’s shares.

The board carries out its responsibilities according to

the following mandate.

• The board should consist of a majority of

non-executive directors.

• At least a third of the directors should be

independent of management and free from any

business or other relationship or circumstance

that could materially interfere with the exercise

of a director’s independent judgement.

• The board’s chair should be a non-executive

director (and not the group chief executive).

• Directors should possess a broad range of skills,

qualifications, and experience and remain up to date

on how best to perform their duties as directors.

• Management must provide information of

sufficient content, quality, and timeliness as the

board considers necessary to allow the board to

effectively discharge its duties.

• The effectiveness and performance of the

board and its individual members should be

re-evaluated annually.

The board consists entirely of non-executive directors.

The directors of the company at 31 March 2021 are

Dr David Kerr, Jo Appleyard, Warren Bell, Claire Higgins,

George Savvides, Geoff Cumming, Anthony Leighs,

Paula Jeffs and Greg Campbell.

The board has determined that Dr David Kerr,

Jo Appleyard, Claire Higgins, George Savvides,

Anthony Leighs, Paula Jeffs and Greg Campbell

are all independent directors for the purposes of

the Listing Rules.

More information on the directors, including their

experience, interests, qualifications, length of service,

and shareholdings, is provided in the Directors’

disclosures section of this report and is on the

company’s website. A summary of the board’s skill

set is detailed in the table below.

Day-to-day management of Ryman is delegated to the

group chief executive and the senior executive team.

The group chief executive and senior executive team

are delegated the responsibility for implementing the

board’s strategy.

ANNUAL REPORT 2021

141

Statement of corporate governance (continued)
Dr David

Kerr

Jo

Appleyard

Warren

Bell

George

Savvides

Claire

Higgins

Geoff

Cumming

Anthony

Leighs

Paula

Jeffs

Greg

Campbell

Governance

••••••••

Executive leadership

••••••

Finance, accounting and taxation

••••••

Risk management

•••••••••

Property and construction

•••••

Health and safety

••••••

Health, clinical and aged care

•••••••

Digital and technology

••

Human resources

••••••

Strategy

•••••••••

The board’s responsibilities

The primary responsibilities of the board are to:

• ensure the company’s goals are clearly established

and that strategies are in place for achieving them

• establish policies for strengthening the

performance of the company and ensure that

management is proactively seeking to build

the business

• monitor the performance of management

• appoint the group chief executive and set the

terms of the group chief executive’s employment

agreement

• decide on what steps are needed to protect the

company’s financial position and its ability to meet

its debts and other obligations when they fall due,

and ensure that such steps are taken

• ensure the company’s financial statements are

true and fair and conform with the law

• ensure the company adheres to high standards of

ethics and corporate behaviour

• ensure the company adheres to its health and

safety obligations and commitments

• ensure the company has appropriate risk

management/regulatory compliance policies

in place.

On appointment to the board by the shareholders,

new directors sign a written agreement that covers the

terms of their appointment.

Every year, the board and sub-committees critically

evaluate their own performance, and their own

processes and procedures. Through this process,

the board identifies any training opportunities for

individual directors to ensure they have relevant and

up-to-date skills for performing their role.

Under the Listing Rules every director must stand for

re-election on the later of 3 years and the third annual

meeting after their appointment. These directors may

offer themselves for re-election.

The Governance, Remuneration and Nomination

Committee undertakes the process for nominating

directors on behalf of the board, and makes

appropriate recommendations to the board.

The committee’s terms of reference include the

process for nominating directors.

Directors appointed by the board must retire at the

next annual meeting following their appointment.

These directors may offer themselves for re-election.

Independent professional advice

With the prior approval of the chair, each director

has the right to seek independent legal and other

professional advice at the company’s expense

about any aspect of the company’s operations or

undertakings to assist in fulfilling their duties and

responsibilities as directors.

Diversity

The board and management ensure that all eligible

people get an equal opportunity to demonstrate that

they have the right skills and experience for a particular

role, which forms the basis of our diversity policy.

RYMAN HEALTHCARE

142

Statement of corporate governance (continued)
Ryman embraces the uniqueness in all of our people

and welcomes diversity. We encourage all of our

employees to listen to each other and to our residents

and their families, and to work to meet the needs of

individual people.

Our approach to diversity is to continually develop a

work environment that supports equality and inclusion,

regardless of difference.

The board sets measurable objectives for assessing

performance against Ryman’s diversity policy (including

achieving gender diversity) and assesses progress

annually. The board ensures Ryman’s objectives are

appropriate for promoting diversity and inclusion.

The gender diversity for our leadership roles at

31 March is as follows.

20212020

DirectorsMale65

Female33

98

Senior Executive TeamMale54

Female23

77

Ryman LeadersMale197143

Female349291

546434

PRINCIPLE 3 – BOARD COMMITTEES

“The board should use committees where this

will enhance its effectiveness in key areas, while

still retaining board responsibility.”

Board committees

The board has five standing committees: Audit and

Financial Risk; People and Safety; Clinical Governance;

Development and Construction; and Governance,

Remuneration and Nomination.

A separate Independent Directors’ Committee

meets as needed.

Each committee operates under specific terms of

reference approved by the board. Any recommendations

they make are recommendations to the board.

The terms of reference for each committee are

reviewed annually.

Audit and Financial Risk Committee

The objective of the Audit and Financial Risk

Committee (AFRC) is to assist the board in discharging

its responsibilities for financial reporting, and risk and

financial/secretarial compliance.

The committee makes recommendations to the board

on appointing external auditors to ensure that they are

independent and to ensure that the company provides

for 5-yearly rotation of the lead audit partner.

The committee provides a forum for the effective

communication between the board and external

auditors. The committee’s responsibilities include:

• reviewing the appointment of the external

auditor, the annual audit plan, and addressing

any recommendations from the audit

• reviewing any dividend proposals and financial

information to be issued to the public

• ensuring that appropriate financial systems

and internal controls are in place

• oversight of the Group’s financial and enterprise

level risk environment.

The AFRC must consist of at least three directors,

who must wherever possible be independent

non-executive directors. The board chair must also

not be the chair of the AFRC. The current members

are Claire Higgins (chair), Warren Bell (deputy chair),

Geoff Cumming, Dr David Kerr, George Savvides, and

Greg Campbell. Dr David Kerr, Claire Higgins,

George Savvides, and Greg Campbell are all

independent non-executive directors. Claire Higgins

is a Fellow of CPA Australia and Warren Bell is a Fellow

of Chartered Accountants Australia New Zealand.

The committee generally invites the group chief

executive, chief financial officer, and the external

auditor to attend AFRC meetings as appropriate. The

committee also meets and receives regular reports

from the external auditor without management

present, concerning any matters that arise in

connection with the performance of the auditor’s role.

The committee maintains direct lines of

communication with the group chief executive, and

the chief financial officer. Any director may attend.

ANNUAL REPORT 2021

143

Statement of corporate governance (continued)
People and Safety Committee

The People and Safety Committee (previously the

Health, Safety and Wellbeing Committee) assists the

board in discharging its responsibilities in overseeing

and reviewing people and health, safety and wellbeing

matters arising out of Ryman’s activities and the

impact of these activities on staff, contractors,

residents, and visitors to Ryman.

The committee recognises the critical role people

and safety forms as part of its day-to-day operations

and wants to ensure a safety-first culture across all

business operations.

The members of the committee are Paula Jeffs (chair),

Claire Higgins, Dr David Kerr, Jo Appleyard,

Geoff Cumming, Greg Campbell, Gordon MacLeod

(Group Chief Executive), as a director of all Ryman

Group subsidiaries and David Bennett (Chief Financial

Officer), as a director of all Ryman Group subsidiaries.

The committee’s responsibilities include:

• reviewing, monitoring and making

recommendations to the board on the health and

safety risk management framework and policies,

and the people and culture plan

• reviewing and making recommendations to

the board on strategies for achieving workforce

health, safety and wellbeing objectives through

oversight of the organisation’s major project or

other improvement plans

• ensuring the board and directors are properly and

regularly informed on matters relating to people

and health, safety and wellbeing governance,

performance, and compliance

• conducting regular assessments and audits of the

risk profile and control processes

• monitoring compliance with people and health,

safety and wellbeing policies and relevant applicable

law through oversight of major assurance functions

• reviewing and making recommendations to the

board on strategies for achieving people and

culture objectives.

The committee maintains direct lines of

communication with the chief operations officer,

the chief construction officer, and the head of

people and culture.

Clinical Governance Committee

The Clinical Governance Committee supports,

and enhances the quality of, the company’s clinical

performance and care and service provision.

The committee assists the board in discharging its

oversight of clinical reporting and clinical compliance

and is focused on innovation in healthcare and ensuring

alignment with emerging best clinical practice.

The committee consists of three non-executive

directors: George Savvides (chair), Dr David Kerr, and

Jo Appleyard, as well as Tim Wilkinson, a professor at

Otago Medical School and a consulting geriatrician,

and Dr Doug Wilson, an author and biotechnologist.

The committee also invite clinically-trained staff to

attend as required.

The committee’s responsibilities are to:

• liaise with internal and external clinical auditors

• review internal and external clinical audit findings

• review significant changes to clinical policies

• review significant complaints and investigations

relating to care of residents

• ensure appropriate clinical information systems

and external controls are in place

• review changes in clinical practice in aged care.

The committee maintains direct lines of

communication with the external clinical auditors, the

group chief executive, the chief operations officer, and

the internal clinical auditor.

External clinical auditors are invited to attend a

meeting each year and report to the committee,

including presenting a review of the internal clinical

audit function.

Development and Construction Committee

The Development and Construction Committee

reviews and enhances the quality of the company’s

development and construction performance.

The committee assists the board in discharging

its oversight of the company’s development and

construction activities and practices.

The committee consists of five non-executive

directors: Anthony Leighs (chair), Jo Appleyard,

Warren Bell, Claire Higgins, and Greg Campbell.

RYMAN HEALTHCARE

144

Statement of corporate governance (continued)
The committee’s responsibilities include:

• ensuring the consent and construction programme

assists in delivering the company’s long-term plan

• investigating new, innovative construction and design

methods to improve resident and staff experiences

• reviewing New Zealand and Victoria cost

trends, buildability, availability of resources and

compliance with regulatory and quality protocols

• reviewing site feasibilities and due diligence

outcomes to provide confirmation of review to

the board

• reviewing systems and procedures supporting the

design, consent and building process.

The committee maintains direct lines of communication

with the group chief executive, the chief financial

officer, the chief development officer and the chief

construction officer.

Governance, Remuneration and

Nomination Committee

The Governance, Remuneration and Nomination

Committee assists the board in establishing

remuneration policies and practices for the company

in discharging the board’s responsibilities for

remuneration. The committee also undertakes the

process for nominating directors on behalf of the

board, and makes appropriate recommendations to

the board.

The committee’s terms of reference include the

process for nominating directors.

Membership of the committee must comprise

non-executive directors, a majority of whom must

be independent. The committee consists of four

non-executive directors: Geoff Cumming (chair),

Dr David Kerr, George Savvides and Paula Jeffs.

Management attends committee meetings only at the

invitation of the committee.

The committee’s objectives are to:

• assist the board in establishing remuneration

policies and practices for the company

• assist in discharging the board’s responsibilities

for reviewing the group chief executive’s and the

directors’ remuneration

• advise and assist the group chief executive in

setting remuneration for the senior executive team

• regularly review and recommend changes

to the composition of the board and identify

and recommend individuals for nomination as

members of the board and its committees.

The directors’ remuneration is set out in the

Directors’ disclosures section of this report.

Detail of the group chief executive’s remuneration is

set out under Principle 5.

Independent Directors’ Committee

The Independent Directors’ Committee is convened

as needed and consists of independent non-executive

directors who address significant conflicts of interest

and any other matters referred by the board.

Ryman has protocols that set out the procedures to be

followed if there is a takeover offer. These procedures

are set out in the Takeover Response Protocols that

have been adopted by the board.

Attendance at board and committee meetings

Director attendance at board and committee meetings

is shown in the table below.

The table details the attendance at the meetings

outlined in the board and committee meeting plan for

the year ended 31 March 2021 plus additional meetings

held during the year. Board meetings consist of a

number of meetings held over multiple days.

In addition to the meetings outlined in the board

and committee meeting plan, the board and Clinical

Governance Committee held additional meetings to

consider the impact of, and the continued response

to, COVID-19. Wherever possible all members of the

board and committee were in attendance at these

additional meetings. However, due to the pace at which

the response to COVID-19 has evolved over the course

of the year and the necessarily short notice given for

some meetings, not all members were available to

attend every meeting.

ANNUAL REPORT 2021

145

Statement of corporate governance (continued)
Attendance at board and committee meetings

BoardAudit and

Financial

Risk

People and

Safety

Clinical

Governance

Development and

Construction

Governance,

Remuneration and

Nomination

Number of meetings held1145776

Dr David Kerr11/11 (chair)4 /45/57/ 76/6

Jo Appleyard11/114/56/76/7

Warren Bell11/114 /47/ 7

Claire Higgins11/114/4 (chair)5/5 (4 as

chair)

1

7/ 7

George Savvides11/114 /47/7 (chair)6/6

Geoff Cumming11/114 /41/16/6 (chair)

Anthony Leighs10/117/7 (chair)

Paula Jeffs11/113/3 (1 as

chair)

1

6/6

Greg Campbell1/1

2

The Independent Directors’ Committee did not meet during the year.

1 Paula Jeffs replaced Claire Higgins as the chair of the People and Safety Committee (previously Health, Safety and Wellbeing

Committee).

2 Greg Campbell joined the board in March 2021.

Summary of committee memberships

CommitteeMembers at 31 March 2021Members at 31 March 2020

Audit and Financial RiskClaire Higgins (chair), Warren Bell

(deputy chair), Dr David Kerr,

George Savvides, Geoff Cumming,

Greg Campbell

Claire Higgins (chair), Warren Bell

(deputy chair), Dr David Kerr,

George Savvides, Geoff Cumming

People and Safety (previously Health,

Safety and Wellbeing)

Paula Jeffs (chair), Claire Higgins,

Dr David Kerr, Jo Appleyard,

Geoff Cumming, Greg Campbell,

Gordon MacLeod (Group Chief

Executive), David Bennett (Chief

Financial Officer)

Claire Higgins (chair), Dr David Kerr,

Jo Appleyard, Gordon MacLeod (Group

Chief Executive), David Bennett (Chief

Financial Officer)

Clinical GovernanceGeorge Savvides (chair), Dr David Kerr,

Jo Appleyard

George Savvides (chair), Dr David Kerr,

Jo Appleyard

Development and ConstructionAnthony Leighs (chair), Jo Appleyard,

Warren Bell, Claire Higgins,

Greg Campbell

Anthony Leighs (chair), Jo Appleyard,

Warren Bell, Claire Higgins

Governance, Remuneration and

Nomination

Geoff Cumming (chair), Dr David Kerr,

George Savvides, Paula Jeffs

Geoff Cumming (chair), Dr David Kerr,

George Savvides

RYMAN HEALTHCARE

146

Statement of corporate governance (continued)
PRINCIPLE 4 – REPORTING AND

DISCLOSURE

“The board should demand integrity in financial

and non-financial reporting, and in the timeliness

and balance of corporate disclosures.”

Reporting and disclosure

The board focuses on providing accurate, adequate,

and timely information both to existing shareholders

and to the market generally. This enables all investors

to make informed decisions about the company.

Ryman, as a company listed on the NZX Main Board,

has an obligation to comply with the disclosure

requirements under the NZX Main Board Listing Rules.

Ryman recognises that these requirements aim to

provide equal access for all investors or potential

investors to material price-sensitive information

concerning issuers or their financial products. This in

turn promotes confidence in the market.

Ryman’s market disclosure policy outlines the

obligations of Ryman and relevant Ryman personnel

in satisfying the disclosure requirements. It also

covers other related matters including external

communications by Ryman.

This annual report is produced using the principles

of Integrated Reporting <IR>. An integrated report

provides more information on the company’s business

model and how we create value over time. As a result,

an annual report produced under the <IR> framework

will have a broader narrative than an annual report that

does not use the framework.

Ryman publishes its key governance and other

relevant documents in the investor centre of the

company’s website at www.rymanhealthcare.co.nz/

about-us/investors/governance.

All significant announcements made to the NZX and

reports issued are also posted on the company’s website.

PRINCIPLE 5 – REMUNERATION

“The remuneration of directors and executives

should be transparent, fair and reasonable.”

The Governance, Remuneration and Nomination

Committee makes recommendations to the board on

remuneration matters in keeping with the committee’s

terms of reference. The committee does not have the

authority to make decisions on behalf of the board.

The committee is also responsible for making

recommendations to the board on the remuneration

of the group chief executive.

The total director remuneration pool is approved by

shareholders at the annual general meeting (AGM)

as required under the Listing Rules.

The board is responsible for the setting of individual

directors’ fees in line with the approved pool and the

Listing Rules.

Details of the directors’ remuneration for the year are

in the Directors’ disclosures section of this report.

Ryman has in place a remuneration policy that

outlines the key principles that influence Ryman’s

remuneration practices.

The remuneration of the group chief executive and

the senior executive team is determined by the

significance of their role and the industry. The total

remuneration is made up of fixed remuneration and

short and medium-term cash-based incentives. The

group chief executive and senior executive team are

also members of the senior leadership share scheme

(see note 26 of the financial statements).

The short and medium-term incentives are at-risk

payments that reward performance. They are

designed to motivate and incentivise senior staff in the

delivery of performance over a 1 and 3-year operating

cycle. The amount payable is set over the performance

period. The payment of the short and medium-term

incentive depends on achieving certain results and

outcomes. Performance over the 1 and 3-year periods

is measured against ‘stretch’ performance targets. The

performance metrics differ with each role.

Every year, the committee reviews the levels and

appropriateness of these incentives and weighting.

There are no long-term incentives for the senior

executive team that are subject to performance risk.

The senior leadership share scheme provides

certain employees with limited recourse loans on

an interest-free basis to support the employees’

participation in the scheme.

ANNUAL REPORT 2021

147

Statement of corporate governance (continued)
For accounting purposes, these shares are treated as

treasury stock when purchased on market, due to the

features of the scheme.

Shares subject to this scheme have a restricted

period of 3 years from the date of purchase, to

appropriately incentivise participants over a longer

period. The loan is repayable if the employee is no

longer employed by Ryman.

Employees’ remuneration

The table below details the number of Ryman group

employees who have earned over $100,000 during

the year ended 31 March 2021. The remuneration

includes salary, short-term incentives, and employer’s

contribution to KiwiSaver and Superannuation.

Remuneration $Number of employees

1,110,000–1,120,0001

560,000–570,0001

540,000–550,0001

470,000–480,0001

460,000–470,0001

410,000–420,0001

370,000–380,0002

340,000–350,0001

330,000–340,0001

320,000–330,0001

310,000–320,0001

300,000–310,0001

290,000–300,0003

280,000–290,0002

270,000–280,0004

250,000–260,0002

240,000–250,0004

230,000–240,0006

220,000–230,0007

210,000–220,0006

200,000–210,0007

190,000–200,0008

180,000–190,0004

170,000–180,00016

160,000–170,00013

150,000–160,00020

140,000–150,00036

130,000–140,00052

120,000–130,00068

110,000–120,00072

100,000–110,00083

Group chief executive remuneration

Gordon MacLeod’s remuneration for the year is as follows.

20212020

$$

Salary1,080,2841,097,127

KiwiSaver32,40839,514

Subtotal1,112,6921,136,641

Short-term incentive-220,000

Medium-term incentive --

Total remuneration

1

1,112,6921,356,641

Loan provided under the

leadership share scheme1,200,0001,200,000

1 There were no other benefits (including long-term incentives)

received in this financial year.

The at-risk short-term and medium-term incentives

are payable on the achievement of certain key

performance indicators (KPIs). These KPIs are focused

on the financial performance of Ryman, specific

operational targets, and people-related expectations.

At 31 March 2021, the total number of shares owned

by and/or held for the benefit of the group chief

executive totalled 672,309 (2020: 660,963). For these

shares, loans totalling $3,346,298 (2020: $3,136,317)

are outstanding.

PRINCIPLE 6 – RISK MANAGEMENT

“Directors should have a sound understanding of

the material risks faced by the issuer and how to

manage them. The board should regularly verify

that the issuer has appropriate processes that

identify and manage potential and material risks.”

The board is responsible for overseeing the company’s

system of internal controls to manage key risks and

have overall responsibility for managing risk.

The company maintains a group risk register to

identify and manage risk. Specific people and safety,

and clinical risk registers are separately maintained

given the significance of these areas to the business.

The senior executive team is responsible for

maintaining the risk registers.

Ryman operates an extensive internal accreditation

programme that addresses issues such as

RYMAN HEALTHCARE

148

Statement of corporate governance (continued)
service delivery, health, safety and wellbeing, and

administration. Internal audits are undertaken

regularly. The results of these audits and critical

indicators are regularly reported to the board.

Through the AFRC, the board considers the

recommendations and advice of external auditors,

and ensures that those recommendations are

investigated and, where considered necessary,

appropriate action is taken.

Through the board committees, health, safety and

wellbeing is discussed regularly at board, senior

executive team, construction team, and operational

team meetings. Regular reporting of key metrics is

prepared to assist these teams in managing health,

safety and wellbeing risks. Further information is in the

Caring for our people section of this report.

Ryman has a Group Tax Charter that sets out the

Group Tax Strategy of Ryman and its subsidiaries.

The Tax Charter along with the Tax Risk Management

Policy and other operational tax policies forms part of

the Group Tax Governance Framework.

Ryman has identified, through consultation with

external and internal stakeholders, key risks and

the impact of these risks. These risks, and Ryman’s

response, are detailed in the materiality matrix

contained in this annual report.

PRINCIPLE 7 – AUDITORS

“The board should ensure the quality and

independence of the external audit process.”

The Audit and Financial Risk Committee makes

recommendations to the board on the appointment

of the external auditor as set out in the terms

of reference. The committee also monitors the

independence and effectiveness of the external

auditor and reviews and approves any non-audit

services performed by the external auditor.

The committee regularly meets with the external

auditor to approve the terms of engagement, audit

partner rotation (at least every 5 years) and audit fee,

and to review and provide feedback on the annual

audit plan. Every year, a comprehensive review

and formal assessment of the independence and

effectiveness of the external auditor is undertaken.

The assessment uses an external auditors’

assessment tool, which is internationally recognised

and endorsed by the Independent Directors Council.

The AFRC routinely has time with Ryman’s external

auditor, Deloitte, without management present.

Deloitte attends the company’s AGM.

The company continually monitors its internal control

environment. Clinical auditors and health, safety and

wellbeing officers regularly test and assess controls

and report their findings to the Clinical Governance

Committee and the People and Safety Committee.

PRINCIPLE 8 – SHAREHOLDER RIGHTS

AND RELATIONS

“The board should respect the rights of

shareholders and foster constructive

relationships with shareholders that

encourage them to engage with the issuer.”

Information for shareholders

The company seeks to ensure that investors understand

its activities by communicating effectively with them and

providing access to clear and balanced information.

The company website rymanhealthcare.co.nz provides

an overview of the business and information about

Ryman. This information includes details of operational

sites, latest news, investor information, key corporate

governance information, and copies of significant NZX

announcements. The website also provides profiles of

the directors and the senior executive team.

Previous annual reports, financial statements, and

results presentations are available on the website.

Shareholders have the right to vote on major decisions

of the company in line with the requirements set out in

the Companies Act 1993 and the Listing Rules.

ANNUAL REPORT 2021

149

Statement of corporate governance (continued)
Communicating with shareholders

Ryman has a dedicated investor relations manager

and corporate affairs manager. These two roles allow

us to develop strong relationships and ensure our

shareholders and bondholders are kept informed.

Ryman’s investor centre sets out the investor relations

manager’s and corporate affairs manager’s contact

details for communications from shareholders.

We send the notice of the AGM to shareholders and

publish it on the company website at least 20 working

days before the meeting each year.

Voting by shareholders

Voting on all resolutions at Ryman’s shareholder

meetings is conducted by poll. This means that Ryman

shareholders enjoy one share, one vote (subject to any

voting restrictions applying under the Listing Rules).

General disclosures of interest

FOR THE YEAR ENDED 31 MARCH 2021

JO APPLEYARD

PartnerChapman Tripp

1

MemberUniversity of Canterbury Vice-Chancellor Employment Committee

MemberNZ Markets Disciplinary Tribunal

2

WARREN BELL

ChairHallenstein Glasson Holdings Ltd Group

ChairSt George’s Hospital Inc

DirectorMeadow Mushrooms Group of Companies

DirectorCyprus Enterprises Limited

DirectorSabina Limited

DirectorWarren Bell Limited

DirectorCHC Properties Limited

DirectorGlasson Trustee Limited

Director152 Hereford Limited

DirectorHickman Family Trustees Limited (part shareholder of Airport Business

Park Christchurch Limited)

TrusteeEmerald Trust (part shareholder of Airport Business Park Christchurch Limited)

TrusteeWaiwetu Trust (part shareholder of Airport Business Park Christchurch Limited)

Bare trusteeRyman Healthcare Share Scheme (jointly with Dr David Kerr)

Director/ShareholderPoraka Limited

DirectorBildeford Holdings Limited

2

GREG CAMPBELL

DirectorRavensdown Limited Group of Companies (until 31 May 2021)

DirectorChristchurch City Holdings Limited

DirectorDevelopment Christchurch Limited

DirectorTerrequipe Limited

DirectorTransdiesel Limited

Director/ShareholderGreg Campbell Limited

TrusteeGS & NA Campbell Family Trust

RYMAN HEALTHCARE

150

GEOFFREY CUMMING
Chair, CEO and sole

shareholder

Karori Capital Limited

Shareholder, lender

and joint manager

Various commercial property investment companies in the Caniwi Capital Partners

Limited group of entities

Advisory board member

and unit holder

Viewpoint Global Fund Trust

Advisory board member

and sponsor

Cumming Medical Research Fund, University of Calgary

Director/ShareholderAmira Medical Technologies Inc

CLAIRE HIGGINS

Chair REI Superannuation Fund Pty Ltd

ChairGMHBA Limited and subsidiaries

DirectorMargin Clear Pty Ltd

DirectorQE042 Pty Ltd

TrusteeHelen Macpherson Smith Trust

PAULA JEFFS

(None)

DR DAVID KERR

ChairCentercare Limited

Bare trusteeRyman Healthcare Share Scheme (jointly with Warren Bell)

DirectorForté Health Limited

ChairEcoCentral Limited

2

DirectorNgāi Tahu Property

2

DirectorThird Age Health Services Limited

2


ANTHONY LEIGHS

Managing DirectorLeighs Construction Holdings Limited and associated entities

Director/ShareholderAlisanca Holdings and associated entities

DirectorPortus Property Limited and associated entities

DirectorStar Scaffolding Limited

DirectorChrist Church Cathedral Reinstatement Limited

DirectorLabour Logistics Auckland Limited

GEORGE SAVVIDES

ChairSpecial Broadcasting Service (SBS) Australia

DirectorIAG Insurance Australia Group

Director/ShareholderTeamflow Asset Management Pty Ltd

ChairNext Science Limited

3

1 Jo has been a director since 2009 and since that time has performed no professional services for the company in her capacity as

a partner at Chapman Tripp.

2 Resigned during the year.

3 Resigned 5 May 2021.

General disclosures of interest (continued)

FOR THE YEAR ENDED 31 MARCH 2021

ANNUAL REPORT 2021

151

Directors’ disclosures
FOR THE YEAR ENDED 31 MARCH 2021

DIRECTORS’ REMUNERATION FOR THE YEAR ($)

Director

Board

fees

Board

deputy

chair

Audit and

Financial

Risk

chair

Clinical

Governance

chair

Development

and

Constructon

chair

Governance,

Remuneration

and

Nomination

chair

People

and

Safety

chair

Foreign

exchange

Total

directors’

fees

Jo

Appleyard 110,500 ------- 110,500

Warren

Bell 110,500 18,000 ------ 128,500

Geoffrey

Cumming 110,500 ------ 537 111,037

Claire

Higgins 110,500 - 18,000 ---- 7,064 135,564

Paula

Jeffs 110,500 ----- 6,000 6,076 122,576

Dr David

Kerr 222,000 ------- 222,000

Anthony

Leighs 110,500 --- 18,000 --- 128,500

George

Savvides 110,500 -- 18,000 --- 7,060 135,560

995,500 18,000 18,000 18,000 18,000 - 6,000 20,737 1,094,237

DIRECTORS’ REMUNERATION POOL

Directors’ fees are reviewed every 2 years. Fees currently paid to Ryman directors for their board and board

committee responsibilities are paid out of a pool. The pool was set at the amount approved by shareholders

in 2018 ($985,000 based on a board of seven directors). As permitted by Listing Rule 2.11.3 the pool can be

increased by the board to enable any additional non-executive director to be paid the average amount being paid

to the other non-executive directors (excluding the chair). Greg Campbell became the ninth Ryman director with

effect from 19 March 2021, and the board has utilised Listing Rule 2.11.3 to enable Greg to be paid directors’ fees

since that time. Australia-based directors’ fees are paid in Australian dollars (AUD).

MEMBERSHIP OF COMMITTEES

Directors do not receive additional fees for membership of committees. Additional fees are paid to directors

who act as the chair or deputy chair of a committee. During the year George Savvides, Claire Higgins, Anthony

Leighs, Geoff Cumming, Paula Jeffs and Warren Bell held committee chair/deputy chair positions. The chair of the

Governance, Remuneration and Nomination Committee does not receive any additional fees.

DIRECTORS OF SUBSIDIARY COMPANIES

Dr David Kerr, Warren Bell, Gordon MacLeod and David Bennett are directors of all the company’s New Zealand

subsidiaries. Claire Higgins, George Savvides, Gordon MacLeod and David Bennett are directors of Ryman

Healthcare (Australia) Pty Ltd and its subsidiaries. No fees are paid to individuals in their capacity as directors of

the subsidiaries.

SPECIFIC DISCLOSURES

In line with the company’s constitution and the Companies Act 1993, the company has provided insurance for, and

indemnities to, directors of the company and its subsidiaries.

RYMAN HEALTHCARE

152

Directors’ disclosures (continued)
FOR THE YEAR ENDED 31 MARCH 2021

SECURITY HOLDINGS AT 31 MARCH 2021

Director

Ordinary

shares

RYM010

retail bonds

Jo Appleyard

1

78,700 -

Warren Bell 1,500 -

Greg Campbell

2

48,000 -

Geoffrey Cumming

3

48,680,000 -

Claire Higgins

4

15,425 -

Paula Jeffs--

Dr David Kerr

5

358,000 -

Anthony Leighs

6

10,000 -

George Savvides

7

54,030 -

SECURITY TRANSACTIONS DURING THE YEAR

DirectorNature of interest

Number of securities

acquired/(disposed of )Consideration ($)Date

Geoffrey Cumming

1

Beneficial 1,038,323 13,861,612 5 June 2020

Geoffrey Cumming

1

Beneficial (1,038,323) (13,861,612)5 June 2020

Dr David KerrBeneficial 10,000 130,057 18 June 2020

Warren Bell

2

Not beneficial (2,000,000) 26,048,270 2 July 2020

Geoffrey Cumming

3

Beneficial (300,000) (4,092,000)24 July 2020

Claire HigginsBeneficial 2 ,7 75 37,315 27 August 2020

Geoffrey Cumming

3

Beneficial (930,100) (14,425,851)23 November 2020

Geoffrey Cumming

4

Beneficial (215,300) (3,339,303)23 November 2020

Geoffrey Cumming

5

Beneficial (672,500) (10,430,475)23 November 2020

Geoffrey Cumming

6

Beneficial (32,000) (496,320)23 November 2020

Geoffrey Cumming

7

Beneficial (120,000) (1,762,800)25 November 2020

1 Geoffrey Cumming made an off-market charitable donation of shares to Horizon Housing Society. He then made an off-market

purchase of shares for the same value.

2 Warren Bell is a director of Hickman Family Trustees Limited, which is the registered holder of the shares as trustee of

The Hickman Family Trust.

3 Geoffrey Cumming made an off-market charitable donation of shares to the University of Calgary.

4 Geoffrey Cumming made an off-market charitable donation of shares to the Centre for Affordable Water and

Sanitation Technology.

5 Geoffrey Cumming made an off-market charitable donation of shares to Silvera for Seniors.

6 Geoffrey Cumming made an off-market charitable donation of shares to The Calgary Foundation.

7 Geoffrey Cumming made an off-market charitable donation of shares to the University of Calgary School of Medicine.

Dr David Kerr and Warren Bell, as joint custodians of the Ryman Healthcare Leadership Share Purchase Scheme,

acquired 994,860 shares during the year, disposed of 1,051,087 shares during the year, and held 2,655,017 shares

in total at 31 March 2021 (see note 26 of the financial statements).

1 Held as trustees of The Appleyard and Larkin Family Trust.

2 Shares held by Gregory Shane Campbell and

Nicole Anne Campbell.

3 A substantial product holder (SPH) notice was lodged on

11 December 2020 showing the transfer of legal holding of

48,680,000 shares from Geoffrey A Cumming to Karori

Capital Limited.

4 Held as trustees of Adam Higgins Superannuation Fund Pty Ltd.

5 Shares held by DW & DJ Kerr and The DW Kerr Family

Trust No. 2.

6 Shares held by Alisanca Holdings Limited.

7 Shares held by Teamflow Asset Management Pty Ltd.

ANNUAL REPORT 2021

153

Shareholder information
TOP 20 SHAREHOLDERS AT 13 MAY 2021

Rank Investor nameNo. of shares% Issued capital

1JPMorgan Chase Bank

1

69,957,869 13.99

2HSBC Nominees (New Zealand) Limited

1

66,042,900 13.21

3Karori Capital Limited 48,680,000 9.74

4HSBC Nominees (New Zealand) Limited

1

33,115,670 6.62

5Hickman Family Trustees Limited

2

33,000,000 6.60

6Citibank Nominees (NZ) Ltd

1

31,753,549 6.35

7BNP Paribas Nominees NZ Limited

1

11,943,060 2.39

8Forsyth Barr Custodians Limited 10,601,051 2.12

9Accident Compensation Corporation

1

10,413,773 2.08

10Tea Custodians Limited

1

9,906,959 1.98

11Custodial Services Limited 7,651,991 1.53

12Custodial Services Limited 7,285,472 1.46

13New Zealand Superannuation Fund Nominees Limited

1

7,034,169 1.41

14New Zealand Depository Nominee 5,860,573 1.17

15National Nominees New Zealand Limited

1

5,414,740 1.08

16BNP Paribas Nominees NZ Limited

1

5,144,094 1.03

17FNZ Custodians Limited 4,742,856 0.95

18Cogent Nominees Limited

1

4,727,927 0.95

19Premier Nominees Limited

1

4,609,220 0.92

20Custodial Services Limited 3,845,407 0.7 7

1 Held by New Zealand Central Securities Depository Ltd as custodian.

2 Held as trustee of The Hickman Family Trust.

DISTRIBUTION OF SHAREHOLDERS AT 13 MAY 2021

Size of shareholdingNumber of shareholdersShares held

1–1,000 6,505 42.03% 3,246,392 0.65%

1,001–5,000 6,015 38.86% 15,524,213 3.10%

5,001–10,000 1,564 10.11% 11,758,609 2.36%

10,001–50,000 1,167 7.5 4% 24,272,046 4.85%

50,001–100,000 118 0.76% 8,237,445 1.65%

Greater than 100,000 109 0.70% 436,961,295 87.39%

Total 15,478 100.00% 500,000,000 100.00%

RYMAN HEALTHCARE

154

Shareholder information (continued)
DISTRIBUTION OF BONDHOLDERS AT 13 MAY 2021

RYM010

Size of shareholdingNumber of bondholdersBonds held

1–1,000-0.00%-0.00%

1,001–5,000 34 6.26% 170,000 0.11%

5,001–10,000 112 20.63% 1,076,000 0.72%

10,001–50,000 319 58.75% 8,644,000 5.76%

50,001–100,000 35 6.44% 2,841,000 1.90%

Greater than 100,000 43 7. 9 2 % 137,269,000 91.51%

Total 543 100.00% 150,000,000 100.00%

SUBSTANTIAL PRODUCT HOLDERS AT 31 MARCH 2021

ShareholderRelevant interest

Karori Capital Limited

1

48,680,000 9.74%

Hickman Family Trustees Limited

2

, Kevin James Hickman and Joanna Hickman

3

, Warren Bell

4

, John

Lindsay Holland

4

33,000,000 6.60%

A total of 500,000,000 ordinary Ryman shares were on issue as at 31 March 2021 (the only voting products on issue).

1 A substantial product holder notice was lodged on 11 December 2020 showing the transfer of legal holding of 48,680,000

shares from Geoffrey A Cumming to Karori Capital Limited.

2 Held as trustee of The Hickman Family Trust.

3 Joint holders of 100 percent of the shares in, and directors of, Hickman Family Trustees Limited, and beneficiaries of

The Hickman Family Trust.

4 As independent directors of Hickman Family Trustees Limited and associated voting provisions attached to the shares (alongside

the other directors of Hickman Family Trustees Limited).

ANNUAL REPORT 2021

155

We would like to thank all
Rymanians who contribute

so much every day

Aachal Gautam · Aakanksha Abrol · Aakriti Aakriti · Aaron Brown · Aaron Edwards · Aaron Enriquez

· Aaron Essenberg · Aaron Eyles · Aarti Rawat · Abbe King · Abbey Bray · Abbey Mason · Abbey

Santos · Abbie Windsor · Abby Fernandez · Abby Power · Abhijot Kaur · Abhishek Vashisht · Abigael

Bagaygay · Abigail Gacutan · Abigail Gumban · Abigail Ibanez · Abigail Passmore · Abigail Webb ·

Able Mathew · Ace Somosot · Achaal Prakash · Adalia Campbell · Adam Allan · Adam Joyce ·

Adam Young · Adele Jacobs · Adele Lings · Adele Wood · Adeline Plamenco · Adheesha Perera ·

Adi Sakiti · Adnan Mahamud · Adriana Draganidis · Adrianna Pavlekovic · Adrianne Tate · Adrienne

Marsh · Adrienne Sincock · Adrienne Todd · Adrienne Wadham · Aela Manabat · Aez Pega · Afroz

Sreekandh · Aga Gonzales · Agata Zieba · Aggie Butler · Agitha Joseph · Agnes Cuanan · Agnes

Lakner · Agnes Wallace · Agustine Affandi · Ahmed Naji · Ai Kikuchi · Aida Cachuela · Aidan Mills ·

Aik Eng · Aila Tan · Ailen Gaw · Ailen Luste · Ailyn Estopace · Ailyn Muyano · Aimee Bell · Aimee

Court · Aimee Horsefield · Aimee McKendry · Aimee Verran · Aimee Wright · Aimi Tsunekawa ·

Ainslee Buchanan · Aira Quijano · Aiza Amongo · AJ Lasaca · Ajay Gautam · Ajay Philip · Ajay Singh

· Ajesh Mankayill Avarachan · Ajo Jose · Akhil Viswambharan · Akhila Antony · Akku Thomas ·

Aklima Akter · Aku Acharya · Al Lim · Aladina Durian · Alan Wood · Alana Ferguson · Alana

Sanderson · Alana Wallace · Alana Watson · Alanah French · Alannah Smith · Alastair Joyce ·

Alastair Ryall · Albie Calope · Aldrin George · Alefina Baleisuva · Aleisha McDonald · Alena

McCulloch · Alena McKenzie · Aletta Beneke · Alex Brasic · Alex Cagalitan · Alex Carter · Alex

Fausett · Alex Lopez · Alex Mallon · Alex Mathew · Alex McNeillie · Alex Pope · Alex Purcell · Alexa

Alcantara Claudio · Alexis Popovic · Algine Ingking · Ali Amin · Alias Kurian · Alice Jones · Alice

McDuff · Alice Peram · Alice Stevens · Alice Tao · Alice Vargas · Alicia Prima · Alina George · Alina

Jose · Alisha Alex · Alisha Aliperio · Alisha Poudel · Alisha Ward · Alison Kelly · Alison Naylor · Alison

Westoby · Alison Winstanley · Alister Safaei · Alix Fabi · Aljie Famulagan · Alka Thakur · Allan Brown

· Allan Dempsey · Allan Macala · Allan Murillo · Alleah Munoz · Allen Lee · Allison Doak · Allison

Murphy · Alma Azarcon · Alma Cagalitan · Alma Eparaima · Alma Ramirez · Alma Sicat · Almira

Beniasan · Alona Wandas · Alpho George · Alphonsa George · Alphy Thankachan · Alphy Thomas ·

Althea Santos · Alvin Campbell · Alwin Jose · Aly Procter · Alyse Hill · Alyse Hurley · Alysha Russell

· Alyshia Kemper · Alyssa Apacible · Alyssa Jerusalem · Alyssa Saljay · Amal Sunil · Aman Balassi ·

Aman Kaur · Aman Kaur · Aman Kaur · Aman Kaur · Aman Kaur · Aman Kaur · Aman Kaur · Amanda

Beauchamp · Amanda Bell · Amanda Brocklebank · Amanda Gilbert · Amanda Goudie · Amanda

He · Amandeep Dhillon · Amandeep Kaur · Amandeep Sidhu · Amanpreet Kaur · Amanpreet Kaur ·

Amar Kaur · Amber Aguilar · Amber Bottomley · Amber Howard · Amber McKenzie-Takau · Amber

Parkinson · Amber-Lee Kelliher · Ambika Kolanji · Ambily Abraham · Amelia Ong · Amendra

Samantilake · Ami Reid · Amiel Ubarra · Amit Khanchi · Amit Patel · Amita Prasad · Amita Vyas ·

Amith Sabu · Amol Adhokar · Amrit Kaur · Amrit Kaur · Amrit Kaur · Amrita Raj · Amy Amtman · Amy

Bishara · Amy Blandford · Amy Buck · Amy Carpenter · Amy Duncan · Amy Flood · Amy Gagasa ·

Amy Hii · Amy Irwin · Amy Mian · Amy Morris · Amy Morrison · Amy Power · Amy Reive · Amy

Richardson · Amy Shen · Amy Thornton · Amy Yin · Ana Fangupo · Ana Hintay · Ana Illaventhan ·

Ana Leite · Ana Moala · Ana Savou · Ana Marie Salibay · Anabel Konigstorfer · Analyn Irorita · Anan

Du · Anande Botha · Anastazya Forde · Anchal Sharma · Anchitha George · Andre Battrick · Andre

Kassal · Andrea Adams · Andrea Ansell · Andrea Burgos · Andrea Butler · Andrea Gaskell · Andrea

Hills · Andrea Latoa · Andrea Manuel · Andrea Marr · Andrea Pangan · Andrea Smith · Andrea Stout

· Andrei Pirlea · Andres Reble · Andresa Mendes Teles · Andrew Crerar · Andrew Cullen · Andrew

Gibson · Andrew Goldfinch · Andrew Hayward · Andrew Heels · Andrew Hilbert · Andrew Hill ·

Andrew Hughes · Andrew Inch · Andrew Jones · Andrew Knewstubb · Andrew Maglangit · Andrew

Moulding · Andrew Otto · Andrew Quezon · Andrew Searancke · Andrija Vuksa · Andy Battersby ·

Andy Clarke · Andy Heap · Andy Martin · Andy OBrien · Andy Reid · Andy Singh · Ane Pulou · Aneely

Bhatt · Aneesh Kattikatt George · Ange Dickson · Ange Knibb · Angel Augustine · Angel Jose · Angel

Mendoza · Angel Montanez · Angela Aballog · Angela Barraclough · Angela Ferguson · Angela

Gower · Angela Hayes · Angela Kimber · Angela MacKay · Angela McMeekin · Angela O’Connor ·

Angela Ravlich · Angela Redgewell · Angela Simpson · Angela Stewart · Angeli Suson · Angelica

Araiza · Angelica Moreno Baumann · Angelica Ona · Angelina Adams · Angelina Bostrovas ·

Angelina Taiaroa · Angelique Roberts · Angelo Trabado · Angie Cope · Angie Sidhu · Ani Tuilau ·

Anika Snell · Anish Anto · Anisha Chaudhary · Anisha Walker · Anishma Raj · Anit Dominic · Anita

Bhusal Banjade · Anita Chapman · Anita Dayal · Anita Devi · Anita Devi · Anita Farmer · Anita Smith

· Anitha Paul · Anitha Shijan · Anja Thorne · Anjali Manoj · Anjali Mitra · Anjana Lama · Anjana Paul ·

Anjani Chaudhary · Anjani Suresh · Anjelyn Pocession · Anjila Shrestha · Anju Keenan · Anju

Malakunnel Isac · Anju Sajan · Anjumol Saju · Ankita Joshi · Ankitaben Patel · Ann Beom · Ann Brady

· Ann Cuaresma · Ann Dombroski-Scheliin · Ann Fernando · Ann Joy · Ann Lee · Ann Martin · Ann

Mongcal · Ann Moorman · Ann Olbinado · Ann O’Neill · Ann Sebastian · Ann Vo · Ann Wongchan ·

Ann-Maree Vincent · Ann-Marie Innes · Anna Benadie · Anna Casaje · Anna Chin Daclan · Anna

Claridge · Anna de Jager · Anna Groome · Anna Hill · Anna Johnson · Anna Lai · Anna Maharjan ·

Anna McCorkindale · Anna Ormsby · Anna Ouyang · Anna Pochron · Anna Scott · Anna Smith ·

Anna Thomson · Anna Trushin · Anna Woodwiss · Anna-Lee Lyons · Annabel Arcipe · Annabel

Macdonald · Annabel Sharp · Annabelle March · Annabelle Payne · Annamay Toa · Anne Cameron

· Anne Cantos · Anne Flint · Anne Hall · Anne Hovell · Anne Kenna · Anne Larita · Anne O’Donnell ·

Anne Somarathne · Anne Streatfeild · Anne Verano · Anneke Van Straaten · Annette Adams ·

Annette Holdaway · Annette Hollis · Annette Jeffares · Annette Lawrence · Annette Molloy ·

Annette Rains · Annie Armstrong · Annie Bruce · Annie Craike · Annie Dao · Annie Eunson · Annie

Glossop · Annika Lindquist · Annmarie Fernando · Annu Gaur · Anoma Gunaratne · Anshal Hussain

· Anshu Singh · Ansilin Tressa Siby · Ansu Anna Varkey · Ansu Babu · Anthea Gernetzky · Anthea

Johnson · Anthea Lemberiadis · Anto Sundaram · Antoinette Morgan · Anton Reble · Antonette

Asuncion · Antonio Lavin Delgado · Anu Aloysius · Anu Baby · Anu Gill · Anu Karthika

Reghunathapanickar · Anu Kumar · Anu Pathirage · Anu Paul · Anu Raju · Anu Samuel · Anu

Sebastian · Anu Xavier · Anuja Kunwar · Anuja Shrestha · Anuradha Shrestha · Anusha Peddina ·

Anusha Vikram · Ao Fuifui · Aom Mahem · Api Arpanpreet · Api Lacanivalu · Apple Uy · April

Agpalasin · April Deraja · April Lacson · April Ladia · April Mahuika · April Morillo · April Nino · Arahia

Wilson · Archa Rajan · Archanau Devi · Arge Colado · Argie Forteza · Argielyn Sanchez · Ariana

Guerin · Ariana Thompson · Ariane De La Pena · Arianne Alzaga · Aribo Timaai · Arieta Bebenisala

· Arieta Faalau · Arishma Arti · Arjun George · Arleen Kaur · Arlen Evangelista · Arlene Simadari ·

Arlene Smart · Arlet Anastasia · Arma Dacyon · Armie Estevez · Armie Magcale · Aroha Marumaru

· Aroha Ngatuere · Arpana Khadka · Arraminda Ariate · Arthur Keane · Arti Bhan · Arti Devi · Arti

Karan · Arti Kumar · Arti Patel · Arti Prakash · Artika Lata · Artika Naidu · Arun James · Aruna

Prakash · Aruna Reddy · Arvin Singh · Arvin Treebhowan · Arzoo Utreja · Asa Porter · Asfeen Khan

· Ash Devi · Ash Hape-Tonihi · Ash Kant · Ash Prasad · Asha Babu · Asha John · Asha Kiran · Asha

Mariyarasa · Asharif Rahman · Ashika Chand · Ashika Mandri · Ashika Singh · Ashim Singh ·

Ashishni Goundar · Ashka Patel · Ashleigh Griffiths · Ashleigh Kavanagh · Ashleigh Scown · Ashley

Campbell · Ashley Dacyon · Ashley Gray · Ashley Kearney · Ashley Son · Ashley Willis · Ashmita

Lata · Ashnee Prakash · Ashupreet Kaur · Ashvin Mendonca · Ashween Singh · Ashwina Ashwina ·

Ashwindar Kaur · Ashwini Naicker · Asma Akram · Asmita Bhandari · Asmita Hirachan · Asmita

Nepali · Asmita Rai · Asset Galeno · Asti Suliastari · Aswathy Padmanabhan · Aswathy Sreedas ·

Aswathy Thulaseedharansheela · Atani Chwa · Atawhai Reweti · Ateliana Ah Kuoi · Athena

Tangonan · Athulya Jestin · Athulya Rakesh · Athulya Thankappan · Atiesha Harris · Atin Suprihatin

· Atish Suresh · Aubrey Uri · Audrey Filgate-Davis · Aurora Catu · Aurora Orogo · Ava McFadgen ·

Avrill Burchell · Avrisha Singh · Awanui Tangiia · Awhina White · Axis Donato · Axl Funtila · Ayako

Oyama · Ayesha Bashir · Ayomee Wanninayaka · Aysha Ideris · Ayteya Lopez · Ayu Hardy · Ayumi

Maruyama · Ayumi Sato · Azel Ramos · Azumi Kemmotsu-Watt · Ba Sigola · Babita Baluri · Bailey

Coombs · Bailey Trotter · Balbir Ghuman · Baljeet Kaur · Baljinder Kaur · Baljit Kaur · Balpreet Kaur

· Bano Tasheem · Barbara Barker · Barbara Federico · Barbara Large · Barbara Turnbull · Barbie

Bickerton · Barry Ria · Barsha Timalsina · Bawi Siar Ling · Bayley LuuTomes · Beata Buchajczyk ·

Beauty Chua · Bebien Montecillo · Becca Fafeita · Becca Thomas · Beck Little · Beck Wilkins ·

Becks Dell · Becky Gillanders · Becky Moore · Becky Payne · Becs Thompson · Bedi Thapa · Bee

Weiss · Belinda Bargh · Belinda Gonzales · Belinda Greenwood · Belinda Madriaga · Belinda Petitto

· Beloved Vai · Ben Bowles · Ben Campbell · Ben Chesler · Ben Dass Shrestha · Ben Garner · Ben

Hungerford-Morgan · Ben Jordan · Ben Miller · Ben Munro · Ben Walshe · Benita Edwards · Benita

Jessop · Benita Jonathan · Benita Kirkovits · Benita Prasad · Benjamin Cavanagh · Benjilen Pablo ·

Benjula Timsina · Benni Hulme · Benoit Calpe · Benson Mejorada · Benzon De Castro · Bernadette

Bancroft · Bernadette Forsdyke · Bernadette Lerios · Bernard Cagalawan · Bernard Nanai · Bernard

Philpott · Bernie Pask · Bert Barola · Beryl Ryan · Beth Aseniero · Beth Capistrano · Beth Gerbes ·

Beth Haryett · Beth Kampen · Beth Po · Beth Reaney · Beth Smillie · Bethany Douglas · Bethany Edie

· Bethany Read · Bette Baldwin · Betty Groves · Betty Lamb · Beulah Rajesh · Bev Dela Cruz · Bev

Fockenga · Bev Tembo · Bev Todd · Bev Toms · Bev Walker · Bevan Harris · Beverley Henley · Bex

Coster · Beza Esclamado · Bharat Singla · Bharti Bedi · Bhavneet Kaur · Bheng Escano · Bhumi Jain

· Bianca de Agrella · Bianca Knowles · Bianca Solis · Bianca Van Doren · Bibin Christopher · Bibin

Philip · Bibin Vijayan · Biddhya Gurung · Bien Padilla · Bijo Mathew · Bill Jin · Bimala Galaju · Bimala

Galaju · Bimbika Sirimane · Bina Limbu · Bina Patel · Bina Pun · Bini Eldhose · Bini Gurung · Binky

Marsh · Binu Tiwari · Blair Cullen · Blake Jackson · Blanche Laroga · Blessie Lintag · Blythe Ward ·

Bobby Abhilash · Bobby Beck · Bobin Pullikkattil Jose · Bokang Ngwerume · Bonnie Butson · Bonnie

Lee · Brad Thomas · Brandi Ireton · Brando Bartolome · Brandon Paul · Breanna Woolley · Brechell

Dela Vega · Bree Jones · Bree Rayment · Bren Hurring · Brenda Dudson · Brenda Ferguson · Brenda

Hobbs · Brenda Schroeder · Brendan Joicey · Brendan Sammut · Brenden Moore · Brent Lee · Brent

Maru · Brent Morfett · Brent Sweeney · Brett Johnson · Brian Bark · Brian Robinson · Brian Tidey ·

Brian Ward · Bridget Bisset · Bridget Lyons · Bridgette des Landes · Brieanna Hobbs · Briee

Robinson · Brin Downie · Bristy Jahan · Brittany Cottam · Brittany Francis · Brittany Jeffcott-Moore

· Brittany Kerebs · Brodie Hewitt · Brodie McPhail · Bronnie Carston · Bronwyn Barry · Bronwyn

Thomas · Brook Spedding · Brooke Henderson · Brooke Muirsmeath · Brooke Roberts · Brooke

Tainui · Brooke Tyler · Bruce Andrews · Bruce Court-Patience · Bruce Hodge · Bruce Hudson ·

Bruna Manduci · Bryan Bolong · Bryan Giray · Bryan Manlangit · Bryant Fernandez · Bryce Rae ·

Brydie Baxter · Bunny Balane · Byron Schreuder · Caelan Hill · Cairo Wilson · Caitlin Bartlem · Caitlin

Couling · Caitlin Fleming · Caitlin Foster · Caitlin Thomas · Caitlyn Cole · Caleb Lepper · Callum

MacLean · Callum Morrish · Cam Holland · Cameron Scott · Camila West · Camille Reyes · Camille

Santos · Campbell Elliott · Candice Camingawan · Candy Martin · Cara Floreza · Cardona Castro ·

Carina Toscano · Carl Arnst · Carla Barnard · Carla Dela Cruz · Carla Eser · Carla Jones · Carla

Lofredo · Carla Mantella · Carly Peek · Carmel Marino · Caro Swanston · Carol Bothamley · Carol

Dadivas · Carol Duke · Carol Kay · Carol Luttrell · Carol Mathias · Carol Restrepo Ledesma · Carol

Toohill · Carola Acevedo · Carole Quickfall · Carolina Russi Serrato · Caroline Hart · Caroline Kean ·

Caroline Martin Salas · Caroline Nyo Nyo Aye · Caroline Potgieter · Caroline Reyland · Caroline

Skegg · Caroline Topia · Carolyn Bovey-Brown · Carolyn Delugar · Carolyn Faloon · Carolyn

Greenaway · Carolyn Grogan-Tinney · Carolyn Lennox · Carolyn MacDonell · Carolyn Mulder ·

Carolynn Aicken · Carolynn Phillips · Carrie Duncan · Carroll King · Casey Cowley · Cassandra

Osborne · Cassandra Wallis · Cassidy McMillan · Cassidy Woods · Cassie Chen · Cassie Scaife ·

Cassie Stephens · Cassim Nawaz · Cath Magbaton · Cath Seguan · Catherine Bunting · Catherine

Cordwell · Catherine Jalbuena · Catherine King · Catherine McKellar · Catherine Piastro · Catherine

Ramos · Catherine Scullin · Catherine Wright · Cathley Balaan · Cathy Byrne · Cathy Lata · Cathy

Malone · Cathy Morris · Cathy Stevenson · Cathy Watkins · Cathy Yang · Cecilia Hansson · Cecilia

Huet · Cecilia Nguyen · Cecille Winspear · Ceena Jacob · Cel Amante · Cel Padayogdog · Celeste

Boonzaaier · Celeste Payne · Celeste Wallbank · Celly Wilson · Celthea Yu · Cha Juco · Chakri

Siluveru · Chamara Hettiarachchige · Chami Mannage Dona · Chan Manuel · Chanel Kisina ·

156

RYMAN HEALTHCARE

Chanpreet Kaur · Chantal Atngag · Chantal Guiguit · Chantal Kennedy · Chantel Paul · Chantel
Pilcher · Chantelle Hand · Chantelle Hocking · Charan Dhillon · Charie Paytocan · Charith

Ruwanpathirana · Charlene Lardizabal · Charlene Serino · Charlene Tabigne · Charles Bushell ·

Charles Han · Charles Hannaford · Charles Serino · Charlie Dennis · Charlie Johnson · Charlie Uy ·

Charlotte Baker · Charlotte Bullock · Charlotte Scragg · Charlotte Senining · Charlotte Turner ·

Charlyne Casil · Charmae Golosino · Charmagne Castillo · Charmaine Cabalagnan · Charmaine

Infante · Charmaine Lim-Capendit · Charmaine Smith · Charmaine Staines · Charmaine Tan ·

Charmaine Urbano · Charmaine Volschenk · Charmayne Clarke · Chau Bui · Chayle Argallon · Chea

Fraser · Chee Chang Ho · Chelcei Ninal · Chell Biato · Chelsea Gray · Chelsea Hill · Chelsea Hodgson

· Chelsea Ngamotu · Chelsea Richdale · Chelsea Woolf · Cherie Brosnan · Cherry Casama · Cherry

Gallego · Cherry Lagare · Cherry Quiros · Cherry Ramel · Cherry Taleno · Cherry Venegas · Cherryl

Bauzon · Cheryl Alba · Cheryl Buchanan · Cheryl Damatac · Cheryl Jackson · Cheryl Lopez · Cheryl

Roach · Cheryl Rom Liu · Cheryl Zhang · Cherylene Fatupaito · Cherylynn Stevenson · Chessie Yap

· Cheyenne Flockton · Cheyne Chalmers · Chhiring Lama · Chi Zhao · Chikaina Makatea · Chike

Seguban · Chinchu Boban · Chinju Paul · Chit Escalon · Chitra Devi · Chitt Fajardo · Chiyori Yasu ·

Chloe Fitzgibbon · Chloe Gao · Chloe Hollows · Chloe Perez · Chris Ackerman · Chris Ashton · Chris

Baet · Chris Balanci · Chris Beckett · Chris Bull · Chris Camm · Chris Caselton · Chris Church · Chris

Combrink · Chris Corriea · Chris Dias · Chris Dombroski · Chris Downes · Chris Evans · Chris Hall ·

Chris Harwood · Chris Henry · Chris James · Chris Jobe · Chris Keilty · Chris Ngataierua · Chris

Parker · Chris Saxon · Chris Sinclair · Chris Storer · Chris Sutton · Chris Tunbridge · Chris Wright ·

Chrissy Atkins · Chrissy Macpherson · Chrissy Mathews · Chrissy Nkya · Chrissy Smith · Chrissy

Stanton · Chrissy Telekesi · Chrissy Thompson · Chrissy Toa · Christe Capisnon · Christeen

Abraham · Christelle Sazon · Christi Essex · Christian Borja · Christin Yu · Christina Niutao ·

Christina Potgieter · Christina Reed · Christine Buck · Christine Clarke · Christine De Leon ·

Christine Dhariwal · Christine Han · Christine Hawley · Christine Hill · Christine Javier · Christine

Kwiatkowski · Christine Labiton · Christine Langley · Christine Liclican-Coloma · Christine

McCurdy · Christine Miller · Christine Pauling · Christine Primrose · Christine Tubio · Christine

Tweedie · Christine Voller · Christine Wang · Christine Ann Elizalde · Christo Paulraj · Christopher

Singer · Christy Solina · Chu Kohlman · Chu Templa · Chummy Madarieta · Cindy Cao · Cindy

Evangelista · Cindy Hou · Cindy Le Hur · Cindy Phillips · Cindy Velasquez · Cintia de Camargo · Ciska

McGrath · CJ Barcelona · Claire Bate · Claire Daunivavana · Claire Farrell · Claire Flanagan · Claire

Harris · Claire Mooiman · Claire Park · Claire Watt · Claire Whitfield · Clara Chiong · Clarace Codyre

· Clare Bower · Clare Burgess · Clare Glasspool · Clare Manders · Clare McKone · Clarissa Alojado ·

Claudete Silva · Claudette Simmer · Claudia May · Claudia Permatasari · Claudia Rogers · Claudia

Rueda De La Serna · Claudine Nair · Claudine Uy · Clem Von Ellerts-Martinoli · Cliff Lasmarias ·

Clinton Palmer · Coco Prak · Colin Butler · Colin Caldwell · Colin Cameron · Colin Habgood · Colin

Vose · Colleen Johnson · Colleen McCann · Colleen Watson · Collette Backhouse · Collette Gordon

· Colm Boyle · Comaneci Ong · Con Ciobanu · Con Van Niekerk · Conie Pulgao · Connie Fernandez ·

Connie Tagle · Connor Sim · Cora Jambalos · Cora Van der Heul · Coralea Potgieter · Coralie Vine ·

Coralize Legge · Correen Steyn · Corrine Belencion · Corrine Fernando · Corrine Gillan · Corrinne

Cooper · Cory Bryan · Courtney Skene · Courtney Taylor · Courtney Trautvetter · Craig Atkinson ·

Craig Buist · Craig Dixon · Craig Gibbons · Craig Pascoe · Cris Viernes · Criselda Agbayani · Crish

Landiza · Cristal Lozada · Cristel Carter · Cristina Alejandro · Cristina Corre · Cristina Uy · Cristine

Bayliss · Crystal Payne · Crystal Saldanha · Csilla Feherne Kincses · Cushla Manaia · Cyd

Maclachlan · Cym Seguan · Cynthia Bunag · Cynthia Humphreys · Cynthia Mercado · Cynthia

Soriano · Cyril Balloso · Cyrus Vallecera · Czarina Ederango · Czhanna Dayo · Dada Dayrit · Dafydd

Evans · Dahlia Bontilao · Dainah Magonde · Daisy Duka · Dale Basinal · Dale Bell · Dale Burton · Dale

Whearty · Daly Anna Devasia · Daman Kaur · Damani Lata · Damian Forde · Damith Amarathunga ·

Dan Bromley · Dan Domalanta · Dan Liu · Dan Pega · Dan Reid · Dan Vajc · Dana Bilous · Danae

Shipston · Danelle Franklin · Danessa Cuyno · Dani Bartle · Dani Basilan · Dani Bonoan · Danica Little

· Daniel Bakht-Khosh · Daniel Halengo · Daniel Knell · Daniel Mulcahy · Daniela Aguilar Felix · Daniela

Diederichs · Daniela Restrepo · Danielle Jeffery · Danielle Moran · Danielle Newton · Danielle Numan

· Danielle Steer · Danielle Tweed · Danilly-Rose Simpson · Danni Wood · Dannie Digiandomenico ·

Danny Burns · Danny Connery · Darlene Ross · Darnell Bonita · Darren Hicarte · Darren Jago · Darrin

Findlay · Darsana Ram Bindu · Darshan Patel · Daryl Dominguez · Daryl Page · Dashan Kaur · Dati

Sherpa · Dave Clearwater · Dave Cooper · Dave Cronin · Dave Murrell · Dave Pogson · Dave

Robertson · Dave Sevilleno · Dave So · Dave Wand · Dave Wu · David Baker · David Ballouz · David

Bennett · David Cartwright · David Datoy · David de Veth · David Gibson · David Herrera-Rodriguez

· David Kenny · David King · David Laing · David Macdonald · David Mahony · David Nevin · David

Oldham · David Ravenscroft · David Swann · Davinna McDonald · Davis Thadathil · Davu Deol ·

Dawn Hunt · Dawn White · Dawn Yrigollen-Hammond · Dawny Thomas · Daylinda Durango · Dayna

George · Dealia Long · Dean Jackson · Deanna Glasson · Deb Habershon · Deb Ray · Deb

Richardson · Deb Smith · Debbie Austin · Debbie Bontuyan · Debbie Bridger · Debbie Buchanan ·

Debbie Chapman · Debbie Dixon · Debbie Edwards · Debbie Espartinez · Debbie Fraser · Debbie

Gemmell · Debbie Gray · Debbie Hartley · Debbie Hicks · Debbie Horne · Debbie Kennedy · Debbie

Knight · Debbie Komarkowski · Debbie Lin · Debbie Mindoro · Debbie Ogden · Debbie Quennell ·

Debbie Rountree · Debbie Smith · Debbie Wells · Deborah Forde · Deborah Ibale · Deborah Swingler

· Debra Goodman · Debra Stone · Debs Smith · Declan Rhodes · Dedeh Karyati · Dee Broad · Dee

Dilhani · Dee Mantell-Harding · Dee Nadan · Dee Yonzan · Dee Lal Lal · Deep Kaur · Deepa Bhandari

G C · Deepa Lohala · Deepa Magar · Deepa Sudhakaran · Deepak Aggarwal · Deepani Hewa

Batagodage · Deepankshi Deepankshi · Deepika Saudiyal · Deepika Wijesekara · Deeviya Patel ·

Deidre MacGregor · Del Wellington · Del Whitehouse · Delia Espenido · Denice Jamieson · Denis

Goodwin · Denis Marra · Denise Boese · Denise Carppe · Denise Cunniffe · Denise Greenbank ·

Denise Hutchison · Denise Laney · Denise Martin · Denise Scott · Denise Thompson · Denisse

Valdrez · Dennis Chireshe · Dennis De Leon · Dennis Frazer · Denzel Bonifacio · Deotheny Arenajo ·

Derek Gibbs · Derek Greening · Desirie Diwa · Desley Lawrence · Destinee Duthie · Dev Little · Devi

Nagalingam · Devika Naidu · Devika Reddy · Devon Eastlake · Devon Maurice · Dewi Astuti · Dewshi

Wittachchi Koralage · Dhang Navarro · Dhanju Rana · Dhanya Dominic · Dhanya Francis · Dhanya

Lukose · Dhara Patel · Dhruvi Shah · Di George · Di Lister · Di McKenzie · Di Sinclair · Di Tahi · Di

Tarling · Diana Brown · Diana Cleveland · Diana Ettema · Diana Hanafin · Diana Keith · Diana

Kozlowski · Diana Maiquez · Diana Narulita · Diana Nicolescu · Diana Plesovs · Diana Sian · Diane

Anderson · Diane Brown · Diane Evans · Diane Headifen · Diane Smiler · Diane Smith · Diane Taylor

· Diane Vergara-Galang · Dianna Alexander · Dianne Amolong · Dianne Austin · Dianne Burgess ·

Dianne Casimiro · Dianne Daniels · Dianne Dona · Dianne Durham · Dianne Kei · Dianne Melhuish ·

Dianne Newton · Dianne Rosado · Diedri Bates · Diksha Mainh · Dilpreet Kaur · Dilpreet Kaur · Dina

Fitria · Dina Garcia · Dinithi Medagedara · Dipal Patelia · Dipika Dipika · Disha Gandhi · Dishna

Karunarathna · Divina Cruz · Divya Chauhan · Divya Sebastian · Diya Baby · Dolly Alekar · Dolor

Raposas · Don MacKay · Donah Cagalawan · Donald Ferguson · Donald Pool · Donna Barnes ·

Donna Bradford · Donna Campbell · Donna Dael · Donna Dungey · Donna Flaws · Donna Garcia ·

Donna Gonzales · Donna Holmes · Donna Lewis · Donna Munoz · Donna Rose · Donna Summerfield

· Donnelle Dean · Dora Martinez-Velandia · Doreen Dacanay · Doreen Kumar · Doreen Lata · Doreen

Maha · Doreen Narayan · Dorothy Belleza · Dorothy Harris · Dorothy Kudinha · Dorothy Withers · Dot

Luna · Dot Wright · Dottie Abuyabor · Doug Holt · Dovie Villalobos · Dragan Mitrevski · Drew Oakley

· Dronah Villarino · Dulari Withana Ranasinghe · Duncan Phillips · Dustin Dominic · Dwi

Wangsawidjaja · Dylan Bell · Dylan Geldard · Dylan Sharma · Earl Te · Eda Galias · Eddie Deo · Eddie

Ovansian · Eddie Parker · Eddie Tandy · Eden Dawson · Edgar Condino · Edgar Mamaril · Edgardo

Blaya · Eduard Bradley · Edvard Tanzo · Edward Paterson · Edwina Hutchings · Edy Sayson · Egroeg

Orlino · Eileen Kielty · Eileen Welford · Eileen Wu · Eina Campos · Ekta Sharma · Elaine De Leon ·

Elaine Galbraith · Elaine Hubbard · Elaine Luay · Elaine Marsh · Elaine Mulholland · Ele Bibby · Eleana

Nash · Eleanor Gaffley · Eleanor Lee · Eleanor Reo · Eleen Kee · Eleeza Jilson · Elena Braza · Elena

Delector · Elena Kubesh · Eleni Heaven · Eleni Meimaris · Eleonor Moral · Elesha Clark · Elia Mia ·

Eliane Machado · Elina Rajie · Elina Yang · Elisel Valoria · Eliseo Lapus · Eliza Thapaliya · Elizabeth

Caboverde · Elizabeth Dibanadane · Elizabeth Hunter · Elizabeth Okanga · Elizabeth Okpaleke ·

Elizabeth Sellick · Elizabeth Sunny · Elizabeth Waghorn · Eljo Joseph · Ella Brownrigg · Ella Dan-

Lualua · Ella Griffin · Ella- Rose Henderson · Ella-Rose Knowles · Elle Coker · Ellen Baguip · Ellen

Cribb · Ellen Encarnacion · Ellen Ganzon · Elleni Emmanouel-Christo · Ellie Wilson · Ellora Santos ·

Elly Brown · Elma Reoma · Elmer Carreon · Eloisa Obnial · Eloise Viscarra · Elona Walker · Elsa

Marneweck · Elsie Lovell · Elsie Pablo · Elsie Warriner · Elva Latonio · Elvira Gomez · Elvira Tangonan

· Ely Masil · Emalyn Prosia · Emelita Cagas · Emilie Field · Emily Brooke · Emily Burgess · Emily Chen

· Emily Hayward · Emily Joyce · Emily Langdon · Emily Li · Emily Lingard · Emily Lond · Emily Narawa

· Emily Palamountain · Emily Truong · Emily White · Emily Xi · Emma Baker · Emma Begg · Emma

Coles · Emma Cumberbeach · Emma Eason · Emma Hanley · Emma Harper · Emma Harrison ·

Emma Hibbert · Emma Hogan · Emma Holder · Emma Hope · Emma Kielty · Emma Knott · Emma

Lim-Yip · Emma McLeod · Emma Ngoc · Emma Raho · Emma Reardon · Emma Reece · Emma

Saquiban · Emma Scott · Emma Singh · Emma Tarunge-Wasi · Emma Theochari-Mitchell · Emma

Waetford · Emma Webb · Emman Galve · Emmy Dolotina · Ena Pastrana · Entani Naidu · Eric Demo

· Eric van Diggele · Erica Bacasen · Erick Abille · Ericka Sauquillo Adoyo · Erik Homena · Erin Lu · Erin

Pole · Erin Woodcraft · Ernesto Espiritu · Esmie Gonzaga · Esteban Llano · Estela Garcia · Estela

Guiao · Estelle O’Neil · Estelle Ramtano · Ester Da Rosa · Esther Cole · Esther Curtis · Esther Gupana

· Esther Hukui · Esther Kingi · Esther Lawangen · Esther Lin · Esther Mulligan · Esther Zvenyika ·

Ethan McCarthy · Ethan Prentice · Ethan Turner · Ethel Mondarte · Eti Aunese · Eugene Ortile ·

Eugenie May · Eunika Reinecke · Eurita Balazo · Eva De Jong · Eva Kubala · Eva Mago · Eva Schilder

· Evanya Fraser-Le’au · Eve Espanta · Eve Ojales · Evelinda Elan · Evelyn Booth · Evelyn Cadzow ·

Evelyn Calaunan · Evelyn Doropa · Evelyn Espina · Evelyn Ritchie · Ewa Jasinska · Ey-Ey Reyes · Ezra

Erueti · Faamanu Simeona · Faamanu Smith · Faeona Wallace · Fair Rupal · Faith Fawcett · Faith

Sakalia · Fallon Eynon · Fana Raveora · Fang Zhou · Fara Naicake · Farah Abuyabor · Farah Ali ·

Farida Shilpi · Farisha Begum · Farishta Samadi · Farron Moke · Farzana Begum · Farzana Bi ·

Faseela Thodi · Fatemeh Khorami · Fatima Hima · Fay Lilley · Fay Ramirez-de Jong · Faye Taylor · Fe

Asinas · Fe Cuevas · Fe Taganas · Fefiloi Tausi · Felicity King · Felis Pael · Felix Lacerna · Felix Tso ·

Felmi Thomas · Fely Magpantay · Ferdi Roncal · Fern Tanoi · Finau Kafoa · Fincy Francis · Fiona Dube

· Fiona Justine · Fiona Kingi · Fiona Le Gros · Fiona Quinn · Fiona Rolland · Fiona Scotland · Fipe

Lama · Fletcher Olsen · Floey Limjoco · Flor Anasarias · Flora Torres · Florance Nikeeta · Floren

Guira · Florence Esteban · Florence Taylor · Fonda Burt · Fran Denton · Fran Knapman · Fran Spitzer

· Frances Bingham · Frances Twaalfhoven · Francesca Kidd · Francie Cappleman · Francine

Palendeng · Francis Abrigo · Francis Almendra · Francis Caluya · Francis Deferia · Francis Delia ·

Frank Ryan · Frank Wang · Franklin Laban · Fransiska Aren · Franz Sale · Fred Cleaver · Freda Chase

· Freda Raptopoulos · Freda Van Schouten · Freddy Akkara · Frelyn Acuzar · Fritz Lozano · Frozan

Azizi · Gab Pontanos · Gabby Barnett · Gabby Da Rosa · Gabby Whall · Gabriel D’Alberto · Gabriella

Schulz · Gabrielle Raife · Gaby Maniloff · Gael Barthelet · Gael Coory · Gagan Kaur · Gagan Kaur ·

Gagan Kaur · Gagan Kharoud · Gagan Malhi · Gagandeep Kaur · Gagandeep Kaur · Gaganpreet

Kaur · Gagneet Kaur · Gail Brown · Gail Castro · Gail McGuinness · Gail Miller · Gail Oats · Gail

Sangiorgio · Gail Te Au · Galina Shipina · Gamage Priyangika Sandamali · Ganga Mati · Gareth Salt ·

Garlett Ceniza · Garry Bott · Garry Dhall · Garry Singh · Garry Singh · Gary Cox · Gary Robinson ·

Gary Stewart · Gary Sutcliffe · Gavin Lucas · Gavin Till · Gay Benabaye · Gay Libatog · Gay Ordonio

· Gayani Welikala · Gayathri Kahawidanalage Dona · Gayathri Kumar · Gayleen Watkins · Gaylene

Allen · Gaylene Downs · Gaylene Graham · Gaylene Hill · Gaylene Hutcheson · Geena George ·

Geetha Marupati · Gelyn Dalusag · Gem Evans · Gemeda Wesho · Gemma Fernandez Duck ·

Gemma Rolland · Gemma Tattley · Gen Baoa · Gen Bautista · Gen Cabarles · Gen McEwan · Gena

Agnes · Genalyn Arca · Genelil Gonzales · Generose Jocson · Geneveve Van Dooren · Genuine

Naniong · Geordie Dewhirst · George Mathew · Georgekutty Joseph · Georgia Berry · Georgia

Butler · Georgia English · Georgia Hopkins · Georgia Reeves · Georgia Ritchie · Georgia Sherlock ·

Georgia Smaill · Georgia Taylor · Georgia Thompson · Georgie Hamilton · Georgina Aitken ·

Georgina Syme · Gerald Estevez · Geraldine Kevill · Gerlie Navaja · Ghela Domalanta · Gihani

Chathurika · Gil Fielding · Gil Ona · Gilanne Natividad · Gilbert Romero · Gina Parkinson · Gina Salt ·

Gina Schenkel · Gina Villanueva · Gina Yan · Gino Magsino · Giovanna Falchi · Girley Pingol · Girlie

Stevens · Giroma Labradores · Gisha Chandy · Gladys Gaspar · Glaiza Alwit · Glaiza Bernardo ·

Glaiza Saul · Glen Thomson · Glenda Aggarao · Glenn Griffin · Glenn Matthews · Glenn McNickle ·

Glenn Scott · Glennis Kingi · Glenys Percy · Glenys Popenhagen · Glenys Stewart · Gloria Kavanagh

· Gloria Kawadza · Gloria Wardle · Glyn Jenkins · Glynn Pegarro · Glynnis Mackay · Gong

Padayogdog · Gordon Lambagan · Gordy MacLeod · Gorica Brasic · Goswin Kanta · Govind

Yelagani · GR Taala · Grace Aldridge · Grace Anacleto · Grace Arbitrario · Grace Bilagot · Grace

Blake · Grace Boyle · Grace Gubatan · Grace He · Grace Kamuhangire · Grace Kim · Grace Lubos ·

Grace Martinez · Grace Nathan · Grace Nieto · Grace Nochefranca · Grace Rennie · Grace Samuel

· Grace Tabut · Grace Tavara · Grace Tubo · Grace Wei · Grace Wilson · Graeme Thomson · Graeme

Wilson · Graham Beal · Grant Clayton · Grant Costello · Gray Mabasa · Greece Tade · Greema Paul

· Greeshma Susham · Greg Barclay · Greg Conquest · Greg Evans · Greg Giles · Greg Pearce · Greg

Small · Greta Kennedy · Gretch Tacuyan · Grishma Pudasaini · Guang Tian · Gul Kaur · Gunpreet

Tiwana · Gurjeet Kaur · Gurjit Kaur · Gurleen Kaur · Gurmeet Kaur · Gurneet Kaur · Gurpreet Dhillon

· Gurpreet Kaur · Gurpreet Kaur · Gurpreet Kaur · Gurpreet Kaur · Gurpreet Kaur-Gill · Gursharan

Kaur · Gursharan Kaur · Gurvinder Singh Mudhar · Gurwinder Kaur · Guy Warburton · Gwen Cajigas

· Gwen Ward · Habiba Neniel · Hadrian Sultan · Hailey Byun · Hailey Smith · Hamida Khan · Hamish

Kennedy · Hamish O’Neill · Hamish Owens · Hanan Alshbrawi · Hani Fatu · Hannah Apurillo · Hannah

Audas · Hannah Barlow · Hannah Barry-Goss · Hannah Bryan · Hannah Carter · Hannah Casia ·

Hannah Diaz · Hannah Espanola · Hannah Hamilton · Hannah Mackay · Hannah MacLean · Hannah

Martin · Hannah Mayol · Hannah McMurray · Hannah Riches · Hannah Shaw · Hannah Undan · Hans

Koman · Happy Nijjar · Harbhajan Kaur · Hardeep Kaur · Harish Uthirapathy · Harjeet Kaur ·

Harjinder Kaur · Harkamal Minhas · Harleen Johal · Harman Kaur · Harmonee Scott · Harparveen

Kaur · Harper Connolly · Harpinder Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet

Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet Kaur · Harpreet Khohar · Harpreet Pabla · Harry

Capacite · Harry Coronel · Harry Hemus · Harry Huynh · Harry Makhloga · Harry Purohit · Harry

Sampson · Harry Snell · Harry Tesorio · Harsha Kottarathil · Harshani Jayasinghe · Harsimran Kaur

· Harveer Kaur · Harwinder Kaur · Hash Devgan · Hashini Ekanayake · Hassel Sapanta · Havana

A’aifou · Hayden Beaton · Haylee Guy · Haylee Newport · Haylee Syverston · Hayley Berriman ·

Hayley Brown · Hayley Hendra · Hayley House · Hayley Jenkinson · Hayley Kluytmans-Smith ·

Hayley Mackintosh · Hayley Moreton · Hayley Sharp · Hazel Baliza · Hazel Dodunski · Hazel Guillen

· Hazel Magar · Hazel Watene · Hazella Abayan · Heather Adams · Heather Barnett · Heather Booth

157

ANNUAL REPORT 2021

· Heather Jury · Heather Maynard · Heather Parnell · Heather Seddon · Heather Sharp · Heather
Snodgrass · Heather Turney · Heather Tutaki · Heather Wallace · Heather Wilson · Heather Wooles

· Hebbe Xia · Hedda Viray · Heena Arora · Heide Barkman · Heidi Cartwright · Heidi Holm · Heidi

O’Reilly · Heike Voit · Heleen Webb · Helen Bailey · Helen Bridge · Helen Burnley · Helen Cowie ·

Helen Danielsen · Helen Davy · Helen Hayes · Helen Higgins · Helen Highcazony · Helen Mason ·

Helen Maxwell · Helen McKinnel · Helen Van Der Meys · Helen Wehipeihana · Helen Weston · Helen

Xu · Hellen Grenfell · Helly Shrimali · Hema Baldania · Hemal Patel · Henny Villaverde · Henry

Arunjaroen · Henry Davis · Henry Neo · Henry Stuart · Hepi Matapa · Hermie Nuqui · Hermie

Pabulario · Herminia Thompson · Hetal Pansuria · Hieu Lam · Hilary Freeth · Hilary Ward · Hilary

West · Hilary Westley · Hilda Dimalibot · Hildah Muthui · Hima Pauly · Himshikha Paneri · Hina

Veituna · Hine Kameta · Hiromi Mizushima · Hitkumar Patel · Hoani Brown · Hollee McKay · Hollie

Ruddick · Hollie Thomlinson · Holly Binnie · Holly Conway · Holly Duff · Holly French · Holly Gillett ·

Holly Grant · Holly Murrell · Holly Whitaker · Holly Wilson · Honey Arceo · Honey Duque · Honey Gill

· Honey Honey · Honey John · Honey Neilson · Honey Pagtanac · Honeylane Bautista · Hope

McKenzie · Hope Sakalia · House Yuan · Hua Chen · Hui Kian Chua · Huiling Lu · Hymavathi

Gantyada · Hyojoo Lee · Hyun Jun Yoon · Iain Doody · Iain Jagger · Ian Bell · Ian Corry · Ian Whyte ·

Ida Leimi · Ike Abellana · Ildiko Fibik · Ilthon Tomo · Indika Abeykoon · Indika Warnakula · Indu

Gounder · Indy Putri Trilford · Ine Wheeler · Inge Rickards · Ingrid Cagalawan · Ingrid Hurst · Ingrida

Jones · Inigo Holmes · Inno Chiu · Inoka Jayaweera · Inosha Hettiarachchi · Iosefo Bahn · Irene Burt

· Irene Domingo · Irene Jose · Irene Lee · Irene Morgan · Irene Rapa · Irene Yang · Iresha Jahinge · Irin

Babu Pallan · Irina Davis · Irina Shcherbinia · Irish Cantalejo-Emerson · Irish Pelegren · Iritana Tua ·

Isaac Bright · Isabel Jimenez · Isabel Seville · Isabelita Ceniza · Isabella Wild · Ishan Kolothodi · Ishina

Adhikari · Ishu Koirala · Isi Uata · Iskima Bhandari · Isla Jean Tregonning · Isobel OBrien · Ita Living ·

Italia Taka · Itayi Ruvando · Ivana Tan · Ivane Parba · Ivy Araujo · Ivy Carino · Ivy Carreon · Ivy

Chatterjee · Ivy Johnson · Ivy Liza · Izel Martinez · Izzy Byfleet · Izzy Getty · Izzy Hutcheson · Izzy

Partridge · Jaala Attewel · Jabeline Obra · Jac George · Jacinta Afamasaga · Jacinta Maxwell ·

Jacinta Neilson · Jack Foster · Jackie Batoy · Jackie Hotter · Jackie Miller · Jackie O’Fee · Jackie

Rangihuna-Atkins · Jackie Silva · Jackson Sumich · Jacky Adam · Jacky Basongit · Jaclyn Aitken ·

Jaco Malan · Jacob Cherian · Jacob Wood · Jacoeb Uprichard · Jacque Hunter · Jacque Manzano

Leadbetter · Jacqueleen Nyangweso · Jacquelyn Cottam · Jacqui Clarke · Jacqui Devezas · Jade

Bedel · Jade Hemi · Jade Magno · Jade O’Connor · Jade Te Awhe · Jade Washbourn · Jadi Cubita ·

Jagath Wijetilleke · Jaime Clews · Jaime Redmond · Jaimee Bell · Jaimie Novotny · Jalpa Patel ·

Jam Bolivar · Jam Rivera · James Aoys · James Davies-Collins · James Goodman · James Grieves

· James Inobaya · James Marshall · James Ward-Johnson · Jamie Murphy · Jamie Murray-

Macgregor · Jamie Quigg · Jamie Roberts · Jamie Rumbold · Jamie Sheary · Jamila Khaled · Jan

Bandala · Jan Corbett · Jan Low · Jan McCann · Jan Thomson · Jan Villacorta · Jan-Marie Houliston

· Jana Dinusova · Janaki Shrestha · Jane Baker · Jane Bell · Jane Elle · Jane Escalera · Jane Gordon

· Jane Hickman · Jane Hockey · Jane Jordan · Jane Magan · Jane McCall · Jane O’Connell · Jane

Pallett · Jane Paredes · Jane Patrick · Jane Pow · Jane Ram · Jane Sun · Jane Tattley · Janeil Tan ·

Janelle Broughton · Janelle Reade · Janes Castro · Janet Bucag · Janet Hagonoy · Janet Jesen ·

Janet Ngamaru · Janet Spaabaek · Janet Stacey · Janette Boyd · Janette Llesis · Janice Liu ·

Janice Lomosco · Janice Munro · Janice Peralta · Janice Rothwell · Janice Roy · Janice Salmons ·

Janice Stent · Janice Tuuta · Janice Walsh · Janice Wright · Janie Keelan-Hammond · Janie Nolan

· Janine Aitken · Janine Amacio · Janine Davidson · Janine Lipsys · Janine Snape · Janine Spiers ·

Janine Waugh · Janine Wilde · Janith Fernando · Janna Caneda · Jannel Escueta · Jans Amuwala

Mesthrige · Janzelle Marasigan · Jared Kemsley · Jas Bhotea · Jas Taala · Jash Jattana · Jashan

Kaur · Jasmeen Kaur · Jasmeet Kaur · Jasmeet Virk · Jasmin Cataquiz · Jasmin Raju · Jasmine

Dalkie Drummond · Jasmine Evans · Jasmine Kim · Jasmine Kipa · Jasmine Lee · Jasmine Mann ·

Jasmine Mcilraith · Jasmit Kaur · Jason Adam · Jason Browne · Jason Davey · Jason Hopkins ·

Jason Kenna · Jason Mack · Jason Van der Hulst · Jason Zhao · Jasond Jamboy · Jaspinder Kaur ·

Jaspreet Brar · Jaspreet Gill · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Kaur ·

Jaspreet Kaur · Jaspreet Kaur · Jaspreet Kaur · Jaspreet Singh · Jasprit Kaur · Jass Kaur · Jass

Kaur · Jass Kaur · Jass Reddy · Jasvir Kaur · Jaswinder Kaur · Jatinder Kaur · Jay Kang · Jay Kirk ·

Jay Moore · Jay Parag · Jay Pascua · Jay Payot · Jay Sukhdarshan Singh · Jaya Mohan · Jaya

Murugan · Jaya Vandhana · Jayde Galbraith · Jayde Kumsawng · Jayde Simpson · Jayn Baker ·

Jayna Burnett-Brown · Jayne McIlroy · Jayne Money · Jaypee De Peralta · Jayson Ehn · Jaz

Morrison · Jaz Spicer · Jazel Madlangbayan · Jazmyn Fox · Jazz Lord · Jazz Phillips · Jazz Rabbett ·

Jean Farrell · Jean Raga · Jean Ramos · Jean Rigor · Jean Villarin · Jeanafe Abelarde · Jeanel

Gutong · Jeanet Bagares · Jeanette Erestingcol · Jeanette Tebbutt · Jeanette Trueman · Jeanette

Wensor · Jeanie Gamboa · Jeanie Gradwell · Jeanie Salcedo · Jeanne Paterson · Jeanne Walker ·

Jeannette Subritzky · Jeannie Bautista · Jeannie Sales · Jeannie Wang · Jee Manipis · Jeema Lijo ·

Jeena Jose · Jeena Oshana · Jeeva Vakkachan · Jeff De Los Reyes · Jeff Parkins · Jeff Ragragio ·

Jejay Sen · Jele Papellero · Jeli Howes · Jelica Ceballos · Jem Curran · Jen Garcia · Jen Lemery ·

Jen Magrath · Jen Nuevo · Jen Prasad · Jen Rea · Jenelyn Ragadi · Jeni Keogh · Jenn Valavala ·

Jenna Maire · Jenna Moore · Jenni Harris · Jenni Stevenson · Jenni Thompson · Jennie South ·

Jennie Teodoro · Jennielyn Juachon · Jennifer Dela Cruz · Jennifer Ferrier · Jennifer Gonzalo ·

Jennifer Roberts · Jennifer Rodriguez · Jennifer Southee · Jennifer Storer · Jennifer Trasmil ·

Jennifer Tufuga · Jennifer Wong · Jennilyn Maneja · Jenny Abalos · Jenny Achilles · Jenny Bongcog

· Jenny Bower · Jenny Buhat · Jenny Campbell · Jenny Christmas · Jenny Coleman · Jenny Cooper

· Jenny de Peralta · Jenny Dominguez · Jenny Griffiths · Jenny Guanco · Jenny Halliday · Jenny

Jackson · Jenny Kaur · Jenny Lane · Jenny Leader · Jenny Magsilang · Jenny Parker · Jenny Pasiol

· Jenny Penfold · Jenny Segundo · Jenny Simons · Jenny Thiele · Jenny Vaipapa · Jenny Wilson ·

Jenny Wood · Jenny Wood · Jenny Zhang · Jeo James · Jerald Isleta · Jerald Sunto · Jeremiah

Barclay · Jeremy Fabio · Jeremy Moore · Jeremy Wood · Jeriah Balo · Jerin Joy · Jerlene Cruz ·

Jermae Aguilon · Jermaine Masangkay · Jerome Wong Yit · Jerry Shi · Jervilou Santiago · Jesilyn

Delgado · Jeska Beardsmore · Jesna Jose · Jess Bonustro · Jess Foster · Jess Hatfield · Jess Herkt

· Jess Jacques · Jess Jewell · Jess Lay · Jess Lewis · Jess Malaque · Jess McKnight · Jess Morris ·

Jess Nathan · Jessa Getuya · Jesse Grove-Gowans · Jessica Apperley · Jessica Castro · Jessica

Crook · Jessica Csengo · Jessica Martin · Jessica Matheson · Jessica Rice · Jessica Taningco ·

Jessica Tonacao · Jessie Chu · Jessie McKay · Jessie Tang · Jessiely Vibandor · Jessy Arthur-

Worsop · Jesty Nelson · Jevy Badilla · Jewel Galang · Jharmane Catolico · Jhiede Tormis · Jho

Magon · Jhonaliza Detera · Jhong Solen · Jhunnelle Tabay · Jiaxin Bu · Jibin John · Jie Zhang · Jie

Yu Zeng · Jihan Mayor · Jijo Laurence · Jiju Joy · Jil Chua · Jill Clark · Jill Gregson · Jill Job · Jill Patel

· Jill Smith · Jill Turner · Jill White-Northcroft · Jillian Cole · Jilsy Joy · Jim Allardyce · Jim Frost · Jim

Jin · Jim Otimi · Jimaima Naikatini · Jimmy Clemente · Jimmy Franks · Jimmy Silich · Jimmy

Veidemanis · Jimmy Wei · Jince Jose · Jinell Fernandes · Jing Cui · Jing Meipieza · Jini Joy · Jinky

Munoz · Jinky Romero · Jins Kurian · Jinsa Joseph · Jinsha Jiju · Jinson Abraham · Jinu Thomas ·

Jiny Johny · Jiratha Khamsungnoen · Jisbin Siby · Jit Chhetri · Jo Anam · Jo Baker · Jo Bando · Jo

Base · Jo Campbell · Jo Cant · Jo Clare · Jo De Los Angeles · Jo Dickson · Jo Duncan · Jo Foley · Jo

Goode · Jo Hender · Jo Hendry · Jo Hermogenes · Jo Hunt · Jo Johns · Jo Lim · Jo Luijk · Jo Mooney

· Jo Nelson · Jo Rojo · Jo Seed · Jo Turner · Jo Villaester · Jo Ward · Jo Webley · Jo-An Alipin · Jo-

Anne Buhler · Jo-Anne Keating · Joan Lagman · Joan Rubio · Joana Caramoan · Joanna Forbes ·

Joanna Gumangam · Joanna Legall-Misikini · Joanna Nituma · Joanna Taylor-Spedding · Joanne

Bennett · Joanne Eaton · Joanne Hart · Joanne Manger · Joanne McConchie · Joanne Ramirez ·

Joanne Robinson · Joanne Satchwell · Joanne Smith · Joanne Snalam · Joanne Steele · Joanne

Wang · Joanne Wong · Joash Felipe · Joban Singh · Jobcy John · Jobi Paul · Jocel Dorado · Jocelyn

Davidson · Jocelyn Hansen · Jocelyn Infante · Jocelyn Lines · Jocelyn Prospero · Jocelyn Reyes ·

Jock Robinson · Jodie Ellis · Jodie Kirk · Jodie Robb · Jody Coverdale · Jody Keating-Gorton · Joe

Muttumpurath · Joe Nio-Aporo · Joe Rooney · Joe Sturrock · Joe Suedad · Joe Vas · Joe Won ·

Joeben Roxas · Joena Baculio · Joenita Florendo · Joey Bawas · Joey Weaver · Johanna Aguiar ·

Johannes Bronkhorst · John Beuth · John Bland · John De Leon · John Entice · John Foster · John

Gavin · John Goss · John Graham · John Ibarra · John Jenkins · John Katiyo · John Keighron · John

Nayga · John Outten · John Poral · John Taylor · John Van Turnhout · John Young · Johncy Joseph

· Jojo Archer · Jojo Diquit · Jolden Fernandes · Jomarie Guarnes · Jomy Jose · Jona Arganda · Jona

Kayan · Jona Osmena · Jonald Laurico · Jonalyn Angopa · Jonathan Ball · Jonathan Barber ·

Jonathan Barrett · Jonathan Santamaria · Jonathon Hean · Jonelyn Valeroso · Joni-Lou Arcelo ·

Jonna Mangahas · Jonnel Tan · Jono Burch · Jordan Cruickshank · Jordan Elvy · Joreena Mabini ·

Jorefel Sato · Joris Bolijn · Josafa Magallones · Jose Palathunkal · Jose Reeves · Joseph Aquino ·

Joseph Go · Josephine Cunado · Josephine Slater · Josh Dench · Josh Jones · Josh Orchard · Josh

Rasolo · Joshi Nandini · Joshua Smith · Josiane Bizoza · Josie McCrone · Josie Placino · Josmin

Jose · Joti Chand · Joti Kumari · Joti Reena · Jova Marquez · Jovana Brasic · Jovi Obias · Joy Abella

· Joy Abellar-Sinha · Joy Albano · Joy Breward · Joy Brinkmann · Joy Campo · Joy Cho · Joy Duran

· Joy Harrison · Joy Mason · Joy Notman · Joy Yang · Joyce Kinyua · Joyce Kydd · Joyce Li · Joyce

Roa · Jude Fegi · Jude Kerr · Jude Van Bommel · Judette Froilan-Algodon · Judi Wetere · Judith

Babu · Judith Ditablan · Judith Rutledge · Judith Taylor · Judy Aitken · Judy Barron · Judy Campbell

· Judy Christie · Judy Lubanga · Judy McAuley · Judy Miguel · Judy Montero · Judy Patterson · Judy

Petersen · Juffin Koshy · Juhee An · Julia Charteris · Julia Delahunty · Julia Evans · Julia Hamilton ·

Julia Main · Julia Murphy · Julia Walker · Juliana Baxter · Juliana Joseph · Julie Akinyele · Julie

Camay · Julie Collings · Julie Copping · Julie Corkill · Julie Crayford · Julie Crofts · Julie Day · Julie

Deticio · Julie East · Julie George · Julie Gumban · Julie Hoskin · Julie Leilua · Julie Madden · Julie

Madden · Julie Mallia · Julie McGhie · Julie Morrish · Julie Parker · Julie Quine · Julie Rodwell · Julie

Russ · Julie Ryan · Julie Seymour · Julie Simpron · Julie Thompson · Julie Toevai · Julie Wallis · Julie

Williamson · Julie Rose Guinyang · Julie-Ann Beattie · Juliet Findlay · Juliet Smith · Juliette

Brownlow · Julius Macaraeg · Jully Cui · Julyn Cancino · Jun Lam · Jun Montajes · June Marshall ·

June Savage · June Wano · Junessa Shotter · Junior Tai · Junn Alminaza · Justin Regidor · Justin

Reinecke · Justine Hilado · Justine Michel · Juvilyn Hallazgo · Jyothy Gopakumar · Jyoti Bhanot ·

Jyoti K C · Jyoti Kumar · Jyoti Kunwar · Jyoti Phuyal · Jyoti Sharma · Kabita Lamichhane · Kaden Ko

· Kae Tayong · Kael Fallu · Kaelan Healy · Kaitlin Ruscoe · Kaito Hayashi · Kal Sherchan · Kalaivani

Logeswaran · Kaleb Dunstan · Kaleshni Devi · Kalisi Savu · Kalpa Kumarasinghe · Kalpana Negi ·

Kalvi Selvaraj · Kalyan Alluri · Kamal Dhaliwal · Kamal Jajoria · Kamal Kaur · Kamal Kaur · Kamal

Pandher · Kamal Sharma · Kamala Phuyel · Kamalpreet Kaur · Kamalpreet Kaur · Kamalpreet Kaur

· Kamini Prasad · Kanchan Dangol · Kanchi Peiris · Kani Davis · Kaniata Halanukonuka · Kanta Mani

· Kanti Karan · Kara Belcher · Kara Montilla · Kareen Galang · Karel Atilano · Karen Andrews · Karen

Bensemann · Karen Borland · Karen Castel · Karen Clark · Karen Ikimata · Karen Jackson · Karen

Jellyman · Karen Jenkins · Karen Kelly · Karen Kenny · Karen Lake · Karen Layman · Karen Mabao ·

Karen Melo · Karen Merrilees · Karen Moriyama · Karen Nasser · Karen Nel · Karen Parata · Karen

Prothero · Karen Reataza · Karen Rodger · Karen Sears · Karen Shaw · Karen Wellard · Karen

Wellington · Karen Williams · Karin Duval · Karin McDonald · Karin Smits · Karina Choirunisa · Karina

Landero · Karina Misterio · Karishma Naidu · Karizza Miranda · Karl Drent · Karl Holden · Karl

Holloway · Karl Rosales · Karla de Wet · Karla Diaz · Karla Marrs · Karm Kaur · Karuna Maharaj ·

Karuna Neupane · Karuna Singh · Karyl Saavedra · Karyn Marshall · Karyn Nobilo · Karyn Porter ·

Karyn Small · Kasa Katene · Kase Woolley · Kasun Silva · Kat Atkins · Kat Hanson · Katalina Aitaua ·

Katalina Kisina · Katarina Biaukula · Kate Anderson · Kate Bowden · Kate Bruce · Kate Carr · Kate

Clayton · Kate Donaldson · Kate Ensor · Kate Johnson · Kate Milne · Kate Morgan · Kate Ren · Kate

Sharples · Kate Tran · Kate Wood · Kath Abelligos · Kath Collett · Kath Daveis · Kath Dwyer · Kath

Hart · Kath Morgan · Kath Pegalan-Bataanon · Katherine Cade · Katherine Smith · Kathie Carter ·

Kathie Dimock · Kathleen Corcuera · Kathleen de Gracia · Kathleen McMillan · Kathlen Gingoyon ·

Kathrine Tan · Kathryn Francis · Kathryn Geopano · Kathryn McMahon · Kathryn Van de Westerlo ·

Kathy Petersen · Katie Benson · Katie Hilleard · Katie Longden · Katie Matatia · Katie-Jane Knight ·

Katie-Rae Botica · Katrin Marundan · Katrina Armstrong · Katrina Boyd · Katrina Copland · Katrina

Ede · Katrina Mann · Katrina McLean · Katrina Stevens · Katty Maya · Katy Fryer · Katy Hodder · Katy

Van Nieuwenhuizen · Katz Melebo · Kavitha Sukumar · Kawana Hing · Kay Clarke · Kay Jeffs · Kay

Katene · Kay Merekula · Kay Spick · Kaya Edwards · Kaycee Borja · Kaye Clyne · Kaye Francisco ·

Kaye Kaur · Kaye Nieva · Kaye Stoddart · Kaye Wesley · Kayla Myles · Kayla Richmond · Kaylah Ross

· Kaylee Du Preez · Kaylene Brock · Kaylene Tipene · Kayley Taylor · Kaylyn Merrall · Keann Alojado

· Keefe Martinez · Keeta Shrimpton · Keiko Simpson · Keisi Puafuti · Kelera Bourke · Kellie Hura ·

Kelly Barnes · Kelly Cooke · Kelly Dacanay · Kelly Engelen · Kelly Jackson · Kelly Jansen · Kelly

Jones · Kelly Reuelu · Kelly Zeng · Kelsey Wilson · Kelsie Grantham · Kelvin Weston · Ken Go · Ken

Wongsomboon · Ken Yeung · Kendall Charles · Kendall Johnson · Kendall Stobart · Kendyl Hudson-

McDonald · Kennely Atilano · Kenneth Alo · Kenneth Baldivinos · Kenneth Penolbo · Kenny

MacAskill · Keran Taylor · Keri Brickmann · Keri Ladbrook · Kerianne Harmon · Kerri Martin · Kerri

Roberts · Kerri Taylor · Kerrin Riches · Kerry Gall · Kerryn Drever · Kertch Berzabal · Keryn

Johnston-Dixon · Kevin Bowgett · Kevin Butcher · Kevin Durkin · Kevin Grimwood · Kevin Selner

Maniego · Kevin Taylor · Keysha Ericksen · Khina Neupane · Khush Arora · Kianna Wang · Kie Kassal

· Kiely Buttell · Kiera Bradford · Kieran Angus · Kieran Cox · Kieti Kalava · Kika Fosita · Kili Li · Kim

Baker · Kim Brougham · Kim Buere · Kim Chayag · Kim Cunard · Kim Grundmann · Kim Hammersley

· Kim Henry · Kim Housiaux · Kim Machado · Kim Manansala · Kim Nanscawen · Kim Perez · Kim

Wallace · Kim White · Kimberly Bakian · Kimi Donaldson · Kimlea Howard · Kimmy Beringuel · Kinu

Nagaya · Kira Slimin · Kira Wetere · Kiran Dhillon · Kiran Gudopp · Kiran Joseph · Kiran Joshi · Kiran

Kaur · Kiran Lata · Kiran Singh · Kirandeep Basram · Kirandeep Kaur · Kirandeep Kaur · Kirby

Chunaco · Kirk Lubos · Kirk Serafica · Kirn Brar · Kirsten Bell · Kirsten Liggett · Kirsten Merrett ·

Kirstin Charters · Kirstin Jenkinson · Kirstin Murdoch · Kirsty Gunn · Kisa Faauli · Kisa Tanuvasa ·

Kishore Kurian · Kit Montilla · Kitty Tamayo · Klarissa Dacyon · Kolotita Makalio · Komal Goundar ·

Komal Komal · Komal Patel · Komalpreet Kaur · Koppel Sorono · Korinna Dela Cruz · Koshala

Waduwatta · Kreeti Kumar · Kris Domondon · Kris Perkins · Krishma Singh · Krishna Malcampo ·

Krishna Nagalla · Krishna Rajput · Krissy Talavera · Krista Lee · Kristell Paqueo · Krister Borja ·

Kristin Bayhon · Kristin Cadavis-Khiathani · Kristina Bonsol · Kristina Thomas · Kristine Baring ·

Kristine Bello · Kristine Dalauidao · Kristine Fegi · Kristine Llave · Kristine Ostrea · Kristine Pancho ·

Kristine Singh · Kristofer Toledo · Kristoff Bawayan · Krystal Manson · Krystyna Bostrovas · Kuldeep

Kaur · Kuldip Singh · Kulwinder Kaur · Kumar Mekala · Kurt Hiller · Kushla Raju · Kushma Gurung ·

Kyamala Magar · Kyan Rumbold · Kyla Ellis · Kyla Graf · Kyla van Heerden · Kyle Thomson · Kylie

Campbell · Kylie Dearing · Kylie Martin · Kylie Maxwell · Kylie Thomas · Kyoungmi Kim · La Drew ·

Lachmi Kanta · Ladine Hobson · Ladonna De Asis · Lady Canda · Lailanie Gray · Lailega Iosefa ·

Laiza Peters · Lami Taua · Lana Boynton · Lana Fraser · Lana Tuipulotu · Lance Clendon · Lance

Fletcher · Lancy Lawrence · Lanei Dimaano · Laney Tomkins · Lanie Mabale · Lanna Schnetler ·

Lara Durand · Lara Formentera · Lara Giles · Larissa Sedouch · Larissa Te Ao · Larry Montoya ·

158

RYMAN HEALTHCARE

Latchmi Murti · Lateesha Douglas · Latoya Brownlee · Laura Blunsdon · Laura Carrington · Laura
Hawkes · Laura Herman · Laura Luague · Laura Manalaysay · Laura McCullough · Laura Menzies ·

Laura Moffett · Laura Richmond · Laura Walker · Laura Whicker · Lauren Baldock · Lauren

Beaumont · Lauren Clark · Lauren Heyes · Lauren Odgers · Lauren Strachan · Lauren Wells ·

Laurence Alojado · Laurence Llenes · Lavanya Perumandi · Lavina Varghese · Lavinia Kelly ·

Lavpreet Kaur · Lawale Baigern · Lawrence Azul · Lawrence Manohara-Seelan · Laya Mary Veliyil

Shaji · Lazel Nieto Baungally · Lea Brown · Lea Sullivan · Lea Valdez · Leah Hand · Leah Ouano · Leah

Soliva · Leah Villaruz-Foo · Leah White · Lealyn Ramos-Llanera · Leanna Harding · Leanne Booth ·

Leanne Fabish · Leanne Gillie · Leanne Hunter · Leanne King · Leanne McFarlane · Leanne

Nukunuku · Leanne O’Meara · Leanne Paekau · Leanne Stewart · Leanne Watson · Leba

Leqakowailutu · Lebron Suedad · Lee Gao · Lee Hancock · Lee Parkhill · Lee Rodgers · Lee Wilson ·

Lee-Anne Mahadeo · Leeba Babu · Leela Pathirannahelage · Leema Alias · Leen Porathur · Leena

Kumar · Leeza Stone · Lehanna Pio · Leia Bishop · Leigh Kench · Leigh Pakome · Leila Salac · Leilane

Alforo · Leilani Loibl-Beach · Leis de Vernon · Leisa Brown · Len Ferrer · Len Medalla · Lena Gawler

· Lena Te Miha · Lenin Moncy · Leo Dumagan · Leo Hahn · Leo Salac Jr · Leon Hewitt · Leon van den

Berg · Leonie Kebbell · Leonie Taylor · Leroy Sisnett · Leshani Gunawardana · Leshika Arachchige ·

Lesila Tamale · Lesley Crampton · Lesley Harris · Lesley Pells · Lesley Te Maiharoa-Sykes · Leslie

Ortega · Lester Toms · Lester Salvosa · Letitia Corcoran · Leva Latu · Lewis Bradford · Lez Pencz ·

Li Feng · Li Hayman · Li Ma · Lia Pou · Liam Claringbold · Liam Riddiford · Lianne Woolford · Libby

Doran · Libby Esguerra · Libby Hetaraka · Lie Fiu · Liesl Kruger · Liezl de Waal · Ligaya Cobile · Ligi

Johnson · Ligi Pailikutty · Ligy John · Lijo Ittoop · Likhwa Sigola · Lila Patel · Lili Dong · Lili Latu · Lili

Talega · Lili Volpicelli · Lilian Ferreira · Liliana Romero · Lill Wawatai · Lillian Lian · Lilly-Belle James ·

Lily Elliott · Lily Forcadilla · Lily Fraser · Lily Graciano · Lily Isleta · Lily Nicolescu · Lily Xiao Ying · Lima

Ugapo · Lin Lim · Lin McLaughlin · Lina Benedetti · Lina Tuimana · Linda Burnside · Linda Churchill ·

Linda Lockington · Linda Maharjan · Linda McGill · Linda McKee · Linda Morey · Linda Odhiambo ·

Linda Pettigrew · Linda Reid · Linda Richards · Linda Skelton · Linda Soloman · Linda Street · Linda

Vescherre · Linda Warren · Linda Yu · Lindsay Harrison · Lindsay O’Connor · Lindy Havinga · Lionel

Kho · Lionel Pillay · Lisa Carr · Lisa Crichton · Lisa Gilligan · Lisa Humphrey · Lisa Laforgia · Lisa

Leger · Lisa Marr · Lisa More · Lisa Neiman · Lisa Ngatai · Lisa Petana · Lisa Puklowski · Lisa Raika ·

Lisa Robinson · Lisa Ross · Lisa Walton · Lisa Whitcombe · Lisha Alias · Lisi Fifita · Lit-Lit Lacerna ·

Lita Naude · Liviana Ketewai · Liyana Bandara · Liz Beresford · Liz Bradford · Liz Close · Liz Dilger ·

Liz Gill · Liz Hampton · Liz Hickling · Liz Keeman · Liz Nancollis · Liz Penman · Liz Thrush · Liz Wells ·

Liza Dong · Liza Hendry · Liza Mierzejewski · Liza Siano · Lizell Umayam · Lizeth Monzalo · Lizz Read

· Lizzy McKenzie · Lloyd Landiza · Lloyd Tipudan · Loa Tuiolemotu · Lochlan Wilson · Logan

Fairbairn · Logan Sears · Loida Malanyaon · Loida Zarandona · Lois Battersby · Lois Chirume · Lois

Partridge · Lois Tooley · Lonita Tejano · Lordei Ledesma · Lorelle Brljevich · Loren De Chavia ·

Lorena Sadler · Lorenza Macayba · Lorie Anderson · Lorie Bantugan · Lormie Talape · Lorna

Alcasabas · Lorna Carter · Lorna Jenkin · Lorraine Barcibal · Lorraine Dawson · Lorraine Fuller ·

Lorraine Hulse · Lorraine Kelly · Lorraine Knight · Lorraine Leigh · Lorraine Price · Lorraine Tippett ·

Lorraine White · Lotis Baldozano · Lotis Caranguian · Loto Foaese-Aiolupo · Lou Anisy · Lou

Cabuyadao · Lou Camargo · Lou Moyle · Lou Tubig · Louie Dalida · Louis Rountree · Louis

Wolmarans · Louisa Bradburg · Louisa Liang · Louisa Lote · Louisa Morton · Louise Addis · Louise

Brown · Louise Caudwell · Louise Davies-Collins · Louise Dawson · Louise James · Louise Nicholas

· Louise Rayner · Louise Tanner · Louise Woods · Lourde Riotoc · Lovaine Glariada · Love Valderrosa

· Lovely Begum · Lovely Bieles · Lovely Chauhan · Lovepreet Kaur · Lu Southern · Lua Tauaneai · Luc

Wong · Luca Chiavola · Lucia Meyer · Lucilee Balbarino · Lucky Schuster · Lucky Shakya · Lucresia

Caitor · Lucy Ayers · Lucy Banaba · Lucy Bothwell · Lucy Caldwell · Lucy Fan · Lucy Levi · Lucy

Mataki · Lucy Nordstrom · Lucy Ryan · Lucy Uro · Lucy van Deursen · Lucy Zhou · Luis Leh · Luis

Lencioni · Luisa Filimoehala · Luisa Giraldo Gallon · Luisa Rokotuiloma · Luke Flynn-Mackenzie ·

Luke Hutchinson · Luke Patience · Luna Touzel · Lupe Finau · Lusia Makihele · Lusiana Khan · Lusila

Perez · Lydia George · Lydia Lophus · Lydia Morintat · Lydia Renu · Lylene Nuguid · Lyn Aragon · Lyn

Brown · Lyn Caylan · Lyn Elton · Lyn King · Lyn Menor · Lyn Metran · Lyn Nickel · Lyn Zalavarria ·

Lynda Dean · Lynda Ellington · Lynda Goston · Lynda Hill · Lynda Schuler · Lynde DeAndres ·

Lyndon Harper · Lyndon Taylor · Lyndsay Richards · Lyndy Direen · Lynette Darling · Lynette Neale

· Lynette Pido · Lynette Polley · Lynley Ballantine · Lynley Gillies · Lynn Buist · Lynn Charlton · Lynn

Garner · Lynn Matthews · Lynn Rollo · Lynne Bretherton · Lynne Domigan · Lynne Egging · Lynne

Kane · Lynne Lepoidevin · Lynton Parkinson · Lyree Sayers · Lyric Hoani · Lyssa Foreman · Ma

Kathrina Concepcion · Ma Kriezl Ramos · Maaimoa Latu · Maan Singh · Mabel Mathews · Mable

Stewart · Maddie Anthony · Maddie Prime · Maddy Jones · Madelein Brooks · Madeleine Dela Rosa

· Madelyn Premacio · Madelynne Casison · Madhu Singh · Madison Gray · Madison Wright · Mae

Flores · Mae Resos · Mae Toreja · Maelene Gatinao · Maffy Coates · Maggie Cornelio · Maggie Kam

· Maggie Malone · Maggie Roberts · Maha Ramachandran · Maia Clare · Maia Scott-Wheeler · Maia

Seaward · Maia Tagod · Mak Eketi · Makelesi Vula · Malav Patel · Malcolm Tolman · Malcolm

Zuppicich · Maleesa Daniel · Malia Carter · Malia Savelio · Malia Va’afusuaga · Mallory Currier · Malo

Tauaneai · Mamata Gurung · Mamta Gusain · Man Wai Fung · Manasa Mohan · Manda Ross ·

Mandeep Gill · Mandeep Kaur · Mandeep Kaur · Mandy Clutterbuck · Mandy Errington · Mandy

Hemmingsen · Mandy Jiang · Mandy Tarquinio · Mandy Tipoki · Mandy Uren · Mandy Wright · Mandy

Zhang · Mani Arora · Manilyn Calda · Maninder Kaur · Manisha Baniya · Manisha Gurung · Manisha

Majhi · Manisha Mane · Manjali Abeysekara Mudiyanselage · Manjeet Kaur · Manjit Mahi · Manju

Benoy · Manju Bothara · Manjula Devi · Manmeet Kaur · Mannu Kaur · Manohari Mendis · Manpreet

Gill · Manpreet Kaur · Manpreet Kaur · Manpreet Kaur · Manpreet Kaur · Manpreet Kaur · Manpreet

Kaur · Manpreet Sekhon · Mantha Thou · Manu Mathew · Manu Sherchan · Manuela Jaramillo

Gonzalez · Manwinder Sangha · Mara Hernando · Marama Lomia · Marc Archbold · Marc Ytom ·

Marcelle Sherwood-Whall · Marcia Bernardo · Marcia Geronimo · Marcus Cullen · Marcus Gildon ·

Marcus Rimington · Marcy Dolar · Maree Crozier · Maree Hughes · Maree McCorkindale · Maree

Morris · Maree Ockwell · Maree Vaile · Maree Washbourne · Mareike Bohte · Mareta Tokannata ·

Marg Vicente · Marg Vince · Margaret Chambers · Margaret Haami · Margaret Hamilton · Margaret

Lethbridge · Margaret Manson · Margaret Osage · Margaret Rakai · Margie Bell · Margo Beale ·

Margot Boock · Margot Taylor · Mari Gomes-Bradford · Mari Isnit · Maria Achari · Maria Aguilos ·

Maria Baby · Maria Bautista · Maria Bayan · Maria Bunsato · Maria Cavan · Maria Cuizon · Maria

Flores · Maria Fong · Maria Francisco · Maria Fuga · Maria Gregorio · Maria Havea · Maria Inocencio

· Maria Isnit · Maria James · Maria Jordan · Maria Joseph · Maria Kurian · Maria Martinez · Maria

Mathieson · Maria McNeilly · Maria Neill · Maria Nuval · Maria Ralawa · Maria Ramos · Maria Restrepo

· Maria Rivera · Maria Soares · Maria Torralba · Maria Walker · Maria Warriner · Marian De La Cruz ·

Marian Magpantay · Mariane Vicente · Marianel Miralles · Marianita Pelaez · Marianne Cobeldick ·

Marianne Heikkila · Marianne Hernandez · Marianne Regala · Marianne Ventura · Maricar Blancaflor

· Maricar Santos · Maricel Angeles · Maricel Atienza · Marichelle Roxas · Marichille Bandales ·

Marichu Calpo · Marichu Siao · Marie Aki · Marie Araneta · Marie Chandra · Marie Darling · Marie

Deverell · Marie Domingue · Marie George · Marie Gonzales · Marie Hodges · Marie Jenkins · Marie

Molina · Marie Percy · Marie Rutherford · Mariel Simblante · Mariela Durnhofer Rubolino · Marien

Fabillar · Marievan Tan · Marife Galvez · Marife Patterson · Marika Laflamme · Marilou Callo · Marina

John · Marina Wildbore · Marion Gordobe · Marion Jackson · Marion Paquit · Marion Ver Esguerra ·

Maris Banal · Maris Taueki · Mariss Yamson · Marissa Hirawani · Marites Suaring · Marivic Sinio ·

Mariya Antony · Mariya Johnson · Mariya Yacob · Marizz Maneng · Marjan Aghakarimi · Marjo Engel

· Marjorie Gomez · Marjorie Guillemer · Marjorie Masangkay · Marjorie Sojor · Mark Adams · Mark

Aliado · Mark Balute · Mark Clorion · Mark Cooley · Mark Cooper · Mark Dimaano · Mark Florendo ·

Mark Gela · Mark Harper · Mark Nunn · Mark Owens · Marko Meingassner · Marlene Barbosa Da

Silva · Marmyl Robson · Marnie Castillo · Marnie Higgins · Marta Manicia · Martha Diprose · Martha

Peka · Martin Collins · Martin Greenfield · Martin Lau · Martin Westley · Martina Himme · Martine

Mathews · Martley Mitikulena · Martyn Osborn · Marvie Rongavilla · Mary Bayona · Mary Boyce ·

Mary Cho Aung · Mary Compoc-Canoy · Mary Cyriac · Mary Freeman · Mary Gipsy · Mary Gonzales

· Mary Jacob · Mary Kasperski · Mary MacLeod · Mary Nicy · Mary Papadopoulos · Mary Rongo ·

Mary Shiju · Mary Tait · Mary Thompson · Mary Vasaya · Mary Wagwag · Mary Ann Domingo · Mary

Ann Noquilla · Mary Ann Velarde · Mary Grace Ladianghibong · Mary Jo Giray · Mary Jo Matullano

· Mary-Anne MacAskill · Mary-Anne Stone · Maryanne Gilmore · Marybeth Perez · Marylyn Narayan

· Maryvonne Gray · Masayo Burke · Mascha Florisson · Mason Woods · Matakeu Timms · Mathew

Josipovic · Mathias Sackey · Mathura Arachana · Mati Fryer · Matt Bell · Matt de Jong · Matt Fane ·

Matt Hutchinson · Matt Orr · Matt Poskitt · Matt Sheehan · Matt Southwick · Matt Wright · Matthew

Brown · Matthew Coates · Matthew Gowdy · Matthew Somosot · Maui Padilla · Mauree Parker ·

Maureen Glentworth · Maureen Johnson · Maurice Schroeder · Max Wilson · Maxine Hansen · May

Bilalat · May Bonicatto · May Carinan · May Checa · May De Los Santos · May Duong · May

Hemtanont · May Magsino · May Poligrates · May Raquepo · May Sino-Ag Sargento · Maya Daniel ·

Maya Prasad · Maybel Bumanglag · Maychelle Bechayda · Mayda Bromley · Maye Agdigos · Mayumi

Shinzaki · Mayuri Mistry · Meagan Leqakowailutu · Mealofa Faimalo · Meegan Potts · Meehee Kim ·

Meena Meenakshi · Meenu Bandara · Meenu Devasia · Meenu Jose · Meenu Sheeja · Meet Kaur ·

Meg Fraser · Megadryl Atas · Megan Ashton · Megan Coffey · Megan Dempsey · Megan Fowlie ·

Megan Green · Megan Grey · Megan Knight · Megan Willis · Meghan Blackwell-Hart · Mei Bitanga ·

Mei Boderick · Mei Yu · Meidy Maza · Meise Misa · Mel Hamlin-Tuck · Mel Maxwell · Mel Tolete · Mela

Matairavula · Mela Moceiwai · Melanie Asuncion · Melanie Reyes-Tagle · Melanie Torwick · Melannie

Marasigan · Melchor Velandria · Mele Ekenasio · Mele Leha · Mele Palelei · Mele Vaka · Mele Vi ·

Melesia Kautai · Meliame Nimmo · Melina Darvish · Melina Vasu · Melinda Opray · Melinda Reside ·

Melis Casimiro · Melissa Allan · Melissa Burgoyne · Melissa Caldwell · Melissa Clark · Melissa Cross

· Melissa Escretor · Melissa Fluit · Melissa Greentree · Melissa Knight · Melissa Wayland · Melita

Tivalu · Melkame Kebede · Mellissa Page · Melvin Manglicmot · Melvyn Khatri · Mely Cruz · Memoree

Wishart · Menaka Silva · Mengyao Luo · Menik De Silva · Mennen Oebanda · Menno Blom · Mercy

Ponniah · Mercy Sneddon · Mere Caginiveisaqa · Mere Korotuku · Mere Mana · Mere Manukonga ·

Mere Nasoli · Mere Tabataba · Mereani Boi · Meredith Fricker · Merewalesi Rogasagasa · Meri

Janevska · Merin Puthenthara Joy · Merin Sabu · Merin Thomas · Meriya Dias · Merlin Varghese ·

Merline Daniel · Merlyn Clarke · Merlyn Raciles · Merrin Jack · Merryl Espanol · Meryll Totanes · Merz

Maximo · Meserat Mulegata Cherente · Mezzy Bi · Mhel Agpaoa · Mhel Alfaro · Mhel Bautista · Mhel

Lopez · Mi Chaw · Mia Azogue · Mia Gallao · Mia Joseph · Mia Maranan · Mia McKinley · Mia Mihaila

· Mia Wong Yit · Miah Dunn · Miao Tian · Michael Ablan · Michael Aninon · Michael Apat · Michael

Balazo · Michael Borostyan · Michael Cummings · Michael Esguerra · Michael Ledama · Michael

Malicse · Michael Maranan · Michael Mcdonald · Michael Medina · Michael Mitchelson · Michael

Pascual · Michael Sanders · Michael Spahn · Michaela Benkova · Michaela Claridge · Michaela

Forgus · Michaela Manu-Adams · Michaela Reyes · Michaella Faaita · Michele Elenio · Michele

Morrison · Michelle Abad · Michelle Attard · Michelle Barnard · Michelle Berridge · Michelle Blackler

· Michelle Blanchard · Michelle Canning · Michelle Child · Michelle Cowan · Michelle Dew · Michelle

Forgus · Michelle Forman · Michelle Garland · Michelle Greig · Michelle Houston · Michelle Legaspi ·

Michelle Lewis · Michelle Lord-Roper · Michelle McDonnell · Michelle Paco · Michelle Parker ·

Michelle Perkins · Michelle Pickworth · Michelle Priest · Michelle Robinson · Michelle Shaw ·

Michelle Sims · Michelle Smith · Michelle Stewart · Michelle Sutherland · Michelle Tan · Michelle Ung

· Michelle Vermeer · Michelle Wright · Mihiri Meemanage · Miho Tomoike · Mika Fuentes · Mika Kato

· Mika Nacionales · Mika Reid · Mikaela Abraas · Mikayla Miller · Mike Adair · Mike Arsenio · Mike

Davidson · Mike Gebbie · Mike Munslow · Mike Narido · Mike Yang · Mikey Payumo · Mikey Villatuerte

· Miki Dablio · Mila Biaukula · Mila Slavinskaya · Mildred Gaspar · Miles Pancho · Millie Edwards ·

Millie Fraser · Millie McKernan · Millie Stratta · Milly Bergshoeff · Milu Mathew · Mimi Anterea · Mimi

Mendoza · Min Cho · Min Kim · Min Lee Phang · Mindy Duggan · Minerva Hosena · Mini Poulose ·

Minty Walia · Miraina Rimon · Miranda Barnes · Mirasol Beattie · Miruna Karki · Misa Patterson ·

Mitali Patel · Mitch Luby · Mitchell Griffin · Mitchell Johnson · Mitchell McCutcheon · Mitz Abucejo ·

Miyoung Kim · MJ Basilio · Mlete Asfaw · Moana Fifita · Moana Martin · Mohini Nand · Mohini

Narayan · Mohini Olds · Molly Elliott · Molly Mathers · Molly Steel · Momena Begum · Mona Ali · Mona

Sami · Mona Singh · Monette Angadol · Monica Blanca · Monica Cho · Monica Manao · Monica Martir

· Monica Relucio · Monica Sebastian · Monika Monika · Monika Prasad · Monika Rani · Monika Yadav

· Monima Thapa · Monique Awab · Monique Leeson · Monique Villalobos · Monique Voermanek ·

Monish Kumar · Monita Mala · Montana Asovale · Monty Rose · Monu Pradhan · Moon Young Kim ·

Morag Davidson · Moreen Kaur · Morgan Davis · Morgan Owen · Morne Wium · Morvana da Silva ·

Mouli Liyanaarachchi · Mounata Shrestha · Mounika Bathula · Mufida Nisha · Mukish Yelanchezian

· Muna Nonu · Munah Miller · Munaza Azmie · Muriel Apablaza Navarrete · Murphy Bartle · Murray

Bain · Murray Parkes · Mykie Scott · Mylah Morandarte · Mylen Lingaolingao · Mylene Bugo · Myra

Attwood · Myra Gotz · Myra Tonks · Myrna Hatosa · Myrna Tulloch · Myrtle Brown · Myungju Chung

· Nadee Asanka · Nadeera Talagala · Nadia Conn · Nadia Heggland · Nadine Diack · Nafeeza Manga

· Naina Benny · Naina Gupta · Naincy Rastogi · Naise Palusa · Naj Nahar · Najmoon Noorani · Nalanie

Munasinghe · Namiko Uehara · Namita Puri · Namita Shyam · Namrata Joshi · Nancy Hayden ·

Nancy Kumaradhas · Nancy Strapp · Nancy Taua · Nancy Wan · Nancy Watta · Nancy Wilson ·

Nandie Maung · Nandika Silva · Nandini Ram · Nani Bulicakau · Nani Rokotuisuva · Nanise Bulicakau

· Nao Osato · Naoko Matsuo · Naomi Busby · Naomi Kaba · Naomi Keegan · Naomi Silva · Naomi

Tulaga · Naomi Vaea · Narmadha Dissanayake · Narumon Murray · Nashvin Natke · Nat McIlwain ·

Natalei Down · Natalia Poulsen-Smith · Natalie Finn · Natalie Fox · Natalie Randall · Natalie Saunders

· Natalie Thomson · Nataliya Tretyakova · Natalya Medlock · Natana Gisma · Natasha Esterhuizen ·

Natasha Henderson · Natasha Rattray · Nathan Ellis · Nathan McPherson · Nathan Salanoa ·

Nathan Tahi · Nav Hehar · Nav Singh · Navdeep Kaur · Navdeep Kaur · Navdeep Kaur · Naveen Allam

· Naveen Pasunooti · Navjeet Multani · Navjot Brar · Navjot Kaur · Navjot Kaur · Navneet Kaur ·

Navneet Kaur · Navneet Navneet · Navpreet Kaur · Nazia Habib · Neekayla McGimpsey · Neeru

Barot · Neethu Babu · Neethu Maxin · Neha Arora · Neha Sehrawat · Nehal Patel · Neil Davies · Neil

Grinter · Neil Sears · Neil Sunil · Neil Watson · Nela Sepuloni · Nelly Chand · Nelly Joseph · Nelson

Pajarillage · Nemo Arriola · Nena Aglosolos · Nena Balbis · Neneth Alicamen · Neri Macolbacol ·

Nessa Ojales · Nestor Monterozo · Nesum Selliah · Nett Taghoy · Nette Gabriel · Neville Dobson ·

Neville Parkinson · Ngaire Moreton · Ngapine Popata · Ngas Gideon · Ngosi Smith-Licorish · Nhu

Nguyen · Niamh McGuigan · Nibin Antony · Nic Thorpe · Nick Bond · Nick Frische · Nick Hew · Nick

Lamb · Nick Male · Nick Phimwong · Nick Wilson · Nicki Hawker · Nicki McLaren · Nicki Wilson ·

Nickie Tani · Nicky Anderson · Nicky Bercich · Nicky Crawford · Nicky Phillips · Nicky Smith · Nicky

Whithair · Nicola Bowick · Nicola Fagan · Nicola Keast · Nicola Martin · Nicola Mitchell · Nicola Steel

· Nicola Tarleton · Nicole Dunn · Nicole Forster · Nicole Hurford · Nicole Langman · Nicole Mills ·

Nicole Sombrea · Nicole Toomey · Nicole Trautvetter-Grodotzki · Nicole Uy · Nicole Yeatman · Nicy

Abraham · Nida Hassan · Nidhi Patel · Nigel Geonanga · Nigel Megaw · Nik Ekdahl · Nika Lafaele ·

159

ANNUAL REPORT 2021

Nikhil Johnson · Nikhil Shetty · Nikhil Thilakan · Niki De La Harpe · Niki Veeran · Nikita Dhungana ·
Nikita McIntosh-Zuppicich · Nikita Van Niekerk · Nikka Bermejo · Nikki Babbington · Nikki Careford

· Nikki Edwards · Nikki Hill · Nikki Johns · Nikki Kirner · Nikki Wester · Nikola Karlikova · Nikolai

Balanski · Nila Boocock · Nila Jayasuriya · Nilda Pagba · Nileshni Devi · Nili Gyawali · Nilma Pettagam

· Nilmini Rajapaksa · Niluka Samarakoon · Nima Kankanamge · Nimi Jacob · Nimisha Bulsara ·

Nimisha Maharjan · Nimisha Shah · Nimmy Thomas · Nina Archvarin · Nina Bulgakova · Nina Kluge ·

Nina Melocotones · Nina Russell · Nina Wozniak · Ninja Chahal · Ninu Augusthy · Nira Gifkins · Niraj

Khatiwada · Nirali Patel · Nirmala Sharma · Nirosa Perera · Niru Chouhan · Nisha Ismail · Nisha

Maharjan · Nisha Thapa · Nita Rataro · Nita Yu · Nitah Rungroungkul · Nithara Jose · Nithila

Thangamony · Nithin Cheriyan · Nittu Mathew · Nivya Paul · Nixie Carter · Nizar Virani · Noah

Graham · Nochelle Visitacion · Noelene Kitto · Noeline Plowman · Noeline Watson · Noema Leota ·

Noemie Flores · Nola Dyers · Nona Chase · Nonie Alicamen · Nora Arango Bedoya · Nora Esplago ·

Nora Tjandrawidjaja · Noreen Zamora · Norman Beattie · Nova Santiago · Nuwan Rathanyake · Nye

Vyas · Oakley Miller · Odessa Abellana · Odette Whitter · Ofa Lolohea · Oksana Kotlyar · Olive Balli ·

Oliver Konigstorfer · Olivia Antonievich · Olivia Chiang · Olivia Clover · Olivia Ferrer · Olivia Gilmore

· Olivia Moorman · Olivia Stacy · Olivia Tustin · Olivia van de Klundert · Ollie Parvin · Om Prasad ·

Omar Damatac · Onanong Bunjumnong · Orada Wisatwongsa · Oreil Siketi · Oscar Lowy · Oshanthi

Maheshika Liyanage · Osien Andaya · Otep Sacristan · Owen De Does · Owen Duncan · Oyahida

Tumpa · Paewai Tume · Paige Cull · Paige Flashoff · Paige Harrison · Paige Linneweever · Paige-Ellen

Field · Palack Sharma · Pam Harliwich · Pam Malang · Pam McCreedy · Pam Mino · Pam Mirk · Pam

Regis · Pami Kariyapperuma · Pankti Modh · Paola Adolfo · Paola Beltran · Paolo Robles ·

Parampreet Kaur · Paras Kundra · Pardeep Brar · Pardeep Kaur · Paris Laurence · Parminder Kaur ·

Parminder Sandhu · Parmjeet Kaur · Parmjit Kaur · Parth Patel · Parvathy Nair · Parvati Gandhi ·

Parveen Brar · Parveena Naicker · Parvinder Kaur · Parwati Kriletich · Parwinder Kaur · Pasepa

Veilofia · Pat Belcher · Pat McKee · Pat More · Pat Sleeman · Pat Turner · Patricia Dela Cruz · Patricia

Hewitt · Patricia Mabunga · Patricia Nand · Patricia Robles · Patrick Fitzgerald · Patty Khunkaew ·

Paul Blackler · Paul Boyle · Paul Camania · Paul Child · Paul Clark · Paul Gurr · Paul Guy · Paul Korunic

· Paul Lenette · Paul Martillana · Paul McLeod · Paul O’Carroll · Paul Shiel · Paul Sutcliffe · Paul Sutton

· Paul Tsang · Paul Viernes · Paula Fa’aoso · Paula Gutierrez · Paula Kennard · Paula Moyles · Paulette

Sheehan · Paulina Woch · Pauline Cody · Pauline Field · Pauline Groves · Pauline Liao · Pauline Linton

· Pauline Murray · Pauline Nickson · Pauline O’Brien · Pauline Robinson · Pauline Rousseaux · Pauline

Waby · Paulini Singh · Paulo Moreira · Pawan Virk · Paz Chan · Paz Checchecan · Peachie Tagaan ·

Peachy Wee · Pedro del Estal · Peggy Chao · Peggy Tonta · Pele Elia · Pele Vaaga · Pelise Muiaa ·

Penelope Stark · Peni Raroa · Penny Honey · Penny Kaye · Pepa Memea · Pepe Toe · Perla Torreja ·

Persis Chavan · Pete Dayo · Peter Bellam · Peter Erian · Peter Gertos · Peter Hollins · Peter Jonson ·

Peter Macintosh · Peter Smith · Peter Ware · Peter Whelan · Petra Klingbeil · Petrice Vincent · Petta

Danny · Pha Taylor · Phailin Chumsombat · Phil Haynes · Phil Price · Phil Quartly · Phil Yarrall · Philip

Jackson-Cox · Philip Mathew · Philip Mealings · Philip Spinks · Philippa White · Phill Larner · Phillip

Hamilton · Phillipa A’Court · Phoebe Edwardes · Phoebe Laureano · Phoebe Neho · Phoebe Ona ·

Phoebe Orola · Phoebe Premacio · Phoebe Tumata · Phoebe Verdadero · Phoebie Wesche · Pieta

Valentine · Pieter Kruger · Pilar Merino Neyra · Pinal Parmar · Pine Konelio · Pinkal Patel · Pinki

Thapa · Pinky Anibo · Pinky Ariar · Pinky Evangelista · Pip Griffin · Pip Nolan · Pip Smith · Pip Wayne

· Pita Bhattarai · PK Karan · Polly Matheson · Polly Maxwell · Poly Judicpa · Pooja Khaire · Pooja Patel

· Poonam B K · Poonam Chauhan · Poonam Kumar · Poonam Mudliyar · Poonam Rani · Poppy

Griffin-King · Portia Chatadza · Prabath Meegoda Gamage · Prabh Kaur · Prabh Kaur · Prabhjot

Sodhi · Pracey Cheriyan · Prachi Didmishe · Pradip Khadka · Pragnesh Limbachiya · Pragya Mahat

· Prajith Ramakrishnan · Prakash Singh · Praneel Singh · Pranisha Shrestha · Prashant Khaire ·

Prasita Prasannan · Pratiksha Wagle · Pratima Ghimire Adhikari · Pratima Singh · Pravin Singh ·

Precy Bond · Preema Jose · Preena Davis · Preet Kaur · Preet Kaur · Preet Kaur · Preet Kaur · Preethi

Meares · Preeti Preeti · Preetyka Preetyka · Prema Gavarriah · Premitha Silva · Preston Wastney ·

Prince Pagtanac · Princess Catostos · Princess Tabay · Princy Xavier · Priscilla Francis · Priscilla

Mihaere · Pritee Gurung Lama Lopchan · Priti Devi · Pritika Devi · Pritisha Kumar · Priya Chand ·

Priya Goundar · Priya Gurung · Priya Narayan · Priya Prakash · Priya Priya · Priya Reddy · Priya

Sharma · Priya Sharma · Priyanka Chhetri · Priyanka Sharma · Priyanka Silswal · Priyanka Tandon ·

Priyankaben Chaudhari · Priyanthi Perera · Prox Tiwari · Prudy Macdonald · Puja Malla · Punam

Kafle · Puneet Bhardwaj · Purissa Abalo · Purnima Devi · Pushpa Balodi · Qiannan Chen · Qin Xueqin

· Queen Samosa · Queenie Cabatingan · Queenie Liu · Quinn van Vierzen · Rabyn Reveche · Rach

Wates · Rachael Boyd · Rachael Davey · Rachael Hearn · Rachael Jepson · Rachael Lahmert ·

Rachael Manson · Rachael Mason · Rachael Seyb · Rachael Tuhi · Rachael Van Aalst · Racheal

Trinidad · Rachel Alford · Rachel Beattie · Rachel Borthwick · Rachel Bulatiko · Rachel Cadzow ·

Rachel Clark · Rachel Garrard · Rachel James · Rachel Joseph · Rachel Lalor · Rachel Lim · Rachel

Llido · Rachel McIvor · Rachel Ratcliffe · Rachel Ren · Rachel Smedley · Rachel Wangui · Rachel

Williams · Rachelle Jones · Rachelle Nuevo · Rachna Mahesh · Radhika Lingam · Radhika Reddy ·

Raeana Ulupano · Raewyn Bishop · Raewyn McLachlan · Raewyn Redfern · Raewyn Sides · Raewyn

Slade · Raewyn Taylor · Raewyn Ward · Raewyn Woolliams · Raewyn Wright · Raewynne Daly · Raf

Lachica · Rafelle Tantia · Rahat Arif · Rahul Suresh · Rahul Sahil Rahul · Raissa Manicad · Raj Grewal

· Raj Kaur · Raj Kaur · Raj Radhakrishnan · Raj Velumula · Raja Thirumugam · Rajan Kumar · Rajani

Acharya · Rajbir Kaur · Rajesh Bansal · Raji Naguleswaran · Rajneel Shankar · Rajni Punia · Rajveer

Brar · Rajvir Kaur · Rajwinder Kaur · Rajwinder Kaur · Rajwinder Kaur · Raken Abiteti · Ralph

Cayanan · Ralph Wang · Ram Amancio · Ram Martir · Rama Niroula · Raman Gill · Raman Kaur ·

Raman Kaur · Raman Kumar · Ramandeep Kaur · Ramandeep Kaur · Ramandeep Kaur ·

Ramandeep Kaur · Ramandeep Kaur · Ramandeep Sharma · Ramanpreet Dhillon · Ramanpreet

Syal · Ramon Supit · Ramya Bellam · Randeep Kaur · Randeep Kaur · Randeep Kaur Parihar ·

Randolph Colas · Rani Blake · Rani Thomas · Ranjana Gurung · Ranjit Kaur · Ranjit Kaur · Ranshan

Nanayakkara · Raoul Bravo · Raphael Rausch · Raquel Bibal · Raquel Rapp · Rasanjana

Kumarasinghe · Rashmi Gurung · Rashmika Senevirathne · Ravandeep Dhaliwal · Ravanjit Sidhu ·

Raven Bitancor · Ravi Kothuru · Ravneet Kaur · Rawinia Tahi · Ray Fairbairn · Raya Aganon · Raziya

Nisha · Razyl Canlas · Rebecca Bullock · Rebecca Burgess · Rebecca Croudace · Rebecca Fielding

· Rebecca Hart · Rebecca Hill · Rebecca Keen · Rebecca Knight · Rebecca Little · Rebecca Lomax

· Rebecca Malaki · Rebecca McKinley · Rebecca McMillan · Rebecca Mushet · Rebecca Orr ·

Rebecca Schumacher · Rebecca Waine · Rebekah Mercer · Rechelle Gonzales · Reema Devi ·

Reena Chandar · Reena Kumar · Reena Waiba · Reet Mann · Reeta Singh · Reeve Lithgow · Regina

Gounder · Reginald Abellana · Rehana Sharif · Rei Paranihi · Reina Bonaobra · Reina Manten · Reina

Saludares · Reis Lectura · Rejena Galimba · Rejena Lazar · Rejina Khadka · Rekha Dawson · Rekha

Manral · Rekha Ramanath · Rekha Rekha · Remya Rajagopal · Ren Abarca · Rena Allen · Rene

Bryant · Renee Green · Renee Mahe · Renee Perreau · Renee Phythian · Renee Tauwhare · Renisha

Senchyury · Renjith Pariyarath Raveendran Nair · Renuka Chuwan · Renuka Gounder · Renuka

Kant · Renuka Renuka · Reshma Mala · Reshma Mathew · Reshma Mathew · Reshma Scott · Reshmi

Lata · Reshmi Narayan · Reshmi Rao · Ressa Larkin · Reuben Mahendran · Revlin Ratishma ·

Reydun Kihi · Reyn Dilag · Rhian Sharman · Rhianne Overell · Rhona Miranda · Rhonda Evans ·

Rhondda Carter · Rhyarna Batchelor · Ria Jamin · Riana van Niekerk · Riarawa Tematau · Ric

Bonacua · Ric Diaz · Ricardo Onate · Ricardo Pureza · Richa Hirani · Richa Kumar · Richard Bennett

· Richard Chisholm · Richard Crump · Richard Dackers · Richard French · Richard Greathead ·

Richard Sherrell · Riche Campaniel · Richelle Martin · Richelle Villanueva · Rick Davies · Ricky

Bruining · Ricky Ciobanu · Ricky Lawrence · Riffy Jahan-Khan · Riji Johny · Rika Hiramatsu · Rika

Kawakami · Riki Dobbs · Rikita Kunwar · Rikki Sran · Rindi Harmse · Rio Lagahit · Ripeka Neera ·

Rishi Kumar · Rishi Mangalat Kokkodan · Rita Chand · Rita Connolly · Rita Duffy · Ritu Devi · Ritu

Sami · Riya Darshani Ram · Riya George · Riya Mahna · Rizza Moron · Rob Carter · Rob Maier · Rob

Miller · Rob Mita · Rob Prior · Rob Shone · Rob Treanor · Rob Wilson · Robbie Blair · Robbie Muller ·

Robby Mendoza · Robert Benadie · Robert Gallagher · Robert Honoridez · Robert Madden ·

Roberta Baxendale · Robin Singh · Robyn Elder · Robyn Erasmus · Robyn Kerr · Robyn McCracken

· Robyn Murray · Robyn Nicholson · Robyn Nicholson-Pepe · Robyn Sullivan · Robyn Thompson ·

Robyn Tomkins · Robyn Tutton · Rochelle Bibal · Rochelle Chau-Lacerna · Rochelle Cohen ·

Rochelle Colas · Rochelle Coleman · Rochelle Concha · Rochelle Craigie-Whitta · Rochelle Davis ·

Rochelle Hart · Rochelle Labial · Rochelle Li · Rochelle Mack · Rochelle McIntyre · Rocky Atendido

· Rod Quan · Roddy Sangalang · Rodela Caldea · Roger Nuttall · Roger Thorpe · Rohini Devi · Rohini

Gayakwad · Rohini Gurung · Rohini Lal · Rohini Lata · Rohini Lata · Rois Gracia · Rojina Dhakal ·

Roland Altamia · Roma Tarranza · Roman Sluga · Romina Carangalan-Rosales · Romisha Timsina ·

Romy Wimalaratne · Ron Anand · Ron Ente · Ron Llanera · Rona Avila · Rona Mendoza · Rona

Tabada · Ronald De Jesus · Ronald Emilio · Ronaliza Labang · Ronalyn Alolor · Ronalyn Corpuz ·

Roni Mathew · Roni Mathew · Ronita Prasad · Ronna Torregosa · Ronny Liew · Ronny Taane · Roop

Bhullar · Roopa Shetty · Roopa Roopa · Rory Edwards · Rory Harris · Rosa Dalgleish · Rosa Hye-

Won · Rosa Pendijito · Rosa Tipa · Rosalind Hayhoe · Rosanne Gee · Rosaria Manjala · Rose Avery ·

Rose Baby · Rose Carina · Rose Coulson · Rose Jenkins · Rose Kaur · Rose Lawlor · Rose Noval ·

Rose Recentes · Rose Tabasan · Rose Taylor · Rose Tom · Rose Velilla · Rose Walker · Roseanne

Maxwell · Rosebelle Presilda · Rosecilla Saulon · Roselee Mudalige · Roseline Sharma · Roselle

Camatis · Roselle Plata · Roselle Rensulat · Rosemary Deane · Rosette Jarabe · Roshan Calustre ·

Roshila Cherman · Roshini De Silva · Roshmen Hussain Ali · Roshni Hicks · Roshni Jeet · Roshni

Lata · Roshni Raja · Roshni Reddy · Rosie Butler · Rosie Kaur · Rosie Malone · Rosie Neilson · Rosie

Williams · Rosina Bano · Roslyn Prentice · Ross Duxfield · Ross Howes · Ross Ireland · Ross

Johanson · Ross Sutherland · Rosy Khokhar · Roula Yianakis · Rowan Moustaid · Rowena Battad ·

Rowena Birch · Rowena Daan · Rowena McClutchie · Rowena Newport · Rowena Wood · Roxanne

Balidio · Roxanne Mores · Roxanne Rosquita · Roxanne Shaw · Roy Staite · Rozalpreet Kaur ·

Rozmin Rasheed · Ruaan Van Den Berg · Ruben Kumar · Ruby Brar · Ruby Galviz · Ruby Johny ·

Ruby Kanwar · Ruby Kaur · Ruby Mitchell · Ruby Shrestha · Ruchi Thakur · Ruel Alcaria · Ruel Infante

· Rufaida Khaled · Rufaro Ndoro · Rufino Gonzaga · Rui Liu · Ruling Huang · Rupa Sherma · Rupi Kaur

· Rupinder Dhaliwal · Rupinder Kaur · Rupinder Kaur · Rupinder Kaur · Rupinder Kaur · Rupinder

Kaur · Rupinderjit Kaur · Ruru Zhang · Russell Dobson · Russell Keetley · Russell Reazon · Ruth

Bullock · Ruth Cammell · Ruth Gavey · Ruth Makin · Ruth Murray · Ruth Payumo · Ruth Waterhouse

· Ruthgil Embalsado · Ruthy Rabo · Ruthy Van Heerden · Ruwan Colombage · Ryan Bensberg · Ryan

Evans · Ryan Haans · Ryan Jarvis · Ryan Junaid · Ryan McLaren · Ryan Patron · Ryan Tri Duc · Ryan

Verbo · Ryan Winks · Rymel Polittude · Saakshi Sunnaina · Sabarine Asif · Sabby Barara · Sabita

Bhattarai · Sabitri Gajurel · Sabnam Pun · Sabrina Cheema · Sabrina De Souza · Sabrina Nutarelli ·

Sadhana Devi · Sadhana Wati · Saggita Devi · Sai Ramisetti · Saifun Nisha · Saijy Lijo · Sajeeve

Rajasuriya · Sajin Mathew · Sake Kovuri · Saku Illaventhan · Sakura Shirakawa · Sala Eastwood · Sala

Manase · Sala Tagata · Salani Penisula · Sale Elisara · Saleem Richards · Salie Alcartado · Sally

Giddens · Sally Haslam · Sally Hayashi · Sally Itaea · Sally Johanson · Sally Sampson · Sally Uolo ·

Sally Veng · Sally Waldek · Sallyann Galodamu · Salochana Naidu · Saloma Faaaoga · Salome Ale ·

Salote Tuivakano · Salve Lastimoso · Sam Anderson-Williamson · Sam Arcus · Sam Carter · Sam

Cassidy · Sam Grave · Sam Hibbs · Sam Hudson · Sam Kingsbury · Sam Lingan · Sam Mahapure ·

Sam Manson · Sam Nicholls · Sam Pewhairangi-Stok · Sam Price · Sam Rusden · Sam Seal · Sam

Shirkey · Sam Singh · Sam Sukan · Sam Thomlinson · Sam Tobias · Sam Twyman · Sam van den

Heever · Sam Wheeler · Sam Williams · Sam Woolford · Samantha Christensen · Samantha

McPherson · Samantha Morris · Samara Hodges · Sami Adhikari · Sami Maharjan · Samiksha

Dhakal · Samira Khan · Samista Subedi · Samjhana Rocka · Sammi Zhang · Sammy Caffell · Samuel

Cheah · Samuel Julian · Samuel Shijo · Sandeep Johal · Sandeep Kaur · Sandeep Kaur · Sandeep

Kaur · Sandeep Kaur · Sandeep Kaur Khalsa · Sandeep Sidhu · Sandeep Waraich · Sandi Keen ·

Sandie Campbell · Sandie Eddy · Sandra Adegbesan · Sandra Bacic · Sandra Batten · Sandra

Berridge · Sandra Champion · Sandra Chapman · Sandra Duckworth · Sandra Hendriks · Sandra

Hodson · Sandra Houston · Sandra McGlade · Sandra Officer · Sandra Rogers · Sandra Severinsen

· Sandra Siakifilo · Sandra Stacey · Sandy Burton · Sandy Hayer · Sandy Kaur · Sandy Kaur · Sandy

Kaur · Sandy Kurukularatne · Sandy Paterson · Sandy Patterson · Sandy Pihema · Sangeeta Lata ·

Sangeeta Shrestha · Sangya Thapa · Sanita Kumar Bai · Sanjana Khadka · Sanjay Rivera · Sanjaya

Sidath Madhusanka · Sanjita Gurung · Sanjita Ratnam · Sanjita Rayamajhi Karki · Sanjuni Thapa ·

Sanna McGavin · Sanumol Antony · Sany Sany Kalappurakkal · Sapana KC · Sapna Walia · Sara

Bray · Sara Fearnley · Sara Hodgson · Sara Kaur · Sara Kuruvila · Sara Lukic · Sara McCunnie · Sara

Vahua · Sarah Affleck · Sarah Andrews · Sarah Arps · Sarah Davis · Sarah Direen · Sarah Ellis · Sarah

Farrell · Sarah Guo · Sarah Henderson · Sarah Keane · Sarah Kim · Sarah Laiz · Sarah Leaf · Sarah

Lomax · Sarah Lovelady · Sarah Maxwell · Sarah McCardle · Sarah McKenna · Sarah Munoz · Sarah

Reid · Sarah Schmidt · Sarah Taylor · Sarah Tomas · Sarah Vesi · Sarah Vivian · Sarah Wallace ·

Sarah Walsh · Sarah-Jane Hamblin · Sarai Smith · Sarath Kundathil · Saravjeet Kaur · Sarda

Gounder · Sarika Asokan · Sarika Prasad · Sarina Hubber · Sarina Shrestha · Sarit Epshteyn · Sarita

Kumar · Sarita Prasad · Saritha Kaithavalappil · Saritha Mathew · Saroj Chauhan · Sarojitharai

Srikanthan · Sarojni Kumar · Sarojni Sarojni · Sarsha Pedersen-Burbery · Sarvin Selvarajan · Sasha

Laiz · Sashi Hutchins · Sashi Lata · Sashi Prasad · Sasi Chakrapani · Saskia Hannink · Satbir Kaur ·

Satinder Kaur · Sau Atinae · Savannah Amies · Savannah Kemp · Savannah Tuapawa · Savita

Kumari · Savita Reddy · Savitri Naidu · Savitri Naidu · Scott Baylis · Scott Crawford · Scott Newey ·

Scott Perry · Scott Thompson · Scott Wallace · Sean Crosby · Sean Jenkins · Sean Morgan · Sean

Ortuoste · Seannice Caliboso · Sebastian Hecker · Seekku Silva · Seema Gangar · Seema Parmar ·

Seema Thapa · Seenal Prasad · Seetha Mwashomah · Seirosa Fakaofo · Selina Khatun · Selja Johny

· Senijiale Fuakilau · Seniya Sebastian · Senjalin Shankar · Senolita Vea · Sequoia Aitken · Serah

Wong · Sha Panapa · Sha Sun · Shabana Jawaid · Shabin Basheer · Shabnam Ali · Shai

Venkitachalam · Shairin Begum · Shakira Kalam · Shaleeni Goundan · Shalesni Kumari · Shalika

Wijethilaka · Shalimar Bawayan · Shalini Shah · Shaluka Pathiraja · Shalveni Narayan · Shaly Lazer ·

Shameena Abdurahiman · Shamshad Begum · Shamsun Partap · Shan Centeno · Shanai Wagener

· Shane Fairbairn · Shane Ferguson · Shane Mudgway · Shane Ormshaw · Shane Pereira · Shane

Vargas · Shani Rathnayaka · Shania Wootton · Shanika Mudiyanselage · Shanimol Joseph · Shanlee

Barnes-Webber · Shanno Chand · Shannon Butler · Shannon Conway · Shanthi Fernando · Shanthy

Gopal · Shanti Prasad · Shaqueena Kerr · Sharalyn Pomare · Sharan Brar · Sharan Kaur ·

Sharandeep Kaur · Shareen Devi · Sharil Narayan · Sharl Absin · Sharleen Warren · Sharlene Garcia

· Sharlene Peters · Sharmaine Nieves · Sharmila Lal · Sharmila Prasad · Sharmila Sharma · Sharol

Sunny · Sharon Armstrong · Sharon Balsom · Sharon Chapman · Sharon Denniston · Sharon

160

RYMAN HEALTHCARE

Thank you!
Grogan · Sharon Hamlyn · Sharon Henderson · Sharon Jackson · Sharon Maich · Sharon McDonald

· Sharon Ritchie · Sharon Tainui · Sharon Wilton · Sharron Lamb · Sharron Neale · Sharyn Basham ·

Sharyn Elliott · Sharyn Kennedy · Sharyn Ward · Sharyn Weightman · Shashi Lata · Shaun Kennedy

· Shaun Steele · Shay Singh · Shayal Naidu · Shayal Raju · Shaylin Simadari · Shazneen Bi · Sheemal

Shiwani · Sheen Reyes · Sheena Benitez · Sheena David · Sheena Morgan · Sheena Taki · Sheena

Villa · Sheena Wiel · Sheenal Chand · Sheetal Bhudia · Sheethal Joseph · Sheevey Quezon · Sheila

Bascara · Sheila Gamboa · Sheila Nelgas · Sheila Opena · Shelah Manaloto · Shelby Bercich ·

Shellden Kruyff · Shelley Austin · Shelley Ferguson · Shelley Harris · Shelley Lester · Shelly Castillo ·

Shelly Mani · Shelly Snodgrass · Shelomy Dollaga · Shemery Sevilleno · Shenal Shivasani · Sheng

Puguon · Shequille Stewart · Sherine Megula · Sherlyn Alquetra · Sheron Kaur · Sherree Wilson ·

Sherry Cruz · Sherry Janagal · Sherryl Sy · Shery Mercado · Sheryl Aguarilles · Sheryl Cosep · Sheryl

Keen · Sheryl Madlangbayan · Sheryl Miller · Sheryl Morris · Sheryll Verga · Shey Landiza · Shiela

Cabauatan · Shiela Llameg · Shiela Nebalga · Shiena Atilano · Shija Koirala · Shikha Shikha · Shikha

Verma · Shiksha Grover · Shinaai Schroeder · Shingi Utete · Shiny Varghese · Shirjana Neupane ·

Shirley Bakulich · Shirley Bucua · Shirley Goodall · Shirley Krishna · Shirley Lagavakatini · Shirley Pan

· Shirline Lubanga · Shivangika Ashok · Shivani Gounder · Shivani Puri · Shivani Shivani · Shiwangni

Prasad · Shiwani Acharya Tiwari · Shobna Kumar · Shoji George · Shom Lata · Shon Frater · Shona

Bayliss · Shona Gomes · Shona Newman · Shoncey O’Brien · Shontelle Cockerill-Doerschel ·

Shraddha Maharjan · Shree Gandhi · Shreta Chand · Shrijana Dahal · Shrisrika Raj · Shruti Sharma ·

Shuaybah Aaliya · Shuba Selvaraj · Shubham Sajwan · Shun Lu · Shunyi Zhang · Shuvayi Mbewe ·

Shweta Bawlekar · Shweta Dabhi · Shweta Devi · Shweta Prasad · Shweta Raheja · Shy Thomas ·

Shyani Weerawansa · Shyji Sebastian · Shyna Boock · Shyrene Bechoo · Shyy Foster · Sia Anand ·

Sia Palusa · Sian Moore · Sianne Pinto · Sibi Antony · Sid Singh · Siddarth Rajmohan · Sidhart Kumar

· Siga Parker · Sigas Bose · Sigfred Lagajino · Sigin Pullemkunnel · Siliva Samuelu · Silva Evangelista

· Silvy Thomas · Simerjit Kaur · Simi John · Simi Sam · Simi Verma · Simin Alipour · Simmi Vahora ·

Simoa Ale · Simon Emett · Simon Jantke · Simon Judd · Simon Judge · Simon Lee · Simon Mitchell ·

Simona Wallwork · Simone Blandford · Simone Coutinho Santos · Simone Donahue · Simone Lamb

· Simone Taylor · Simran Kaur Sra · Simran Singh · Sina Aaifou · Sina Afamasaga · Sina Kampe · Sini

Gibu Joseph · Sini Jose · Siobhan O’Connor · Sione Tonga · Sipa Kiko · Sirisuda Charoensak · Sisi

Fine · Sisi Tawake · Siteri Kama · Siteri Nava · Siu Tapaevalu · Smitha Pulickakunnel Joseph · Snap

Venturanza · Snezhana Bubnova · Snower Singh · Sobin Stephen · Sofia Benitez Castellanos · Sofia

Ditta · Sofia Faagutu · Sofin Mohammed · Sojan Vazhapilly Tomas · Somkhit Lightbourne · Sona

Basnet · Sona Varghese · Sonia Barrett · Sonia Bonaobra · Sonia Cuasito · Sonia McMartin · Sonia

Peter · Sonia Sharma · Sonia Vincent · Sonica Dicks · Sonika Kissun · Sonika Prasad · Sonika

Sharma · Soniya Alex · Soniya Magar · Sonja Karon · Sony Paul · Sonya Brown · Sonya Dunlop ·

Sonya Overy · Sonya Tikoduadua · Sookie Magallones · Sophia Etherington · Sophia Shan · Sophia

Tang · Sophia Zhang · Sophie Beechey · Sophie Campbell-Patston · Sophie Devi · Sophie Harvey ·

Sophie Iceton · Sophie Kirby · Sophie Koroniadis · Sophie McMillan · Sophie Miller · Sophie Reade ·

Soumya Charlie · Sova Nairoroi · Sovandy Kou · Spencer Burchell · Sreypov Ing · Sreytouch Meng ·

Srishti Yelagani · Stacey Hancock · Stacey Magee · Stan Bickerton · Starra Wood · Steen Neal ·

Steffen Muir · Stella Thomas · Stella Wong Mok · Steph Cawte · Steph Griffin · Steph Villarin · Steph

Young · Stephanie Barnard · Stephanie Broadhurst · Stephanie Chen · Stephanie Marsicano ·

Stephen Browning · Stephen Cartwright · Stephen De Jonge · Stephen Denvers · Stephen Dickson

· Stephen Fitchett · Stephen Hammond · Stephen Pitcher · Stephen Radburn · Stephen Tabangcura

· Stephy Joy · Steve Clark · Steve Cotter · Steve Hayes · Steve Herries · Steve Jennings · Steve

Ludford · Steven Tamayo Restrepo · Stevie Gideon-Scurrah · Stevie Taiwhati · Stewart Connolly ·

Storm Raharuhi · Stu Oostdam · Stuart Korunic · Stuart Williams · Subhadra Thakuri Sapkota ·

Subhnam Khan · Suchada Jarupongpimarn · Sudhakar Sudarsanam · Sudina Jose · Sue Adamson

· Sue Bovey · Sue Claxton · Sue Coventry · Sue Frew · Sue Gemmell · Sue Hailstone · Sue Hammond

· Sue Healey · Sue Hine · Sue Horan · Sue Hurcomb · Sue Kaur · Sue Kim · Sue Knight · Sue Liang · Sue

Massie · Sue Miller · Sue O’Brien · Sue O’Malley · Sue Pham · Sue Sloan · Sue Stace · Sue Su · Sue Tan

· Sue Taylor · Sue Wells · Sue Wickham · Sui Lavea · Sujan Sapkota · Sujana John · Sujata Patel ·

Sujee Shrestha · Sujitha Pallissery · Sukh Rai · Sukhbir Kaur · Sukhi Singh · Sukhleen Kaur ·

Sukhmani Khatri · Sukhmeet Kaur · Sukhveer Kaur · Sukriti Jain · Sultan Salauddin · Suman Lata ·

Sumeet Sandhu · Sumit Sharma · Sumitha Raju Pottayil · Sumitra Shrestha · Sumnima Poudel ·

Suna Rijal · Sundar Subedi · Sunil Magar · Sunita Ghimire · Sunita Mehta · Sunita Nepali · Sunita Sami

· Sunita Sharma · Sunny Choi · Sunny Sandeep · Sunny Singh · Sunshine Ramirez · Sunshine Tarcelo

· Supriya Shrestha · Suren Deshar · Suresh Fernando · Surinder Kaur · Susan Bacod · Susan Baird ·

Susan Bekker · Susan Brient · Susan Brister · Susan Cristina · Susan Crozier · Susan Dong · Susan

Henderson · Susan Hughes · Susan Jane · Susan MacLean · Susan Mala · Susan Rae · Susan

Sainsbury · Susan Spittal · Susana Fox · Susanne Boehm · Sushan Rijal · Sushma Bharatham · Susi

Alefosio · Susie Alayne · Susie Cox · Susie de Vaney · Susie Magalhaes · Susinder Rajendran ·

Susmita Basnet · Susmita Chhetri · Suzanna Allan · Suzanne Elliott · Suzanne Gain · Suzanne Mason

· Suzanne Omlo · Suzanne Wells · Suzette Nuyda · Suzette Otacan · Suzleen Lata · Suzy Gibbs ·

Swap Dadlani · Swastika Kumar · Swathy Dev · Sweety George · Sylveniya Dayal · Sylvia Consadine

· Syvelle Baricuatro · Tagi Yabakirua · Tahera Shaikh · Tahmina Rahman · Tai Hooper · Taina

Tuipulotu · Taiyebeh Babakhani · Taka Akagawa · Tala Vea · Talai Ati · Tamara Billing · Tamara

Bradford · Tamara Price · Tamati Wairepo · Tami Trow · Tamsin Eldridge · Tamsyn Davies · Tangi

Ohuka · Tania Anderson · Tania Boyd · Tania Coleman · Tania Hapi · Tania Johnston · Tania Jordan

· Tania Khan · Tania Lilley · Tania Lister · Tania Palomino Vargas · Tania Walker · Tanisha Griffiths ·

Tanja Cary · Tanja Kroch · Tanu Kaur · Tanya Lombardi · Tanya Mandeya · Tanya McGurk · Tanya

Swart · Tanya Waters · Tara Berkett · Tara Clark · Tara Jacobsen-Kedzlie · Tarn Gardner · Tarn Kaur

· Tarnz Morrison · Taryn Eagle · Taryn Jonasen · Tash Brightwell · Tash Richardson · Tash Waddell ·

Tatenda Jack · Tau Faatoto Malaga · Tau Kalepo · Tayla Anderson · Tayla Ball · Tayla Beck · Tayla

Markwick · Tayla Wiperi · Taylor Allison · Taylor Lawson-Smith · Taylor Murphy-Peters · Tayyaba

Latif · Te Kopa Reedy · Te Rangi White · Tee Nathan · Tee Rakena · Teele Prints · Teema Tom · Teenu

Skaria · Tehanie Azcona · Tek Namoori · Tekai Tuneti · Telma Tom · Temi Fayomi · Tenille Pickett ·

Tererei Koura · Teresa Bakewell · Teresa Churchill · Teresa Jurkiewicz · Teresa Sinclair · Teresa

Turner · Terese Izquierdo · Tereza Honkova · Teri Murdoch · Terri McKenzie · Terri Smith · Terri

Taylor · Terry Bacon · Terry Geoghegan · Tesa Leano · Teshi Khatiwoda · Tess Canoy · Tess

Danganan · Tess Desai · Tess Gutierrez · Tess Mallari · Tessa Edwards · Thabitha Joby · Thamara

Fernando · Thanz Lachica · Thavy Mey · Thea Robiso · Theja Kudahetti · Thejani Sasanthika ·

Thelma Escobar · Thelma Littlejohn · Theo Taylor · Theo van de Klundert · Theodore Hernandez ·

Theresa Ada · Theresa Intia · Theresa Maniulit · Theresa Rayner · Theresa Robiso · Theresa Te

Whata · Theresa Turner · Theresa Zamora-Coates · Thomas Field · Thomas Wanke · Thu Nguyen ·

Thushari Withanage · Tianii-jade Simmons · Tiau Itaaka · Tiegan Maru · Tiffa Jumao-As · Tiffany

Grant · Tiffany Hamilton · Tiffany Jefferies · Tigi Thomas · Tillie Laufiso · Tim Garlick · Tim Goodwin

· Tim McAsey · Tim Reihana · Tim Saubuli · Tin Novilla · Tin Tagle · Tin Tin Borres · Tin-Tin Ladisla ·

Tina Aston · Tina Barnett-Peretini · Tina Healy · Tina Mateo · Tina McNally · Tina Schwenke · Tina

Seufale · Tina Strahl · Tina Thomson · Tingy Meyrick · Tintu Thomas · Tinu Abraham · Tisa Gopal ·

Tita Diamante · Tittu Thomas · Todd Clayton · Tofi Lefeau · Toji Nihinsa · Toka Toawea · Tom Bright

· Tom Brownrigg · Tom Farrell · Tom Karamalis · Tom Mantle-Chadfield · Tom Robinson · Tom Sun ·

Tom Zaugg · Tomirose Dela Cruz · Toni Campbell · Toni Cochrane · Toni Pasco · Toni Ryan · Tonia

Shakhova · Tony Burke · Tony Cassidy · Tony Clyne · Tony Howarth · Tony Killip · Tony Thomas ·

Tony Villanueva · Tony Weber · Tony Zinsli · Tori Pascoe-Lane · Tory Hamilton · Toto Ajawas · Tracey

Campen · Tracey Cheshire · Tracey Clapp · Tracey Dewes · Tracey Doody · Tracey Dunn · Tracey

Henricksen · Tracey Irvine · Tracey Lord · Tracey McCauley · Tracey McCullough · Tracey McIndoe

· Tracey Moncur · Tracey Shields · Tracey Vertigan · Tracy Blackadder · Tracy Elliott · Tracy Kemp ·

Tracy Mahoney · Tracy McLeod · Tracy Munford · Tracy Quill · Tracy Thomson · Tracy Webster ·

Tracy Wickman · Trav Maaka · Travis Cocks · Tressa Thomas · Trevor Davies · Tricia Wright · Tricina

Lacey · Trina Michelle · Trini Humphrey · Trish Coker · Trish de Jong · Trish Harris · Trish Malone ·

Trish Murray · Trish Tallott · Trish Warren · Trish Windle · Trisha Valdrez · Trishna Chand · Trix

Fuentes · Troy Noronha · Troy Pedder · Truc Le · Trudi Martin · Trudi McNamara · Trudy Royfee ·

Trudy Shepard · Trudy Stark · Tsitsi Marimi · Tua Brown · Tua’a Simone · Tui Duffull · Tylah Wenlock

· Ubbie Kooma · Udara Wickramaratne · Ula Rakai · Ula Taufao · Ulric Bawayan · Ultric Du Plooy ·

Ulysses Patrick Estrellada · Uma Chinnaiyan · Uma Kumar · Umang Baldaniya · Una Liavaa · Unnti

Madaan · Upekha Fernando · Upul Angappulige · Urvashi Puri · Usha Pratheepan · Usha Subba ·

Uzma Zaveeri · Vaidika Vandhana Kiran · Vaisakh Bijukumar · Val Abarquez · Val Aitken · Val

Rangelova · Val Spalding · Valerie Calvert · Vandana Kazal · Vandana Narayan · Vandana Pillay ·

Vanessa Bates · Vanessa Camba · Vanessa Capistrano · Vanessa Claridge · Vanessa Dinh ·

Vanessa Hallett-Free · Vanessa Jeng · Vanessa Jinayon · Vanessa Manozo · Vanessa Neilson ·

Vanessa Papa · Vanessa Ranger · Vanessa Tang · Vaneza Narsico · Vannida Kheng · Vara Nailawe ·

Varice Mangente · Varinder Singh · Varun Dayal · Vasga Naidu · Vasu Sharma · Veda Kantayapalam

· Vee Zhupikova · Veena Gopika · Veena Prabha · Veer Kaur · Veerpal Kaur · Venice Sayson · Venina

Rauma · Venus Conag-Ochea · Vera Go · Vera Karauia · Verna Jacobs Douglas · Verna Mepana ·

Veronica Basinang · Veronica Freire · Veronica Tellis · Vic Scanlan · Vick Zhou · Vicki Burt · Vicki

Engu · Vicki Leggett · Vicki McLennan · Vicki Mokalei · Vicki Payne · Vicki Taylor · Vicki Waipouri ·

Vicki Webb · Vicky Boswell · Vicky Brown · Vicky Lilley · Vicky Sel-Ayen · Vicky Tunnell · Vicky

Veeran · Vicky Weekley · Vicky Zhang · Vicsha Cabanero · Victor David · Victoria Brevoort · Victoria

Cresswell · Victoria Dalpatan · Victoria Nand · Victoria Slade · Vidhi Ray · Viduni Abeynayake · Vidya

Wati · Vijay Gounder · Vijay Khadka · Vijay Kumar · Vijay Lachmi · Vika Kafa · Vikashni Prasad · Vikki

Searle · Vilma Cahis · Vimal Kaur · Vimesha Ramanayake · Vimla Wati · Vince Santoro · Vincy

Varkey · Vineetha Vavachen · Vinita Nand · Vinita Vishalni · Vinny Naikau · Vipi Vasu · Vir Villacorta

Jr. · Virginia Bryan · Virginia Embile · Virginia Makore · Vishal Patel · Vishnu Somasundranpillai · Vita

Furche-Degener · Viv Nixon-Mead · Viv Sayson · Vivian Phillips · Vivien Noel · Vladimir Mackevic ·

Wai Baker-Taumata · Waiongana Weeks · Wan Yaemkul · Wanfei Cao · Warren Lee · Wati Saravaki ·

Wayne Blazey · Wayne Clark · Wayne Lockhart · Wayne Murray · Weena Aglugub · Weena Evora ·

Wei Chen · Wen Wang · Wendy Arluck · Wendy Bourke · Wendy Burns · Wendy Chinh · Wendy

Gacayan · Wendy Gordon · Wendy Hamilton · Wendy Harris · Wendy Hern · Wendy Johnstone ·

Wendy Kaka · Wendy Kappler · Wendy Kennedy · Wendy Laurie · Wendy MacDonald · Wendy Miller

· Wendy Taylor · Wendy Tran · Wendy Turner · Wendy Turton · Wenna Barrido · Wesi Singh ·

Wharenikau Hing · Whela King · Whetu Maniapoto · Wiian Bundalian · Wil Borres · Wil Yoro ·

Wilhelmina Bloem · Will Chester · Will Locking · William Geck · William Schultz · William See · Wilna

Junio · Wilna van Heerden · Win Win Kyi · Winnie Winstanley · Wyndham Tapsell · Xandi Konigstorfer

· Xavier Loretz · Yae Imaizumi · Yam Karki · Yamuna De Silva · Yan Luo · Yan Wang · Yan Zhang ·

Yancey Valoria · Yani Encarnacion · Yanjana Limbu · Yanping Liu · Yanti Sriyanti · Yaowapa

Somjitsakul · Yasasmi Basnayake · Yashna Prasad · Yasmin Asia · Yasmin Hughes · Yasoda Dewan ·

Yeshi Khatiwoda · Yeshni Rai · Yi Liu · Yi-chen Tsai · Yin Huang · Yin Yin Huang · Ynys Cadogan · Yodi

Uyod · Yok Wongsa · Yolanda Acebedo · Yolanda Grobler · Yolene Pienaar · Yoon Lee · Yoshi

Donnelly · Youmi Lee · Yra Diez · Yuka Minai · Yuki Maeda · Yukie Nakano · Yukiko Falchi · Yulia Lucas

· Yunisha Nakarmi · Yuting Guo · Yvanne Evangelista · Yvette Pearl · Yvonne Bourassa · Yvonne

Carter · Yvonne Lewis · Yvonne Murray · Yvonne Na · Yvonne Robinson · Zac Miller · Zach Morrison

· Zadie Wickremasinghe · Zahra Boloori · Zahra Salot · Zaigere Eales · Zamira Ensor · Zane Allmand

· Zane Strazdina · Zara Nichol · Zarah Masote · Zay Garcia · Zayyan Jahan · Zee Khan · Zelda Watt ·

Zerah Mero · Zingara McDougall · Zoe Attrill-Palmer · Zoe Driver · Zoe Eathorne · Zoe Hunter · Zoe

King · Zoe Noble · Zoe Nyika · Zoe Templeton · Zoreen Nisha · Zuhra Balic · Zyra Ramas

161

ANNUAL REPORT 2021

v
Our village locations


Aberfeldie


Charles Brownlow


Essendon


Highett


John Flynn


Mt Eliza


Mt Martha


Nellie Melba


Ocean Grove


Ringwood East


Weary Dunlop

Our villages in

Victoria, Australia

RYMAN VILLAGE

UNDER CONSTRUCTION

COUNCIL APPROVAL

PROPOSED VILLAGE

CHARLES

BROWNLOW

1

MT MARTHA

1

ABERFELDIE

1

OCEAN GROVE

1

WEARY DUNLOP

1

NELLIE MELBA

JOHN FLYNN

1

RINGWOOD EAST

1

HIGHETT

1

ESSENDON

1

MT ELIZA

1

1

RYMAN HEALTHCARE

162

v
INVERCARGILL

1

DUNEDIN

RANGIORA

1

CHRISTCHURCH

61

NELSON

1

WELLINGTON

42

WAIKANAE

1

PALMERSTON NORTH

1

WHANGANUI

1

NEW PLYMOUTH

1

HAVELOCK

NORTH

1

NAPIER

1

GISBORNE

1

TAURANGA

HAMILTON

CAMBRIDGE

2

1

WHANGĀREI

1

AUCKLAND

10

2

2

1

11

WHANGĀREI


Jane Mander

AUCKLAND


Bert Sutcliffe


Bruce McLaren


Edmund Hillary


Evelyn Page


Grace Joel


Karaka


Keith Park


Kohimarama


Logan Campbell


Miriam Corban


Murray Halberg


Possum Bourne


Takapuna


William Sanders

HAMILTON


Hilda Ross


Linda Jones

CAMBRIDGE


Cambridge

TAURANGA


Bob Owens

GISBORNE


Kiri Te Kanawa

NEW PLYMOUTH


Jean Sandel

NAPIER


Princess Alexandra

HAVELOCK NORTH


James Wattie

WHANGANUI


Jane Winstone

PALMERSTON NORTH


Julia Wallace

WAIKANAE


Charles Fleming

WELLINGTON


Bob Scott


Karori


Malvina Major


Newtown


Rita Angus


Shona McFarlane

NELSON


Ernest Rutherford

RANGIORA


Charles Upham

CHRISTCHURCH


Anthony Wilding


Diana Isaac


Essie Summers


Margaret Stoddart


Ngaio Marsh


Northwood


Park Terrace


Riccarton Park


Woodcote

DUNEDIN


Frances Hodgkins


Yvette Williams

INVERCARGILL


Rowena Jackson

Our villages in

New Zealand

1

1

163

Retirement villages in
New Zealand

Anthony Wilding Retirement Village

5 Corbett Crescent, Aidanfield,

Christchurch

Bert Sutcliffe Retirement Village

2 Rangatira Road, Birkenhead,

Auckland

Bob Owens Retirement Village

112 Carmichael Road, Bethlehem,

Tauranga

Bob Scott Retirement Village

25 Graham Street, Petone,

Lower Hutt

Bruce McLaren Retirement Village

795 Chapel Road, Howick, Auckland

Charles Fleming Retirement Village

112 Parata Street, Waikanae

Charles Upham Retirement Village

24 Charles Upham Drive, Rangiora

Diana Isaac Retirement Village

1 Lady Isaac Way, Mairehau,

Christchurch

Edmund Hillary Retirement Village

221 Abbotts Way, Remuera,

Auckland

Ernest Rutherford Retirement

Village

49 Covent Drive, Stoke, Nelson

Essie Summers Retirement Village

222 Colombo Street, Beckenham,

Christchurch

Evelyn Page Retirement Village

30 Ambassador Glade, Orewa, Auckland

Frances Hodgkins Retirement Village

40 Fenton Crescent, St Clair, Dunedin

Grace Joel Retirement Village

184 St Heliers Bay Road, St Heliers,

Auckland

Hilda Ross Retirement Village

30 Ruakura Road, Hamilton

James Wattie Retirement Village

122 Te Aute Road, Havelock North

Jane Mander Retirement Village

262 Fairway Drive, Kamo, Whangārei

Jane Winstone Retirement Village

49 Oakland Avenue, St Johns Hill,

Whanganui

Jean Sandel Retirement Village

71 Barrett Road, New Plymouth

Julia Wallace Retirement Village

28 Dogwood Way, Clearview Park,

Palmerston North

Kiri Te Kanawa Retirement Village

12 Gwyneth Place, Lytton West,

Gisborne

Linda Jones Retirement Village

1775 River Road, Flagstaff, Hamilton

Logan Campbell Retirement Village

187 Campbell Road, Greenlane,

Auckland

Malvina Major Retirement Village

134 Burma Road, Khandallah,

Wellington

Margaret Stoddart Retirement Village

23 Bartlett Street, Riccarton,

Christchurch

Miriam Corban Retirement Village

211 Lincoln Road, Henderson, Auckland

Murray Halberg Retirement Village

11 Commodore Drive, Lynfield,

Auckland

Ngaio Marsh Retirement Village

95 Grants Road, Papanui, Christchurch

Possum Bourne Retirement Village

5 Lisle Farm Drive, Pukekohe

Princess Alexandra Retirement

Village

145 Battery Road, Napier

Rita Angus Retirement Village

66 Coutts Street, Kilbirnie, Wellington

Rowena Jackson Retirement Village

40 O’Byrne Street North, Waikiwi,

Invercargill

Shona McFarlane Retirement Village

66 Mabey Road, Lower Hutt

William Sanders Retirement Village

7 Ngataringa Road, Devonport,

Auckland

Woodcote Retirement Village

29 Woodcote Avenue, Hornby,

Christchurch

Yvette Williams Retirement Village

383 Highgate, Roslyn, Dunedin

Directory

REGISTERED OFFICE

Airport Business Park

92 Russley Road, Christchurch

PO Box 771, Christchurch 8042

New Zealand

SHARE REGISTRAR

Link Market Services

PO Box 91976, Auckland 1142

New Zealand

P: +64 9 375 5998

E: enquiries@linkmarketservices.co.nz

RYMAN HEALTHCARE

164

Retirement villages in
Australia

Charles Brownlow Retirement

Village

157 South Valley Road, Highton, Victoria

John Flynn Retirement Village

45 Burwood Highway, Burwood East,

Melbourne

Nellie Melba Retirement Village

2 Collegium Avenue, Wheelers Hill,

Melbourne

Ocean Grove Retirement Village

181–199 Shell Road, Ocean Grove,

Victoria

Weary Dunlop Retirement Village

242 Jells Road, Wheelers Hill,

Melbourne

New villages in the

pipeline in New Zealand

Cambridge

1881 Cambridge Road, Cambridge

Karaka

250 Hingaia Road, Karaka, Auckland

Karori

26 Donald Street, Karori, Wellington

Keith Park Retirement Village

3 Scott Road, Hobsonville,

Auckland

Kohimarama

233 Kohimarama Road, Kohimarama,

Auckland

Newtown

192 Adelaide Road, Newtown,

Wellington

Northwood

486 Main North Road, Northwood,

Christchurch

Park Terrace

78 & 100 Park Terrace,

Christchurch

Riccarton Park

25 Steadman Road, Christchurch

Takapuna

41–45 Killarney Street, Takapuna,

Auckland

New villages in the

pipeline in Australia

Aberfeldie

2 Vida Street, Aberfeldie, Melbourne

Essendon

1–3 Moreland Road, Essendon,

Melbourne

Highett

32–40 Graham Road, Highett,

Melbourne

Mt Eliza

60–70 Kunyung Road, Mt Eliza,

Victoria

Mt Martha

180 Bentons Road, Mt Martha, Victoria

Ringwood East

2–16 Mt Dandenong Road,

Ringwood East, Melbourne

MELBOURNE OFFICE

Suite 10.03, Level 10

420 St Kilda Road

Melbourne

PO Box 33119

Melbourne VIC 3004, Australia

AUCKLAND OFFICE

93 Ascot Avenue, Remuera

Auckland 1050

New Zealand

WELLINGTON OFFICE

10B Waterloo Quay

Wellington 6011

New Zealand

New Zealand

0800 588 222

rymanhealthcare.co.nz

Australia

1800 922 988

rymanhealthcare.com.au

For more information on any of Ryman Healthcare’s

retirement villages:

165

ANNUAL REPORT 2021

rymanhealthcare.co.nz
rymanhealthcare.com.au

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.